
<html lang="en"     class="pb-page"  data-request-id="dd99667f-1ee2-4dd6-b571-ee3024ab95ba"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;article:article:10.1021/acs.jmedchem.5b00078;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2015.58.issue-5;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Selective, Nontoxic CB2 Cannabinoid o-Quinone with in Vivo Activity against Triple-Negative Breast Cancer" /></meta><meta name="dc.Creator" content="Paula  Morales" /></meta><meta name="dc.Creator" content="Sandra  Blasco-Benito" /></meta><meta name="dc.Creator" content="Clara  Andradas" /></meta><meta name="dc.Creator" content="María  Gómez-Cañas" /></meta><meta name="dc.Creator" content="Juana María  Flores" /></meta><meta name="dc.Creator" content="Pilar  Goya" /></meta><meta name="dc.Creator" content="Javier  Fernández-Ruiz" /></meta><meta name="dc.Creator" content="Cristina  Sánchez" /></meta><meta name="dc.Creator" content="Nadine  Jagerovic" /></meta><meta name="dc.Description" content="Triple-negative breast cancer (TNBC) represents a subtype of breast cancer characterized by high aggressiveness. There is no current targeted therapy for these patients whose prognosis, as a group,..." /></meta><meta name="Description" content="Triple-negative breast cancer (TNBC) represents a subtype of breast cancer characterized by high aggressiveness. There is no current targeted therapy for these patients whose prognosis, as a group,..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 20, 2015" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b00078" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2015 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b00078" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b00078" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b00078" /></link>
        
    
    

<title>Selective, Nontoxic CB2 Cannabinoid o-Quinone with in Vivo Activity against Triple-Negative Breast Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b00078" /></meta><meta property="og:title" content="Selective, Nontoxic CB2 Cannabinoid o-Quinone with in Vivo Activity against Triple-Negative Breast Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/large/jm-2015-00078c_0008.jpeg" /></meta><meta property="og:description" content="Triple-negative breast cancer (TNBC) represents a subtype of breast cancer characterized by high aggressiveness. There is no current targeted therapy for these patients whose prognosis, as a group, is very poor. Here, we report the synthesis and evaluation of a potent antitumor agent in vivo for this type of breast cancer designed as a combination of quinone/cannabinoid pharmacophores. This new compound (10) has been selected from a series of chromenopyrazolediones with full selectivity for the nonpsychotropic CB2 cannabinoid receptor and with efficacy in inducing death of human TNBC cell lines. The dual concept quinone/cannabinoid was supported by the fact that compound 10 exerts antitumor effect by inducing cell apoptosis through activation of CB2 receptors and through oxidative stress. Notably, it did not show either cytotoxicity on noncancerous human mammary epithelial cells nor toxic effects in vivo, suggesting that it may be a new therapeutic tool for the management of TNBC." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b00078"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b00078">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b00078&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b00078&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b00078&amp;href=/doi/10.1021/acs.jmedchem.5b00078" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2015</span><span class="cit-fg-volume">, 58</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2256-2264</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/58/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b00052" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm501660t" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Selective, Nontoxic CB<sub>2</sub> Cannabinoid <i>o</i>-Quinone with in Vivo Activity against Triple-Negative Breast Cancer</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paula++Morales">Paula Morales</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sandra++Blasco-Benito">Sandra Blasco-Benito</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Clara++Andradas">Clara Andradas</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mar%C3%ADa++G%C3%B3mez-Ca%C3%B1as">María Gómez-Cañas</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Juana+Mar%C3%ADa++Flores">Juana María Flores</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Pilar++Goya">Pilar Goya</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Javier++Fern%C3%A1ndez-Ruiz">Javier Fernández-Ruiz</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Cristina++S%C3%A1nchez">Cristina Sánchez</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nadine++Jagerovic">Nadine Jagerovic</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Instituto de Química Médica, CSIC, Calle Juan de la Cierva 3, 28006 Madrid, Spain</span></div><div class="aff-info" id="aff2"><span class="aff-text"><sup>‡</sup>Departamento de Bioquímica y Biología Molecular I, Facultad de Biología, and <sup>§</sup>Departamento de Medicina y Cirugía Animal, Facultad de Veterinaria, Universidad Complutense de Madrid, 28040 Madrid, Spain</span></div><div class="aff-info" id="aff2a"><span class="aff-symbol">∥</span> <span class="aff-text">Instituto de Investigación Hospital 12 de Octubre, Av Cordova s/n, 28041 Madrid, Spain</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">⊥</span> <span class="aff-text">Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, CIBERNED, IRYCIS, Universidad Complutense de Madrid, 28040 Madrid, Spain</span></div><div class="corresp-info"><strong>*</strong>Phone: +34 913944668. Fax: +34913944672. E-mail: <a href="/cdn-cgi/l/email-protection#a5c6d7ccd6d1cccbc48bd6c4cbc6cdc0dfe5d4d0ccc88bd0c6c88bc0d6"><span class="__cf_email__" data-cfemail="1477667d67607d7a753a67757a777c716e5465617d793a6177793a7167">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>Phone: +34 915622900. Fax: +34915644853. E-mail: <a href="/cdn-cgi/l/email-protection#deb0bfbab7b0bb9eb7afb3f0bdadb7bdf0bbad"><span class="__cf_email__" data-cfemail="046a65606d6a61446d75692a67776d672a6177">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b00078&amp;href=/doi/10.1021%2Facs.jmedchem.5b00078" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2015</span></span><span class="cit-volume">, 58</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2256–2264</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 11, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>14 October 2014</li><li><span class="item_label"><b>Published</b> online</span>20 February 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 March 2015</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b00078" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00078</a></div><div class="article_header-article-copyright"><strong>Copyright © 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2256%26pageCount%3D9%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DPaula%2BMorales%252C%2BSandra%2BBlasco-Benito%252C%2BClara%2BAndradas%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D58%26issueNum%3D5%26contentID%3Dacs.jmedchem.5b00078%26title%3DSelective%252C%2BNontoxic%2BCB2%2BCannabinoid%2Bo-Quinone%2Bwith%2Bin%2BVivo%2BActivity%2Bagainst%2BTriple-Negative%2BBreast%2BCancer%26numPages%3D9%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2264%26publicationDate%3DMarch%2B2015">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b00078"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1688</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">25</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b00078" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Selective, Nontoxic CB2 Cannabinoid o-Quinone with in Vivo Activity against Triple-Negative Breast Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Paula&quot;,&quot;last_name&quot;:&quot;Morales&quot;},{&quot;first_name&quot;:&quot;Sandra&quot;,&quot;last_name&quot;:&quot;Blasco-Benito&quot;},{&quot;first_name&quot;:&quot;Clara&quot;,&quot;last_name&quot;:&quot;Andradas&quot;},{&quot;first_name&quot;:&quot;María&quot;,&quot;last_name&quot;:&quot;Gómez-Cañas&quot;},{&quot;first_name&quot;:&quot;Juana&quot;,&quot;last_name&quot;:&quot;María Flores&quot;},{&quot;first_name&quot;:&quot;Pilar&quot;,&quot;last_name&quot;:&quot;Goya&quot;},{&quot;first_name&quot;:&quot;Javier&quot;,&quot;last_name&quot;:&quot;Fernández-Ruiz&quot;},{&quot;first_name&quot;:&quot;Cristina&quot;,&quot;last_name&quot;:&quot;Sánchez&quot;},{&quot;first_name&quot;:&quot;Nadine&quot;,&quot;last_name&quot;:&quot;Jagerovic&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;20&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;58&quot;,&quot;pages&quot;:&quot;2256-2264&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b00078&quot;},&quot;abstract&quot;:&quot;Triple-negative breast cancer (TNBC) represents a subtype of breast cancer characterized by high aggressiveness. There is no current targeted therapy for these patients whose prognosis, as a group, is very poor. Here, we report the synthesis and evaluation of a potent antitumor agent in vivo for this type of breast cancer designed as a combination of quinone/cannabinoid pharmacophores. This new compound (10) has been selected from a series of chromenopyrazolediones with full selectivity for the nonpsychotropic CB2 cannabinoid receptor and with efficacy in inducing death of human TNBC cell lines. The dual concept quinone/cannabinoid was supported by the fact that compound 10 exerts antitumor effect by inducing cell apoptosis through activation of CB2 receptors and through oxidative stress. Notably, it did not show either cytotoxicity on noncancerous human mammary epithelial cells nor toxic effects in vivo, suggesting that it may be a new therapeutic tool for the management of TNBC.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b00078&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00078" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b00078&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00078" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b00078&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00078" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b00078&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00078&amp;href=/doi/10.1021/acs.jmedchem.5b00078" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b00078" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b00078" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b00078%26sid%3Dliteratum%253Aachs%26pmid%3D25671648%26genre%3Darticle%26aulast%3DMorales%26date%3D2015%26atitle%3DSelective%252C%2BNontoxic%2BCB2%2BCannabinoid%2Bo-Quinone%2Bwith%2Bin%2BVivo%2BActivity%2Bagainst%2BTriple-Negative%2BBreast%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D58%26issue%3D5%26spage%3D2256%26epage%3D2264%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/58/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jmcmar.2015.58.issue-5/20150312/jmcmar.2015.58.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/medium/jm-2015-00078c_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/large/jm-2015-00078c_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00078&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Triple-negative breast cancer (TNBC) represents a subtype of breast cancer characterized by high aggressiveness. There is no current targeted therapy for these patients whose prognosis, as a group, is very poor. Here, we report the synthesis and evaluation of a potent antitumor agent in vivo for this type of breast cancer designed as a combination of quinone/cannabinoid pharmacophores. This new compound (<b>10</b>) has been selected from a series of chromenopyrazolediones with full selectivity for the nonpsychotropic CB<sub>2</sub> cannabinoid receptor and with efficacy in inducing death of human TNBC cell lines. The dual concept quinone/cannabinoid was supported by the fact that compound <b>10</b> exerts antitumor effect by inducing cell apoptosis through activation of CB<sub>2</sub> receptors and through oxidative stress. Notably, it did not show either cytotoxicity on noncancerous human mammary epithelial cells nor toxic effects in vivo, suggesting that it may be a new therapeutic tool for the management of TNBC.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38425" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38425" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Besides their well-known palliative actions in the treatment of chemotherapy-associated unwanted effects,<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> cannabinoids have also demonstrated antitumor effects in numerous in vitro and in vivo models of cancer. In general, the activity of cannabinoids can largely be accounted for by their effects on the endocannabinoid system, which is currently becoming a very attractive target for anticancer therapies.<a onclick="showRef(event, 'ref3 ref4 ref5 ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6 ref7 ref8">(3-8)</a> As reported by various research groups, cannabinoids can reduce tumor growth and progression by modulating cancer cell proliferation and tumor angiogenesis and metastasis among other cancer hallmarks.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The specific mechanisms by which cannabinoids inhibit tumor growth have not been fully elucidated, although it is known that these mechanisms of action seem to depend on the specific type of tumor. In addition, there is evidence of upregulation of cannabinoid receptors and endocannabinoids in some tumor tissues compared to the corresponding normal tissues.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">The antitumor properties of some phytocannabinoids [mainly Δ<sup>9</sup>-tetrahydrocannabinol (Δ<sup>9</sup>-THC) and cannabidiol (CBD)],<a onclick="showRef(event, 'ref9 ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11 ref12">(9-12)</a> endocannabinoids [mainly anandamine (AEA) ],<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and different synthetic cannabinoids (WIN55,212-2, HU-210, CP 55,940, JWH-133, and JWH-105, among others) have been reported<a onclick="showRef(event, 'ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16">(14-16)</a> for a variety of tumor cell lines in culture and different animal models of cancer. Despite the recent advances in the field of cannabinoid ligands as antitumor agents, the clinical development of these compounds has been very limited likely due to their psychoactive properties, which are produced by the activation of CB<sub>1</sub> receptors expressed in the central nervous system. Importantly, CB<sub>2</sub> receptors are mostly located in the immune system and poorly expressed in the brain, and therefore, their activation does not trigger psychoactivity. Therefore, considerable efforts have been recently focused on the therapeutic potential of CB<sub>2</sub> ligands.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> If we refer to the anticancer application, most of the antitumor cannabinoids studied so far activate CB<sub>1</sub> and CB<sub>2</sub> receptors, and few of them (JWH-015,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> JWH-133,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> KM-233,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> HU-308<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a>) are only partially selective for the CB<sub>2</sub> receptor over the CB<sub>1</sub> receptor. Therefore, the design, synthesis, and functional characterization of fully selective CB<sub>2</sub> agonists may constitute an interesting strategy to explore the antitumor potential of cannabinoids, avoiding the potential clinical problems associated with CB<sub>1</sub> activation.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><div class="NLM_p">Triple-negative breast cancer (TNBC) is a subtype of breast cancer characterized by the absence of immunohistochemical expression of estrogen, progesterone, and HER2 receptors.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Although this population accounts for a low percentage of all breast tumors, it represents a disproportionate number of deaths.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> This is mainly due to the high aggressiveness of these tumors and to the lack of targeted and effective therapies. Therefore, and despite the high responsiveness of some individuals, this group of patients has a very poor prognosis.<a onclick="showRef(event, 'ref23 ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25 ref26">(23-26)</a> For this reason, the discovery of new targets and drugs for the treatment of this disease is an urgent and essential clinical challenge.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> In this context, the therapeutic potential of cannabinoids, in particular those targeting selectively the different cannabinoid receptors, has been recently explored as a new hope for TNBC patients.<a onclick="showRef(event, 'ref11 ref28'); return false;" href="javascript:void(0);" class="ref ref11 ref28">(11, 28)</a></div><div class="NLM_p last">Our approach involves multitarget drugs for TNBC relying on molecules whose structure includes cannabinoid and quinone features in a single chemical entity. We previously designed CB<sub>1</sub> cannabinoid <i>p</i>-quinones as antitumor agents for prostate cancer.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The results obtained encouraged us to explore cannabinoid <i>o</i>- and <i>p</i>-quinones in TNBC in vitro and in vivo models.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75184" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75184" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Chemistry</h3><div class="NLM_p">The initial 7-(1′,1′-dimethylheptyl)-1,4-dihydro-4,4-dimethylchromeno[4,3-<i>c</i>]pyrazol-9-ols <b>4</b>–<b>7</b> were synthesized from 5-(1′,1′-dimethyl-<i>n</i>-heptyl)-1,3-dihydroxybenzene (<b>1</b>) following the procedures previously reported by us.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a> outlines the synthesis of the <i>o</i>- and <i>p</i>-chromenopyrazolediones <b>8</b>–<b>13</b>. The regiocontrolled oxidation of the starting chromenopyrazoles to the corresponding 1,2- and 1,4-quinones was achieved by reaction under mild conditions with hypervalent iodine reagents.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Only a few methods have been reported for the preparation of <i>o</i>-quinones by oxidation of phenols. In 2002, Pettus<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> described the use of 2-iodoxybenzoic acid (IBX) as a regioselective oxidant of phenols. Since then, IBX-mediated oxidations have been extended to polyaromatic <i>o</i>-quinones.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33, 34)</a> This hypervalent iodine reagent was efficient in our hands for the preparation of the desired regioselective <i>o</i>-chromenopyrazoldiones <b>8</b>–<b>10</b>. The <i>p</i>-quinone derivatives <b>11</b>–<b>13</b> were conveniently prepared in the presence of [bis(trifluoroacetoxy)iodo]benzene (BTIB) as previously reported by us.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/medium/jm-2015-00078c_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/large/jm-2015-00078c_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Oxidation of Chromenopyrazoles to the Corresponding Quinone Derivatives <b>8</b>–<b>13</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/large/jm-2015-00078c_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00078&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reaction conditions: (i) 3,3-dimethylacrylic acid, CH<sub>3</sub>SO<sub>3</sub>H, P<sub>2</sub>O<sub>5</sub>, 70 °C, microwave (MW), 10 min; (ii) NaH, THF, MW, 46 °C, 20 min, then ethyl formate, THF, MW, 46 °C, 20 min; (iii) 2-iodoxybenzoic acid, DMF, 30 min, room temperature; (iv) [bis(trifluoroacetoxy)iodo]benzene, MeCN/H<sub>2</sub>O (6:1), 15 min, room temperature.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Cannabinoid Receptor Affinity</h3><div class="NLM_p">The affinities of the chromenopyrazolediones <b>8</b>–<b>13</b> for the cannabinoid receptors were determined through radioligand competition assays. Their ability to displace [<sup>3</sup>H]CP55940 from human cannabinoid CB<sub>1</sub> or CB<sub>2</sub> receptors (<i>h</i>CB<sub>1</sub>, <i>h</i>CB<sub>2</sub>) transfected into HEK293 EBNA cells was assessed. Standard cannabinoid ligand WIN55,212-2 was also tested for appraisal with compounds <b>8</b>–<b>13</b>. Initially, the compounds were screened at a concentration of 40 μM. The affinity constant (<i>K</i><sub>i</sub>) of compounds able to displace the radioligand by more than 70% was determined from concentration–effect curves. These <i>K</i><sub>i</sub> values are reported in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Binding Affinity of Chromenopyrazolediones <b>8</b>–<b>13</b> and the Reference Cannabinoid WIN55,212-2 for <i>h</i>CB<sub>1</sub> and <i>h</i>CB<sub>2</sub> Cannabinoid Receptors</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center"><i>K</i><sub>i</sub><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center"><i>h</i>CB<sub>1</sub></th><th class="colsep0 rowsep0" align="center"><i>h</i>CB<sub>2</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">>40000</td><td class="colsep0 rowsep0" align="left">398 ± 49</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">>40000</td><td class="colsep0 rowsep0" align="left">597 ± 77</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">>40000</td><td class="colsep0 rowsep0" align="left">529 ± 26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">324 ± 235</td><td class="colsep0 rowsep0" align="left">134 ± 21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">14180 ± 5638</td><td class="colsep0 rowsep0" align="left">672 ± 191</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">8520 ± 3891</td><td class="colsep0 rowsep0" align="left">3665 ± 878</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">WIN55,212-2</td><td class="colsep0 rowsep0" align="left">45.6 ± 8.6</td><td class="colsep0 rowsep0" align="left">3.7 ± 0.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Values were obtained from competition curves using [<sup>3</sup>H]CP55940 as the radioligand for <i>h</i>CB<sub>1</sub> and <i>h</i>CB<sub>2</sub> cannabinoid receptors and are expressed as the mean ± SEM of at least three experiments each performed in triplicate.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Reference <a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">29</a>.</p></div></div></div><div class="NLM_p last"><i>o</i>-Chromenopyrazolediones <b>8</b>–<b>10</b> are fully selective toward CB<sub>2</sub> cannabinoid receptors. Their lack of affinity for CB<sub>1</sub> receptors (<i>K</i><sub>i</sub> values higher than 40 μM) eliminates any psychotropic side effect that would be derived from activation of central CB<sub>1</sub> receptors. To our knowledge, <i>o</i>-chromenopyrazolediones are the first fully selective CB<sub>2</sub> cannabinoid quinones reported so far. Quinone isomers afforded significant differences in their ability to bind the cannabinoid receptors. <i>p</i>-Chromenopyrazolediones <b>11</b>–<b>13</b> display affinity<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> for both cannabinoid receptors, compound <b>8</b> providing the best binding values for both receptors.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> ADME Parameters in silico</h3><div class="NLM_p">Taking into account the fact that inappropriate absorption, distribution, metabolism, and excretion (ADME) are among the main determinants of drug development failures, these properties have been considered at this early stage of the drug discovery process. Nowadays, in silico approaches are widely accepted because of their fast and precise predictive potential.<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35, 36)</a> Pharmacokinetic properties of compounds <b>8</b>–<b>13</b> were predicted using QikProp (implemented in Maestro software) on each global minimum energy conformer. As presented in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, chromenopyrazolediones follow Lipinski and Jorgensen pharmacokinetics rules.<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37, 38)</a> Due to their lipophilic nature, the solubility of cannabinoids is a great challenge. Interestingly, the cannabinoid quinones described herein display adequate solubility values. Almost all the predicted properties of the tested compounds are within the ranges predicted by QikProp for 95% of known oral drugs (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). These data indicate that chromenopyrazolediones present a satisfactory druggability profile.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Physicochemical Descriptors Calculated on the Global Minimum Energy Conformer of Compounds <b>8</b>–<b>13</b> by QikProp 3.5 Integrated in Maestro (Schrödinger, LLC, New York)</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compd</th><th class="colsep0 rowsep0" align="center" char=".">QPlogS<a class="ref internalNav" href="#t2fn2" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">QlogBB<a class="ref internalNav" href="#t2fn3" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">QPlogHERG<a class="ref internalNav" href="#t2fn4" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">QPPCaco<a class="ref internalNav" href="#t2fn5" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">human oral absorption in GI<a class="ref internalNav" href="#t2fn6" aria-label="e">e</a> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>8</b></td><td class="colsep0 rowsep0" align="char" char=".">–5.35</td><td class="colsep0 rowsep0" align="char" char=".">–1.09</td><td class="colsep0 rowsep0" align="char" char=".">–4.90</td><td class="colsep0 rowsep0" align="char" char=".">611</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>9</b></td><td class="colsep0 rowsep0" align="char" char=".">–5.62</td><td class="colsep0 rowsep0" align="char" char=".">–0.69</td><td class="colsep0 rowsep0" align="char" char=".">–5.11</td><td class="colsep0 rowsep0" align="char" char=".">1562</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>10</b></td><td class="colsep0 rowsep0" align="char" char=".">–5.99</td><td class="colsep0 rowsep0" align="char" char=".">–0.65</td><td class="colsep0 rowsep0" align="char" char=".">–5.03</td><td class="colsep0 rowsep0" align="char" char=".">1976</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>11</b></td><td class="colsep0 rowsep0" align="char" char=".">–5.15</td><td class="colsep0 rowsep0" align="char" char=".">–1.01</td><td class="colsep0 rowsep0" align="char" char=".">–4.69</td><td class="colsep0 rowsep0" align="char" char=".">666</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>12</b></td><td class="colsep0 rowsep0" align="char" char=".">–5.36</td><td class="colsep0 rowsep0" align="char" char=".">–0.62</td><td class="colsep0 rowsep0" align="char" char=".">–4.90</td><td class="colsep0 rowsep0" align="char" char=".">1701</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>13</b></td><td class="colsep0 rowsep0" align="char" char=".">–5.78</td><td class="colsep0 rowsep0" align="char" char=".">–0.63</td><td class="colsep0 rowsep0" align="char" char=".">–5.23</td><td class="colsep0 rowsep0" align="char" char=".">1985</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn2"><div class="footnote" id="t2fn2"><sup>a</sup><p class="last">Predicted aqueous solubility [range of 95% of drugs −6.5 to +0.5].</p></div><div class="footnote" id="t2fn3"><sup>b</sup><p class="last">Predicted log of the brain/blood partition coefficient [range of 95% of drugs −3.0 to +1.2].</p></div><div class="footnote" id="t2fn4"><sup>c</sup><p class="last">HERG K+ channel blockage (log IC<sub>50</sub>) [concern below −5].</p></div><div class="footnote" id="t2fn5"><sup>d</sup><p class="last">Apparent Caco-2 cell permeability (nm/s) [<25, poor; >500, excellent].</p></div><div class="footnote" id="t2fn6"><sup>e</sup><p class="last">Human oral absorption in gastrointestinal tract [<25% is poor].</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> In Vitro Antiproliferative Activity</h3><div class="NLM_p">The antiproliferative activity of chromenopyrazolediones <b>8</b>–<b>13</b> was assessed against a human TNBC cell line (MDA-MB-231). Cell cultures were treated with different doses of the tested compound (<b>8</b>–<b>13</b>) for 48 h, and cell viability was then analyzed by colorimetric measurements using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). All the cannabinoid quinone derivatives (<b>8</b>–<b>13</b>) displayed potent growth inhibitory effects on triple-negative MDA-MB-231 cells (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) with low micromolar IC<sub>50</sub> values (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>).</div><figure id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/medium/jm-2015-00078c_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/large/jm-2015-00078c_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Dose–response curves of the antiproliferative effect of chromenopyrazolediones <b>8</b>–<b>13</b> against the human breast cancer cell line MDA-MB-231.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/large/jm-2015-00078c_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00078&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Half-Maximum Inhibitory Concentration (IC<sub>50</sub>) Values for Compounds <b>8</b>–<b>13</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="char" char="." /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compd</th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">compd</th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>8</b></td><td class="colsep0 rowsep0" align="char" char="±">8.5 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="."><b>11</b></td><td class="colsep0 rowsep0" align="char" char="±">8.2 ± 1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>9</b></td><td class="colsep0 rowsep0" align="char" char="±">5.0 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="."><b>12</b></td><td class="colsep0 rowsep0" align="char" char="±">5.8 ± 0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>10</b></td><td class="colsep0 rowsep0" align="char" char="±">2.8 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="."><b>13</b></td><td class="colsep0 rowsep0" align="char" char="±">2.5 ± 0.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Values are the mean ± SE of three independent experiments performed in triplicate.</p></div></div></div><div class="NLM_p">As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a> and Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>, compounds <b>10</b> and <b>13</b> are the most potent inhibitors of cell proliferation. Due to its antiproliferative capacity and its CB<sub>2</sub>-selective profile, compound <b>10</b> was selected to investigate the mode of action and to validate the concept quinone/cannabinoid.</div><div class="NLM_p last">Since triple-negative breast cancer is a very heterogeneous disease itself,<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39, 40)</a> we first analyzed whether chromenopyrazoledione <b>10</b> was able to decrease the viability of other TNBC cell lines. The additional three TNBC cell lines tested (SUM149, SUM159, and MDA-MB-468) were sensitive to compound <b>10</b> as well (see the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>), with IC<sub>50</sub> values of 4.6, 4.1, and 17.3 μM, respectively.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Cytotoxicity on Human Normal Mammary Epithelial Cells</h3><div class="NLM_p">Selective toxicity for cancer versus noncancer cells is one of the main challenges of anticancer therapies. For this reason, we examined the growth inhibitory activity of compound <b>10</b> against human mammary epithelial cells (HMECs). At all tested concentrations, compound <b>10</b> did not display antiproliferative activity in this nontransformed mammary epithelial cell line (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). Compound <b>10</b> therefore demonstrated effective inhibition of TNBC cell growth in a concentration range that does not affect the proliferation of their nontransformed counterparts.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/medium/jm-2015-00078c_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/large/jm-2015-00078c_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Effect of compound <b>10</b> on the viability of normal HMECs. HMECs were treated with increasing concentrations of the drug. Cell viability was determined 48 h after treatment. Values are the mean ± SE of three independent experiments performed in duplicate. Data were assessed by one-way analysis of variance followed by the Student–Newman–Keuls test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/large/jm-2015-00078c_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00078&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Expression of CB<sub>2</sub> Receptors in Normal and Cancer Cells</h3><div class="NLM_p">To determine whether a different expression of CB<sub>2</sub> is the molecular reason underlying the selectivity of compound <b>10</b> for cancer cells, we analyzed CB<sub>2</sub> mRNA levels in all the cell lines tested in this study by real-time quantitative polymerase chain reaction (RTQ-PCR). CB<sub>2</sub> mRNA was detected in both transformed and nontransformed cells, but no correlation was observed between its relative expression and responsiveness to compound <b>10</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). These results suggest that a differential expression of the cannabinoid receptor is not the main reason for the lack of sensitivity of nontransformed cells to compound <b>10</b>.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/medium/jm-2015-00078c_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/large/jm-2015-00078c_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Expression of CB<sub>2</sub> in transformed and nontransformed breast cancer cell lines. CB<sub>2</sub> mRNA expression in the indicated cell lines, as determined by real-time quantitative PCR. Results are expressed as arbitrary units vs CB<sub>2</sub> mRNA expression in HMECs that has been set as 1 unit.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/large/jm-2015-00078c_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00078&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Molecular Mechanism Underlying the Antiproliferative Effect of Compound <b>10</b></h3><div class="NLM_p">With the aim of unveiling the molecular mechanisms involved in the growth inhibitory activity of compound <b>10</b>, we studied its antiproliferative effect in the presence of different pharmacological tools [the CB<sub>1</sub>-selective antagonist SR141716 (SR1), the CB<sub>2</sub>-selective antagonist SR144528 (SR2), the GPR55-selective antagonist CDI16020046 (CDI), and the antioxidant α-tocopherol (α-Toc)]. We first verified that these compounds had no effect on their own on MDA-MB-231 cell viability (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). Then cells were preincubated for 1 h with each of the mentioned compounds and then challenged with compound <b>10</b> for 48 h at IC<sub>50</sub>. As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>, SR2 and α-Toc were able to significantly prevent the inhibition of cell viability induced by <b>10</b>, indicating that activation of the CB<sub>2</sub> receptor and generation of reactive oxygen species (ROS) were involved in the action of compound <b>10</b>. This experiment confirms the CB<sub>2</sub> agonist nature and ROS production of compound <b>10</b>. Conversely, neither SR1 nor CID altered the effect of compound <b>10</b> on cell viability, suggesting that neither CB<sub>1</sub> nor GPR55 is a target of this compound (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>).</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/medium/jm-2015-00078c_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/large/jm-2015-00078c_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Molecular mechanisms involved in the growth inhibitory activity of compound <b>10</b>. MDA-MB-231 cell viability was determined by the MTT test. The CB<sub>1</sub>-selective antagonist is SR141716 (SR1), the CB<sub>2</sub>-selective antagonist is SR144528 (SR2), the GPR55-selective antagonist is CID16020046 (CID), and the antioxidant is α-tocopherol (α-Toc). The results represent the mean ± SE of three different experiments performed in triplicate. Data were assessed by two-way analysis of variance followed by the Student–Newman–Keuls test (*, <i>p</i> < 0.05 vs vehicle-treated cells; **, <i>p</i> < 0.01 vs vehicle-treated cells; #, <i>p</i> < 0.05 versus the compound alone).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/large/jm-2015-00078c_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00078&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To determine whether the decrease in cell viability elicited by compound <b>10</b> involves the induction of cancer cell death by apoptosis, we analyzed the levels of caspase-3 by Western immunoblotting. The assay was performed following a 48 h treatment of cells with the IC<sub>50</sub> of compound <b>10</b>. Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a> shows an increase in active (i.e., cleavage) caspase-3 in response to compound <b>10</b>, which confirms a proapoptotic effect of <b>10</b> on the TNBC cell line.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/medium/jm-2015-00078c_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/large/jm-2015-00078c_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Analysis of caspase-3 protein expression. Western blot analysis of caspase 3 after 48 h of exposure to compound <b>10</b> at IC<sub>50</sub> in MDA-MB-231 cells. The graph represents the densimetric analysis of protein levels. The optical density is relative to that of control cells set as 1. <i>n</i> = 3. Data were assessed by Student’s <i>t</i> test (*, <i>p</i> < 0.05 vs vehicle-treated cells).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/large/jm-2015-00078c_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00078&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> In Vivo Antitumor Activity</h3><div class="NLM_p">On the basis of its potent antiproliferative effect and its low toxicity in HMEC cells, compound <b>10</b> was selected for in vivo studies. To evaluate its capacity to inhibit TNBC growth, tumor xenografts were generated in nude mice by subcutaneous inoculation of MDA-MB-231 human breast adenocarcinoma cells. Mice were treated intraperitoneally three times a week for 4 weeks with vehicle or 2 mg/kg compound <b>10</b>. As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>, compound <b>10</b> was able to effectively reduce the growth of triple-negative xenografts. Consequently, the final tumor volume and tumor weight were significantly lower in mice treated with compound <b>10</b>. Interestingly, the histopathological analysis of animal organs (liver, spleen, lungs, and heart) showed no sign of toxicity in these animals (data not shown).</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/medium/jm-2015-00078c_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/large/jm-2015-00078c_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>10</b> reduces tumor growth in vivo. (A) Effect of intraperitoneal administration of <b>10</b> on the growth of tumor xenografts generated in nude mice by injection of MDA-MB-231 human breast adenocarcinoma cells (mean ± SEM). The images show representative vehicle- and compound <b>10</b>-treated tumors. (B) Effect of <b>10</b> administration on tumor weight. Data were assessed by two-way (with repeated measures) analysis of variance followed by the Student–Newman–Keuls test (*, <i>p</i> < 0.05 vs vehicle-treated tumors).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/large/jm-2015-00078c_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00078&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33071" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33071" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cancer treatment is among the most promising therapeutic uses for cannabinoids,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> based on solid preclinical evidence clearly showing their antitumor actions in different cell and animal models of cancer.<a onclick="showRef(event, 'ref6 ref7 ref8 ref41'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8 ref41">(6-8, 41)</a> However, so far, only a pilot clinical trial has been reported for this indication in which Δ<sup>9</sup>-THC showed safety and a modest antitumor activity after intracerebral treatment of patients with recurrent glioblastoma multiforme,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> whereas a few more are presently in progress. Meanwhile, numerous pharmacological and biochemical studies are exploring in detail the use of cannabinoids in different type of tumors using several methodological strategies.<a onclick="showRef(event, 'ref9 ref10 ref11 ref12 ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11 ref12 ref13 ref14 ref15 ref16">(9-16)</a></div><div class="NLM_p">Since cancer is a complex multifactorial physiopathology triggered by deregulation of diverse cellular systems, successful cancer treatments should involve the modulation of multiple signaling pathways using combinations of different agents with different mechanisms of action.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43, 44)</a> This is why we associated the antitumor action of quinones as producers of reactive oxygen species (ROS) with the antitumor cannabinoid activity in a single molecule. Quinone derivatives of phytocannabinoid have already been described;<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> however, their antiproliferative effect was not attributed to a mechanism involving cannabinoid receptors since they did not bind to any of them.</div><div class="NLM_p">Due to the versatility of the chromenopyrazole scaffold for cannabinoid ligands as previously reported by us,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> we next explored its quinone derivatives. We recently reported the synthesis of <i>p</i>-quinone chromenopyrazoles that were shown to be mixed CB<sub>1</sub>/CB<sub>2</sub> receptor ligands with antiproliferative effects through CB<sub>1</sub> receptor activation for prostate cancer.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> In the present study, <i>o</i>-quinone chromenopyrazoles <b>8</b>–<b>10</b> have been prepared using the appropriate regioselective oxidant, IBX. All of the <i>p</i>- and <i>o</i>-quinone chromenopyrazoles (<b>11</b>–<b>13</b>) displayed potent antiproliferative effects on triple-negative MDA-MB-231 breast cancer cells. They also showed a satisfactory druggability profile. The most interesting feature was that the <i>o</i>-quinones <b>8</b>–<b>10</b> were shown to be fully selective for the <i>h</i>CB<sub>2</sub> receptor, eliminating any psychotropic effect due to activation of the CB<sub>1</sub> receptor. Therefore, the absence of centrally mediated CB<sub>1</sub> effects of the <i>ortho</i> compounds <b>8</b>–<b>10</b> represents high value for a potential clinical application. This is why one of these compounds (<b>10</b>) was selected to perform mechanistic and in vivo studies.</div><div class="NLM_p">Compound <b>10</b> was evaluated in three additional TNCB cell lines due to the heterogeneity of cancer. It was also tested in normal mammary epithelial cells for toxicity evaluation. Interestingly, while compound <b>10</b> decreased the viability of breast cancer cells, it did not affect that of normal mammary epithelial cells. The selective toxicity of cannabinoids toward cancer cells versus normal cells was previously observed in phytocannabinoids such as Δ<sup>9</sup>-THC.<a onclick="showRef(event, 'ref9 ref12'); return false;" href="javascript:void(0);" class="ref ref9 ref12">(9, 12)</a> Different expression levels could be a molecular reason for the selectivity of compound <b>10</b> for cancer cells. However, real-time quantitative PCR analysis showed no correlation between the relative expression of the CB<sub>2</sub> receptor and responsiveness to compound <b>10</b>. Another explanation of this selectivity could be that the redox status of cancer cells differs from that of normal cells. Therefore, tumor cells are more sensitive to oxidative stress than normal cells. Even though high ROS levels might be detrimental for normal cells as reviewed recently by Gorrini et al.,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> in our system, compound <b>10</b> proved to be very efficient in reducing the viability of cancer cells in a concentration range that did not affect the viability of nontransformed cells.</div><div class="NLM_p">Apart from Δ<sup>9</sup>-THC, other cannabinoids have been reported to possess antitumorigenic activity for TNBC.<a onclick="showRef(event, 'ref9 ref12'); return false;" href="javascript:void(0);" class="ref ref9 ref12">(9, 12)</a> The most studied are JWH-133,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> WIN55,212-2, and cannabidiol even though the molecular bases of the latter are probably not related to activation of cannabinoid receptors but are associated with ROS production.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> In this context, it was of interest to study the mechanisms that contribute to the response of compound <b>10</b>. By using selective antagonists of the CB<sub>2</sub> and CB<sub>1</sub> receptors in vitro, we confirmed that the antiproliferative effects of <b>10</b> were mediated by CB<sub>2</sub> receptor activation but not by CB<sub>1</sub> receptor activation. Thus, despite the significant but modest CB<sub>2</sub> affinity of compound <b>10</b> (submicromolar range), it showed antitumor activity through this receptor. These findings are in agreement with the antiproliferative studies performed with Δ<sup>9</sup>-THC (IC<sub>50</sub> = 5 μM) in the same cell line.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Of interest, the results obtained using an antioxidant agent support the fact that compound <b>10</b> exerts part of its action through the induction of oxidative stress, validating the proposed concept ROS/cannabinoid activity. We also showed that the putative cannabinoid receptor GRP55,<a onclick="showRef(event, 'ref47 ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref47 ref48 ref49">(47-49)</a> highly expressed in the triple-negative MDA-MB-231 cell line, was not involved in compound <b>10</b> antitumor action.</div><div class="NLM_p">Apoptosis is the main mechanism of cannabinoid- and quinone-induced cell death. The process of cell death produced by compound <b>10</b> has been confirmed to be apoptotic by measuring caspase-3 protein expression, a marker of apoptosis, by Western blotting.</div><div class="NLM_p last">The antiproliferative effect of compound <b>10</b> was also reproduced in vivo. Upon 4 weeks of treatment, significant reduction in tumor xenograft growth (MDA-MB-231) was observed. Moreover, the lack of toxicity of compound <b>10</b> in normal cells was further confirmed in vivo. Thus, the histopathological analysis of different organs of mice treated with compound <b>10</b> during one month revealed no signs of toxicity.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06017" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06017" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Although cannabinoids have gained broad interest in the field of cancer research, they have not yet been widely studied in clinical assays. One of the main reasons is the psychotropic effects they produce by activation of the CB<sub>1</sub> receptors expressed in the brain. Our study provides the first fully selective CB<sub>2</sub> cannabinoid quinone (<b>10</b>) producing antitumor responses in vitro and in vivo in TNBC cancer cells via CB<sub>2</sub> activation and ROS production without producing toxic effects.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47681" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47681" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Chemistry</h3><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> General Methods and Materials</h4><div class="NLM_p last">All commercially available reagents and solvents were used without further purification. Column chromatography was performed using silica gel 60 (230–400 mesh). The purity of the final compounds as determined by HPLC/MS and elemental analyses was ≥95%. Analytical HPLC/MS analysis was performed on a Waters 2695 HPLC system equipped with a photodiode array 2996 coupled to a Micromass ZQ 2000 mass spectrometer (ESI-MS) using a reversed-phase SunFire column (C-18, 4.6 × 50 mm, 3.5 μm) and a 5 min gradient of solvents A (MeCN/0.08% formic acid) and B (H<sub>2</sub>O/1% formic acid) visualizing at λ = 254 nm. Elemental analyses of all synthesized compounds were performed using a LECO CHNS-932 apparatus. Deviations of the elemental analysis results from the calculated values are within ±0.4%. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker 300 (300 and 75 MHz) at 25 °C. Samples were prepared as solutions in deuterated solvent and referenced to an internal nondeuterated solvent peak. Chemical shifts are expressed in parts per million (δ) downfield of tetramethylsilane. Melting points were determined on an MP70 Mettler Toledo apparatus. Chromenopyrazoles <b>4</b>–<b>7</b> were prepared according to procedures previously published by us.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The preparation of compounds <b>11</b>–<b>13</b> has been reported by us.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div></div><div id="sec5_1_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 7-(1′,1′-Dimethylheptyl)-1,4-dihydro-4,4-dimethylchromeno[4,3-<i>c</i>]pyrazole-8,9-dione (<b>8</b>)</h4><div class="NLM_p last">To a solution of 7-(1′,1′-dimethylheptyl)-1,4-dihydro-4,4-dimethylchromeno[4,3-<i>c</i>]pyrazol-9-ol (<b>4</b>) (30 mg, 0.08 mmol) dissolved in DMF (1.5 mL) was added solid IBX (36 mg, 0.13 mmol), and the resulting mixture was stirred at room temperature for 30 min. The mixture was then extracted with EtOAc and washed with water and brine. The solvent was removed under vacuum. The resulting residue was purified by chromatography on a silica gel column (hexane/EtOAc, 2:1) to furnish the title compound <b>8</b> as a red solid (9 mg, 29% yield): mp 90.2 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.03 (br s, 1H, NH), 7.66 (s, 1H, 3-H), 7.12 (s, 1H, 6-H), 1.65 (s, 6H, OC(CH<sub>3</sub>)<sub>2</sub>), 1.51–1.49 (m, 2H, 2′-H), 1.37 (s, 6H, C(CH<sub>3</sub>)<sub>2</sub>), 1.29–1.27 (m, 6H, 3′-H, 4′-H, 5′-H), 1.21–1.18 (m, 2H, 6′H), 0.84 (t, <i>J</i> = 7.1 Hz, 3H, 7′-H) ppm; <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 180.1 (9-C), 179.6 (8-C), 164.4 (5a-C), 163.8 (7-C), 142.0 (6-C), 138.5 (9b-C), 131.5 (3-C), 130.3 (3a-C), 110.9 (9a-C), 79.7 (O<i>C</i>(CH<sub>3</sub>)<sub>2</sub>), 45.9 (2′-C), 31.2 (1′-C), 30.0, 29.3, and 28.1 (3′-C, 4′-C, and 5′-C), 25.8 (C(<i>C</i>H<sub>3</sub>)<sub>2</sub>), 24.9 (OC(<i>C</i>H<sub>3</sub>)<sub>2</sub>), 22.5 (6′-C), 13.6 (7′-C) ppm; HPLC/MS [A, 80% →100%] <i>t</i><sub>R</sub> = 2.03 min (99%); MS (ES<sup>+</sup>, <i>m</i>/<i>z</i>) 357 [M + H]<sup>+</sup>. Anal. Calcd for C<sub>21</sub>H<sub>28</sub>N<sub>2</sub>O<sub>3</sub>: C, 70.76 ; H, 7.92. Found: C, 70.41 ; H, 7.57.</div></div><div id="sec5_1_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 7-(1′,1′-Dimethylheptyl)-2,4-dihydro-2,4,4-trimethylchromeno[4,3-<i>c</i>]pyrazole-8,9-dione (<b>9</b>)</h4><div class="NLM_p last">The title compound <b>9</b> was prepared from 7-(1′,1′-dimethylheptyl)-2,4-dihydro-2,4,4-trimethylchromeno[4,3-<i>c</i>]pyrazol-9-ol (<b>5</b>) (45 mg, 0.12 mmol) and IBX (53 mg, 0.18 mmol) by following the procedure described for <b>8</b>. Column chromatography on silica gel (hexanes/EtOAc, 1:1) afforded <b>9</b> as a red solid (11 mg, 24% yield): mp 86.1 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.28 (s, 1H, 3-H), 6.73 (s, 1H, 6-H), 3.89 (s, 3H, NCH<sub>3</sub>), 1.64 (s, 6H, OC(CH<sub>3</sub>)<sub>2</sub>), 1.57–1.55 (br s, 2H, 2′-H), 1.29 (s, 6H, C(CH<sub>3</sub>)<sub>2</sub>), 1.22–1.18 (m, 6H, 3′-H, 4′-H, 5′-H), 1.10–1.03 (m, 2H, 6′H), 0.81 (t, <i>J</i> = 7.0 Hz, 3H, 7′-H) ppm; <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 182.3 (9-C), 180.6 (8-C), 165.1 (5a-C), 160.3 (7-C), 139.8 (9b-C), 137.0 (6-C), 132.2 (3-C), 129.9 (3a-C), 113.8 (9a-C), 83.0 (O<i>C</i>(CH<sub>3</sub>)<sub>2</sub>), 42.3 (NCH<sub>3</sub>), 41.0 (2′-C), 33.1 (1′-C), 32.0, 30.9, and 29.6 (3′-C, 4′-C, and 5′-C), 28.1 (C(<i>C</i>H<sub>3</sub>)<sub>2</sub>), 22.9 (OC(<i>C</i>H<sub>3</sub>)<sub>2</sub>), 21.8 (6′-C), 14.1 (7′-C) ppm; HPLC/MS [A, 80% → 100%] <i>t</i><sub>R</sub> = 2.07 min (96%); MS (ES<sup>+</sup>, <i>m</i>/<i>z</i>) 371 [M + H]<sup>+</sup>. Anal. Calcd for C<sub>22</sub>H<sub>30</sub>N<sub>2</sub>O<sub>3</sub>: C, 71.32 ; H, 8.16. Found: C, 71.19; H 7.82.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 7-(1′,1′-Dimethylheptyl)-1-ethyl-1,4-dihydro-4,4-dimethylchromeno[4,3-<i>c</i>]pyrazole-8,9-dione (<b>10</b>)</h4><div class="NLM_p last">The title compound <b>10</b> was prepared from 7-(1′,1′-dimethylheptyl)-1-ethyl-1,4-dihydro-4,4-dimethylchromeno[4,3-<i>c</i>]pyrazol-9-ol (<b>6</b>) (20 mg, 0.05 mmol) and IBX (22 mg, 0.08 mmol) by following the procedure described for <b>5</b>. Column chromatography on silica gel (hexanes/EtOAc, 4:1) afforded <b>10</b> as a red solid (6 mg, 30% yield): mp 94.8 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.49 (s, 1H, 3-H), 7.11 (s, 1H, 6-H), 4.04 (q, <i>J</i> = 7.1 Hz, 2H, NC<i>H</i><sub>2</sub>CH<sub>3</sub>), 1.49 (s, 6H, OC(CH<sub>3</sub>)<sub>2</sub>), 1.35 (t, <i>J</i> = 7.1 Hz, 3H, NCH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.30–1.26 (m, 2H, 2′-H), 1.22 (s, 6H, C(CH<sub>3</sub>)<sub>2</sub>), 1.19–1.16 (m, 6H, 3′-H, 4′-H, 5′-H), 1.03–1.01 (br s, 2H, 6′-H), 0.87 (t, <i>J</i> = 6.9 Hz, 3H, 7′-H) ppm; <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 182.9 (9-C), 181.0 (8-C), 161.5 (5a-C), 159.3 (7-C), 138.2 (9b-C), 135.9 (6-C), 131.0 (3-C), 129.7 (3a-C), 112.3 (9a-C), 80.1 (O<i>C</i>(CH<sub>3</sub>)<sub>2</sub>), 47.1 (N<i>C</i>H<sub>2</sub>CH<sub>3</sub>), 40.6 (2′-C), 35.3 (1′-C), 31.1, 29.8, and 28.5 (3′-C, 4′-C, and 5′-C), 27.0 (OC(<i>C</i>H<sub>3</sub>)<sub>2</sub>), 25.3 (C(<i>C</i>H<sub>3</sub>)<sub>2</sub>), 22.1 (6′-C), 14.9 (NCH<sub>2</sub><i>C</i>H<sub>3</sub>), 13.7 (7′-C) ppm; HPLC/MS [A, 80% → 100%] <i>t</i><sub>R</sub> = 3.97 min (98%); MS (ES<sup>+</sup>, <i>m</i>/<i>z</i>) 385 [M + H]<sup>+</sup>. Anal. Calcd for C<sub>23</sub>H<sub>32</sub>N<sub>2</sub>O<sub>3</sub>: C, 71.84 ; H, 8.39. Found: C, 71.93; H 8.06.</div></div><div id="sec5_1_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 7-(1′,1′-Dimethylheptyl)-1,4-dihydro-4,4-dimethylchromeno[4,3-<i>c</i>]pyrazole-6,9-dione (<b>11</b>)<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></h4><div class="NLM_p last">Anal. Calcd for C<sub>21</sub>H<sub>28</sub>N<sub>2</sub>O<sub>3</sub>: C, 70.76 ; H, 7.92. Found: C, 71.03; H 8.24.</div></div><div id="sec5_1_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 7-(1′,1′-Dimethylheptyl)-2,4-dihydro-2,4,4-trimethylchromeno[4,3-<i>c</i>]pyrazole-6,9-dione (<b>12</b>)<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></h4><div class="NLM_p last">Anal. Calcd for C<sub>22</sub>H<sub>30</sub>N<sub>2</sub>O<sub>3</sub>: C, 71.32 ; H, 8.16. Found: C, 70.98; H 8.31.</div></div><div id="sec5_1_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 7-(1′,1′-Dimethylheptyl)-2-ethyl-2,4-dihydro-4,4-dimethylchromeno[4,3-<i>c</i>]pyrazole-6,9-dione (<b>13</b>)<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></h4><div class="NLM_p last">Anal. Calcd for C<sub>23</sub>H<sub>32</sub>N<sub>2</sub>O<sub>3</sub>: C, 71.84 ; H, 8.39. Found: C, 72.02; H 8.62.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> In Silico ADME Calculations</h4><div class="NLM_p last">A set of 34 physicochemical descriptors were computed using QikProp version 3.5 integrated in Maestro (Schrödinger, LLC, New York). The QikProp descriptors are shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>. The 3D conformations used in the calculation of QikProp descriptors were generated using the program Spartan ’08 (Wavefunction, Inc., Irvine, CA) as follows: The structure of each molecule was built from the fragment library available in the program. Then ab initio energy minimizations of each structure at the Hartree–Fock 6-31G* level were performed. A conformational search was next implemented using Molecular Mechanics (Monte Carlo method) followed by a minimization of the energy of each conformer calculated at the Hartree–Fock 6-31G* level. The global minimum energy conformer of each compound was used as input for ADME studies with QikProp.</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Pharmacological Assays</h3><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Binding Assays</h4><div class="NLM_p last">Membranes from transfected cells with human CB<sub>1</sub> or CB<sub>2</sub> expressed cannabinoid receptors (RBHCB1M400UA and RBXCB2M400UA) were supplied by PerkinElmer Life and Analytical Sciences (Boston, MA). The membrane protein added was 8 μg/well for CB<sub>1</sub> assays and 4 μg/well for CB<sub>2</sub> assays. The assay was developed in binding buffer (50 mM TrisCl, 5 mM MgCl<sub>2</sub>·H<sub>2</sub>O, 2.5 mM EDTA, 0.5 mg/mL BSA, pH 7.4 for CB<sub>1</sub> binding; 50 mM TrisCl, 5 mM MgCl<sub>2</sub>·H<sub>2</sub>O, 2.5 mM EGTA, 1 mg/mL BSA, pH 7.5 for CB<sub>2</sub> binding) in a final volume of 200 μL for CB<sub>1</sub> binding and 600 μL for CB<sub>2</sub> binding. The radioligand was [<sup>3</sup>H]CP55940 (PerkinElmer) used at a concentration of 0.8<i>K</i><sub>D</sub> nM following the recommendations indicated in a previous publication.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> The 96-well plates and tubes necessary for the experiment were previously siliconized with Sigmacote (Sigma). Membranes were suspended in the corresponding buffer and were incubated with the radioligand and each compound (10<sup>–4</sup>–10<sup>–11</sup> M) for 90 min at 30 °C. Nonspecific binding was determined with 10 μM WIN55212-2, and 100% binding of the radioligand to the membrane was determined by its incubation with membrane without any compound. Filtration was performed by a Harvester filtermate (PerkinElmer) with Filtermat A GF/C filters pretreated with 0.05% poly(ethylenimine). After filtering, the filter was washed nine times with ice-cold binding buffer and dried, and a melt-on scintillation sheet (Meltilex A, PerkinElmer) was melted onto it. Then radioactivity was quantified by a liquid scintillation spectrophotometer (Wallac MicroBeta Trilux, PerkinElmer). Competition binding data were analyzed by using the GraphPad Prism program, and <i>K</i><sub>i</sub> values are expressed as the mean ± SD of at least three experiments performed in triplicate for each point.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Cell Culture and Viability</h4><div class="NLM_p last">MDA-MB-231 cells were obtained from the American Type Culture Collection (ATCC; Manassas, VA) and maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 5 units/mL penicillin, and 5 mg/mL streptomycin. SUM149, SUM159, and MDA-MD-468 cells were kindly donated by Dr. Moreno-Bueno (Instituto de Investigaciones Biomédicas Alberto Sols, Madrid, Spain). SUM149 and SUM159 cells were maintained in Ham’s F-12 medium with 5% FBS, 5 μg/mL insulin, and 0.5 μg/mL hydrocortisone. MDA-MD-468 was maintained in DMEM with 10% FBS. HMECs were obtained from Cambrex and grown in mammary epithelial growth medium (Cambrex, East Rutherford, NJ) according to the manufacturer’s instructions. Cannabinoid ligands were prepared in DMSO. Control incubations had the corresponding DMSO content. The cells were cultured at a density of 5000 cells/cm<sup>2</sup> in a 24-well plate. They were transferred to a serum-free medium or a 0.5% FBS medium (HMECs) at least 6 h before treatment with the compounds at concentrations ranging from 0 to 25 μM for 48 h. When indicated, the cells were preincubated with SR141716 (SR1), SR144528 (SR2), CDI16020046 (CDI), and the antioxidant α-tocopherol (α-Toc) for 1 h before treatment with compound <b>10</b>. Finally, the MTT reduction assay was carried out to evaluate the effects of the different compounds on cell viability and to determine the IC<sub>50</sub>. Briefly, the cells were incubated for 2 h at 37 °C with 0.3 mg/mL MTT (Sigma, St. Louis, MO) and then were solubilized with 100 μL of 2-propanol. Absorbance at 570 nm was measured with a plate spectrophotometer (ELX 800 Bio-Tek Instruments, Inc.).</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> RTQ-PCR</h4><div class="NLM_p last">RNA was isolated with Trizol reagent (Invitrogen), and cDNA was obtained with Transcriptor reverse transcriptase (Roche Applied Science, Penzberg, Germany). The primers used for RTQ-PCR amplification were as follows: human CB<sub>2</sub> receptor, sense 5′-CTGTTCATTGGCAGCTTGG-3′, antisense 5′-AGCTGCATGCAAAGACCAC-3′. Each value was adjusted by using TBP RNA levels as a reference.</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Western Blot Analysis</h4><div class="NLM_p last">MDA-MB-231 human breast cancer cells were treated with DMSO (vehicle) or compound <b>10</b> for 2 days. The cells were then harvested and lysed. Protein concentrations were quantified by the Bradford method with bovine serum albumin as the standard. Equal amounts of total cellular protein extract (25 μg) were separated by electrophoresis in SDS–polyacrylamide gels (12%) and transferred to PVDF membranes. After blocking with 5% nonfat milk, the membranes were incubated at 4 °C with the desired primary antibodies overnight at the following dilutions: anticaspase-3 (1:500, Cell Signaling), β-actin (1:5000, Sigma). Subsequently, the membranes were incubated with appropriate secondary antibodies. Luminograms were obtained with an enhanced chemiluminescence detection kit (Amersham Life Sciences, Arlington Heights, IL), and densitometric analysis was performed with Quantity One software (Bio-Rad, Hercules, CA).</div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> In Vivo Antitumor Assays</h4><div class="NLM_p last">All procedures involving animals were performed with the approval of the Complutense University Animal Experimentation Committee according to European official regulations. Tumors were induced in nude mice by subcutaneous injection of 5 × 10<sup>6</sup> MDA-MB-231 human breast adenocarcinoma cells in PBS. When the tumors reached an average size of 200 mm<sup>3</sup>, the animals were randomly assigned to different groups. At this point, the animals started to receive vehicle or compound <b>10</b> (2 mg/kg/d) in 100 μL of sesame oil three times a week by intraperitoneal injection. The tumors were routinely measured with an external caliper, and the volume was calculated as (4π/3)(width/2)<sup>2</sup>(length/2). After 4 weeks of treatment, the animals were sacrificed. The tumors were excised, weighed, and snap frozen for further analysis. The organs (liver, spleen, heart, and lungs) were also collected and fixed in 4% PFA for histopathological analysis by H&E staining.</div></div><div id="sec5_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Statistics</h4><div class="NLM_p last">Data were assessed by Student’s <i>t</i> test, as well as by the analysis of variance (one-way or two-way) followed by the corresponding posthoc test (Student–Newman–Keuls test), as required.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34"><a href="/doi/suppl/10.1021/acs.jmedchem.5b00078">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45773" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45773" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Viability assays of compound <b>10</b> in different TNBC cell lines (SUM149, SUM159, MDA-MB-231, and MDA-MB-468). Molecular formula strings are saved in .csv format. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00078/suppl_file/jm5b00078_si_001.pdf">jm5b00078_si_001.pdf (43.57 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00078/suppl_file/jm5b00078_si_002.csv">jm5b00078_si_002.csv (0.37 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b00078" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31512" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31512" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cristina Sánchez</span> - <span class="hlFld-Affiliation affiliation">Instituto de Investigación
Hospital 12 de Octubre, Av Cordova s/n, 28041 Madrid, Spain</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c8abbaa1bbbca1a6a9e6bba9a6aba0adb288b9bda1a5e6bdaba5e6adbb"><span class="__cf_email__" data-cfemail="5536273c26213c3b347b26343b363d302f1524203c387b2036387b3026">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nadine Jagerovic</span> - <span class="hlFld-Affiliation affiliation">Instituto
de Química Médica, CSIC, Calle Juan de la Cierva 3, 28006 Madrid, Spain</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#97f9f6f3fef9f2d7fee6fab9f4e4fef4b9f2e4"><span class="__cf_email__" data-cfemail="6d030c090403082d041c00430e1e040e43081e">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paula Morales</span> - <span class="hlFld-Affiliation affiliation">Instituto
de Química Médica, CSIC, Calle Juan de la Cierva 3, 28006 Madrid, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sandra Blasco-Benito</span> - <span class="hlFld-Affiliation affiliation">Instituto de Investigación
Hospital 12 de Octubre, Av Cordova s/n, 28041 Madrid, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Clara Andradas</span> - <span class="hlFld-Affiliation affiliation">Instituto de Investigación
Hospital 12 de Octubre, Av Cordova s/n, 28041 Madrid, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">María Gómez-Cañas</span> - <span class="hlFld-Affiliation affiliation">Departamento
de Bioquímica y Biología Molecular, Facultad de Medicina, CIBERNED, IRYCIS, Universidad Complutense de Madrid, 28040 Madrid, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Juana María Flores</span> - <span class="hlFld-Affiliation affiliation">Instituto
de Química Médica, CSIC, Calle Juan de la Cierva 3, 28006 Madrid, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">‡Departamento de Bioquímica
y Biología Molecular I,
Facultad de Biología, and §Departamento de Medicina y Cirugía Animal,
Facultad de Veterinaria, Universidad Complutense
de Madrid, 28040 Madrid, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">Instituto de Investigación
Hospital 12 de Octubre, Av Cordova s/n, 28041 Madrid, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">Departamento
de Bioquímica y Biología Molecular, Facultad de Medicina, CIBERNED, IRYCIS, Universidad Complutense de Madrid, 28040 Madrid, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pilar Goya</span> - <span class="hlFld-Affiliation affiliation">Instituto
de Química Médica, CSIC, Calle Juan de la Cierva 3, 28006 Madrid, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Javier Fernández-Ruiz</span> - <span class="hlFld-Affiliation affiliation">Departamento
de Bioquímica y Biología Molecular, Facultad de Medicina, CIBERNED, IRYCIS, Universidad Complutense de Madrid, 28040 Madrid, Spain</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d1440e2320-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76541" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76541" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Financial support was provided by Spanish grants from the Spanish Ministerio de Economía y Competitividad (MINECO; SAF2012-40075-C02-02) and from Comunidad Autónoma de Madrid (CAM) (S2010/BMD-2308). P.M. is the recipient of a fellowship (Grant JAE-Pre-2010-01119) from Junta para la Ampliación de Estudios cofinanced by Fondo Socio Europeo (FSE). S.B.-B. is the recipient of an Formación Profesional Universitaria (FPU) fellowship from the Spanish Ministry of Education, Culture and Sports.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i36" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i36"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i37" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i37"> Abbreviations Used</h2><tr><td class="NLM_term">CB</td><td class="NLM_def"><p class="first last">cannabinoid</p></td></tr><tr><td class="NLM_term">TNBC</td><td class="NLM_def"><p class="first last">triple-negative breast cancer</p></td></tr><tr><td class="NLM_term">HMECs</td><td class="NLM_def"><p class="first last">normal human mammary epithelial cells</p></td></tr><tr><td class="NLM_term">THC</td><td class="NLM_def"><p class="first last">tetrahydrocannabinol</p></td></tr><tr><td class="NLM_term">CBD</td><td class="NLM_def"><p class="first last">cannabidiol</p></td></tr><tr><td class="NLM_term">AEA</td><td class="NLM_def"><p class="first last">anandamide</p></td></tr><tr><td class="NLM_term">IBX</td><td class="NLM_def"><p class="first last">2-iodoxybenzoic acid</p></td></tr><tr><td class="NLM_term">BTIB</td><td class="NLM_def"><p class="first last">[bis(trifluoroacetoxy)iodo]benzene</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">HEK</td><td class="NLM_def"><p class="first last">human embryonic kidney</p></td></tr><tr><td class="NLM_term">EBNA</td><td class="NLM_def"><p class="first last">Epstein–Barr nuclear antigen-1</p></td></tr><tr><td class="NLM_term">compd</td><td class="NLM_def"><p class="first last">compound</p></td></tr><tr><td class="NLM_term">ref</td><td class="NLM_def"><p class="first last">literature reference</p></td></tr><tr><td class="NLM_term">MTT</td><td class="NLM_def"><p class="first last">3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">administration, distribution, metabolism, excretion</p></td></tr><tr><td class="NLM_term">SR1</td><td class="NLM_def"><p class="first last">SR141716</p></td></tr><tr><td class="NLM_term">SR2</td><td class="NLM_def"><p class="first last">SR144528</p></td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last">CDI16020046</p></td></tr><tr><td class="NLM_term">α-Toc</td><td class="NLM_def"><p class="first last">α-tocophenol</p></td></tr><tr><td class="NLM_term">ROS</td><td class="NLM_def"><p class="first last">reactive oxygen species</p></td></tr><tr><td class="NLM_term">SE</td><td class="NLM_def"><p class="first last">standard error</p></td></tr><tr><td class="NLM_term">Veh</td><td class="NLM_def"><p class="first last">vehicle</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">standard error of the mean</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">MS</td><td class="NLM_def"><p class="first last">mass spectrometry</p></td></tr><tr><td class="NLM_term">mp</td><td class="NLM_def"><p class="first last">melting point</p></td></tr><tr><td class="NLM_term">ES</td><td class="NLM_def"><p class="first last">electrospray</p></td></tr><tr><td class="NLM_term">ESI</td><td class="NLM_def"><p class="first last">electrospray ionization</p></td></tr><tr><td class="NLM_term">BSA</td><td class="NLM_def"><p class="first last">bovine serum albumin</p></td></tr><tr><td class="NLM_term">EDTA</td><td class="NLM_def"><p class="first last">ethylenediaminetetraacetic acid</p></td></tr><tr><td class="NLM_term">PFA</td><td class="NLM_def"><p class="first last">paraformaldehyde</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36838" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36838" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 50 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Tramèr, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQuay, H. J.</span><span> </span><span class="NLM_article-title">Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review</span> <span class="citation_source-journal">Br. Med. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">323</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1136%2Fbmj.323.7303.16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVSitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2001&pages=16-21&author=M.+R.+Tram%C3%A8rauthor=D.+Carrollauthor=F.+Campbellauthor=D.+J.+Reynoldsauthor=R.+Mooreauthor=H.+J.+McQuay&title=Cannabinoids+for+control+of+chemotherapy+induced+nausea+and+vomiting%3A+quantitative+systematic+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoids for control of chemotherapy induced nausea and vomiting: Quantitative systematic review</span></div><div class="casAuthors">Tramer, Martin R.; Carroll, Dawn; Campbell, Fiona A.; Reynolds, D. John M.; Moore, R. Andrew; McQuay, Henry J.</div><div class="citationInfo"><span class="NLM_cas:title">BMJ [British Medical Journal]</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">7303</span>),
    <span class="NLM_cas:pages">16-21</span>CODEN:
                <span class="NLM_cas:coden">BMJBFE</span>;
        ISSN:<span class="NLM_cas:issn">0959-8146</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Aim of this study was to quantify the antiemetic efficacy and adverse effects of cannabis used for sickness induced by chemotherapy.  Systematic review.  Systematic search (Medline, Embase, Cochrane library, bibliogs.), any language, to August 2000.  30 Randomized comparisons of cannabis with placebo or antiemetics from which dichotomous data on efficacy and harm were available (1366 patients).  Oral nabilone, oral dronabinol (tetrahydrocannabinol), and i.m. levonantradol were tested.  No cannabis was smoked.  Follow up lasted 24 h.  Cannabinoids were more effective antiemetics than prochlorperazine, metoclopramide, chlorpromazine, thiethylperazine, haloperidol, domperidone, or alizapride: relative risk 1.38 (95% confidence interval 1.18 to 1.62), no. needed to treat 6 for complete control of nausea; 1.28 (1.08 to 1.51), NNT 8 for complete control of vomiting.  Cannabinoids were not more effective in patients receiving very low or very high emetogenic chemotherapy.  In crossover trials, patients preferred cannabinoids for future chemotherapy cycles: 2.39 (2.05 to 2.78), NNT 3.  Some potentially beneficial side effects occurred more often with cannabinoids: "high" 10.6 (6.86 to 16.5), NNT 3; sedation or drowsiness 1.66 (1.46 to 1.89), NNT 5; euphoria 12.5 (3.00 to 52.1), NNT 7.  Harmful side effects also occurred more often with cannabinoids: dizziness 2.97 (2.31 to 3.83), NNT 3; dysphoria or depression 8.06 (3.38 to 19.2), NNT 8; hallucinations 6.10 (2.41 to 15.4), NNT 17; paranoia 8.58 (6.38 to 11.5), NNT 20; and arterial hypotension 2.23 (1.75 to 2.83), NNT 7.  Patients given cannabinoids were more likely to withdraw due to side effects 4.67 (3.07 to 7.09), NNT 11.  In selected patients, the cannabinoids tested in these trials may be useful as mood enhancing adjuvants for controlling chemotherapy related sickness.  Potentially serious adverse effects, even when taken short term orally or i.m., are likely to limit their widespread use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPdwo9eb8Co7Vg90H21EOLACvtfcHk0lhOZddNmAYwhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVSitA%253D%253D&md5=fec3eef87a6007455f5ca07956c23c9a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1136%2Fbmj.323.7303.16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.323.7303.16%26sid%3Dliteratum%253Aachs%26aulast%3DTram%25C3%25A8r%26aufirst%3DM.%2BR.%26aulast%3DCarroll%26aufirst%3DD.%26aulast%3DCampbell%26aufirst%3DF.%26aulast%3DReynolds%26aufirst%3DD.%2BJ.%26aulast%3DMoore%26aufirst%3DR.%26aulast%3DMcQuay%26aufirst%3DH.%2BJ.%26atitle%3DCannabinoids%2520for%2520control%2520of%2520chemotherapy%2520induced%2520nausea%2520and%2520vomiting%253A%2520quantitative%2520systematic%2520review%26jtitle%3DBr.%2520Med.%2520J.%26date%3D2001%26volume%3D323%26spage%3D16%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Sharkey, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darmani, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, L. A.</span><span> </span><span class="NLM_article-title">Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">722</span><span class="NLM_x">, </span> <span class="NLM_fpage">134</span><span class="NLM_x">–</span> <span class="NLM_lpage">146</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1016%2Fj.ejphar.2013.09.068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=24184696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslyqtbnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=722&publication_year=2014&pages=134-146&author=K.+A.+Sharkeyauthor=N.+A.+Darmaniauthor=L.+A.+Parker&title=Regulation+of+nausea+and+vomiting+by+cannabinoids+and+the+endocannabinoid+system"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system</span></div><div class="casAuthors">Sharkey, Keith A.; Darmani, Nissar A.; Parker, Linda A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">722</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">134-146</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Nausea and vomiting (emesis) are important elements in defensive or protective responses that animals use to avoid ingestion or digestion of potentially harmful substances.  However, these neurally-mediated responses are at times manifested as symptoms of disease and they are frequently obsd. as side-effects of a variety of medications, notably those used to treat cancer.  Cannabis has long been known to limit or prevent nausea and vomiting from a variety of causes.  This has led to extensive investigations that have revealed an important role for cannabinoids and their receptors in the regulation of nausea and emesis.  With the discovery of the endocannabinoid system, novel ways to regulate both nausea and vomiting have been discovered that involve the prodn. of endogenous cannabinoids acting centrally.  Here we review recent progress in understanding the regulation of nausea and vomiting by cannabinoids and the endocannabinoid system, and we discuss the potential to utilize the endocannabinoid system in the treatment of these frequently debilitating conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdD3X4DMvEz7Vg90H21EOLACvtfcHk0lhOZddNmAYwhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslyqtbnJ&md5=435db4360b96bc8c63f7ccb2e94ab9ad</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2013.09.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2013.09.068%26sid%3Dliteratum%253Aachs%26aulast%3DSharkey%26aufirst%3DK.%2BA.%26aulast%3DDarmani%26aufirst%3DN.%2BA.%26aulast%3DParker%26aufirst%3DL.%2BA.%26atitle%3DRegulation%2520of%2520nausea%2520and%2520vomiting%2520by%2520cannabinoids%2520and%2520the%2520endocannabinoid%2520system%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D722%26spage%3D134%26epage%3D146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Cridge, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosengren, R. J.</span><span> </span><span class="NLM_article-title">Critical appraisal of the potential use of cannabinoids in cancer management</span> <span class="citation_source-journal">Cancer Manage. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">301</span><span class="NLM_x">–</span> <span class="NLM_lpage">313</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=24039449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFKmt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=301-313&author=B.+J.+Cridgeauthor=R.+J.+Rosengren&title=Critical+appraisal+of+the+potential+use+of+cannabinoids+in+cancer+management"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Critical appraisal of the potential use of cannabinoids in cancer management</span></div><div class="casAuthors">Cridge, Belinda J.; Rosengren, Rhonda J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Management and Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">301-313, pp.</span>CODEN:
                <span class="NLM_cas:coden">CMRACP</span>;
        ISSN:<span class="NLM_cas:issn">1179-1322</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Cannabinoids have been attracting a great deal of interest as potential anticancer agents.  Originally derived from the plant Cannabis sativa, there are now a no. of endo-, phyto- and synthetic cannabinoids available.  This review summarizes the key literature to date around the actions, antitumor activity, and mechanisms of action for this broad range of compds.  Cannabinoids are largely defined by an ability to activate the cannabinoid receptors - CB1 or CB2.  The action of the cannabinoids is very dependent on the exact ligand tested, the dose, and the duration of exposure.  Some cannabinoids, synthetic or plant-derived, show potential as therapeutic agents, and evidence across a range of cancers and evidence in vitro and in vivo is starting to be accumulated.  Studies have now been conducted in a wide range of cell lines, including glioma, breast, prostate, endothelial, liver, and lung.  This work is complemented by an increasing body of evidence from in vivo models.  However, many of these results remain contradictory, an issue that is not currently able to be resolved through current knowledge of mechanisms of action.  While there is a developing understanding of potential mechanisms of action, with the extracellular signal-regulated kinase pathway emerging as a crit. signaling juncture in combination with an important role for ceramide and lipid signaling, the relative importance of each pathway is yet to be detd.  The interplay between the intracellular pathways of autophagy vs. apoptosis is a recent development that is discussed.  Overall, there is still a great deal of conflicting evidence around the future utility of the cannabinoids, natural or synthetic, as therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrse4lnbMcrzrVg90H21EOLACvtfcHk0lhMi5JpmWsShw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFKmt7o%253D&md5=ff3c01baec1b9250c675cb13525b3cea</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCridge%26aufirst%3DB.%2BJ.%26aulast%3DRosengren%26aufirst%3DR.%2BJ.%26atitle%3DCritical%2520appraisal%2520of%2520the%2520potential%2520use%2520of%2520cannabinoids%2520in%2520cancer%2520management%26jtitle%3DCancer%2520Manage.%2520Res.%26date%3D2013%26volume%3D5%26spage%3D301%26epage%3D313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Velasco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sánchez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzmán, M.</span><span> </span><span class="NLM_article-title">Towards the use of cannabinoids as antitumour agents</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">436</span><span class="NLM_x">–</span> <span class="NLM_lpage">444</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1038%2Fnrc3247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=22555283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsFCgs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=436-444&author=G.+Velascoauthor=C.+S%C3%A1nchezauthor=M.+Guzm%C3%A1n&title=Towards+the+use+of+cannabinoids+as+antitumour+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Towards the use of cannabinoids as antitumour agents</span></div><div class="casAuthors">Velasco, Guillermo; Sanchez, Cristina; Guzman, Manuel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">436-444</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Various reports have shown that cannabinoids (the active components of marijuana and their derivs.) can reduce tumor growth and progression in animal models of cancer, in addn. to their well-known palliative effects on some cancer-assocd. symptoms.  This Opinion article discusses our current understanding of cannabinoids as antitumor agents, focusing on recent insights into the mol. mechanisms of action, including emerging resistance mechanisms and opportunities for combination therapy approaches.  Such knowledge is required for the optimization of preclin. cannabinoid-based therapies and for the preliminary clin. testing that is currently underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIsOuHpKgJRLVg90H21EOLACvtfcHk0lhMi5JpmWsShw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsFCgs70%253D&md5=4ec6d1bee283a5145c5c83f4c3eb5cfb</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrc3247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3247%26sid%3Dliteratum%253Aachs%26aulast%3DVelasco%26aufirst%3DG.%26aulast%3DS%25C3%25A1nchez%26aufirst%3DC.%26aulast%3DGuzm%25C3%25A1n%26aufirst%3DM.%26atitle%3DTowards%2520the%2520use%2520of%2520cannabinoids%2520as%2520antitumour%2520agents%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D436%26epage%3D444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Guzmán, M.</span><span> </span><span class="NLM_article-title">Cannabinoids: potential anticancer agents</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">745</span><span class="NLM_x">–</span> <span class="NLM_lpage">755</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1038%2Fnrc1188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=14570037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotFCiu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=745-755&author=M.+Guzm%C3%A1n&title=Cannabinoids%3A+potential+anticancer+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoids: Potential anticancer agents</span></div><div class="casAuthors">Guzman, Manuel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">745-755</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cannabinoids, the active components of Cannabis sativa and their derivs., exert palliative effects in cancer patients by preventing nausea, vomiting and pain and by stimulating appetite.  In addn., these compds. have been show to inhibit the growth of tumor cells in culture and animal models by modulating key cell-signaling pathways.  Cannabinoids are usually well tolerated, and do not produce the generalized toxic effects of conventional chemotherapies.  So, could cannabinoids be used to develop new anticancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRgBVHSjJfJrVg90H21EOLACvtfcHk0lhMi5JpmWsShw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotFCiu7c%253D&md5=22894eccf99e509e3948c6c2a5dcd513</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrc1188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1188%26sid%3Dliteratum%253Aachs%26aulast%3DGuzm%25C3%25A1n%26aufirst%3DM.%26atitle%3DCannabinoids%253A%2520potential%2520anticancer%2520agents%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26spage%3D745%26epage%3D755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Chakravarti, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganju, R. K.</span><span> </span><span class="NLM_article-title">Cannabinoids as therapeutic agents in cancer: current status and future implications</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">5852</span><span class="NLM_x">–</span> <span class="NLM_lpage">5872</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=5852-5872&author=B.+Chakravartiauthor=J.+Raviauthor=R.+K.+Ganju&title=Cannabinoids+as+therapeutic+agents+in+cancer%3A+current+status+and+future+implications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChakravarti%26aufirst%3DB.%26aulast%3DRavi%26aufirst%3DJ.%26aulast%3DGanju%26aufirst%3DR.%2BK.%26atitle%3DCannabinoids%2520as%2520therapeutic%2520agents%2520in%2520cancer%253A%2520current%2520status%2520and%2520future%2520implications%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D5852%26epage%3D5872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Guindon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohmann, A. G.</span><span> </span><span class="NLM_article-title">The endocannabinoid system and cancer: therapeutic implication</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">1447</span><span class="NLM_x">–</span> <span class="NLM_lpage">1463</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1111%2Fj.1476-5381.2011.01327.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=21410463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BC3MXps1Sju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2011&pages=1447-1463&author=J.+Guindonauthor=A.+G.+Hohmann&title=The+endocannabinoid+system+and+cancer%3A+therapeutic+implication"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The endocannabinoid system and cancer: therapeutic implication</span></div><div class="casAuthors">Guindon, Josee; Hohmann, Andrea G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1447-1463</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The endocannabinoid system is implicated in a variety of physiol. and pathol. conditions (inflammation, immunomodulation, analgesia, cancer and others).  The main active ingredient of cannabis, Δ9-tetrahydrocannabinol (Δ9-THC), produces its effects through activation of CB1 and CB2 receptors.  CB1 receptors are expressed at high levels in the central nervous system (CNS), whereas CB2 receptors are concd. predominantly, although not exclusively, in cells of the immune system.  Endocannabinoids are endogenous lipid-signaling mols. that are generated in the cell membrane from phospholipid precursors.  The 2 best characterized endocannabinoids identified to date are anandamide (AEA) and 2-arachidonoylglycerol (2-AG).  Here we review the relationship between the endocannabinoid system and anti-tumor actions (inhibition of cell proliferation and migration, induction of apoptosis, redn. of tumor growth) of the cannabinoids in different types of cancer.  This review will focus on examg. how activation of the endocannabinoid system impacts breast, prostate and bone cancers in both in vitro and in vivo systems.  The therapeutic potential of cannabinoids for cancer, as identified in clin. trials, is also discussed.  Identification of safe and effective treatments to manage and improve cancer therapy is crit. to improve quality of life and reduce unnecessary suffering in cancer patients.  In this regard, cannabis-like compds. offer therapeutic potential for the treatment of breast, prostate and bone cancer in patients.  Further basic research on anti-cancer properties of cannabinoids as well as clin. trials of cannabinoid therapeutic efficacy in breast, prostate and bone cancer is therefore warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_omB4D6NVN7Vg90H21EOLACvtfcHk0lhMi5JpmWsShw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXps1Sju7g%253D&md5=fb5ec332b401d12e51c229d291c1909d</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01327.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01327.x%26sid%3Dliteratum%253Aachs%26aulast%3DGuindon%26aufirst%3DJ.%26aulast%3DHohmann%26aufirst%3DA.%2BG.%26atitle%3DThe%2520endocannabinoid%2520system%2520and%2520cancer%253A%2520therapeutic%2520implication%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D163%26spage%3D1447%26epage%3D1463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Van Dross, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soliman, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jha, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukhopadhyay, S.</span><span> </span><span class="NLM_article-title">Receptor-dependent and receptor-independent endocannabinoid signaling: a therapeutic target for regulation of cancer growth</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">466</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2013&pages=463-466&author=R.+Van+Drossauthor=E.+Solimanauthor=S.+Jhaauthor=T.+Johnsonauthor=S.+Mukhopadhyay&title=Receptor-dependent+and+receptor-independent+endocannabinoid+signaling%3A+a+therapeutic+target+for+regulation+of+cancer+growth"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BDross%26aufirst%3DR.%26aulast%3DSoliman%26aufirst%3DE.%26aulast%3DJha%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DMukhopadhyay%26aufirst%3DS.%26atitle%3DReceptor-dependent%2520and%2520receptor-independent%2520endocannabinoid%2520signaling%253A%2520a%2520therapeutic%2520target%2520for%2520regulation%2520of%2520cancer%2520growth%26jtitle%3DLife%2520Sci.%26date%3D2013%26volume%3D92%26spage%3D463%26epage%3D466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Caffarel, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarrió, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palacios, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzmán, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sánchez, C.</span><span> </span><span class="NLM_article-title">Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">6615</span><span class="NLM_x">–</span> <span class="NLM_lpage">6621</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=6615-6621&author=M.+M.+Caffarelauthor=D.+Sarri%C3%B3author=J.+Palaciosauthor=M.+Guzm%C3%A1nauthor=C.+S%C3%A1nchez&title=Delta9-tetrahydrocannabinol+inhibits+cell+cycle+progression+in+human+breast+cancer+cells+through+Cdc2+regulation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCaffarel%26aufirst%3DM.%2BM.%26aulast%3DSarri%25C3%25B3%26aufirst%3DD.%26aulast%3DPalacios%26aufirst%3DJ.%26aulast%3DGuzm%25C3%25A1n%26aufirst%3DM.%26aulast%3DS%25C3%25A1nchez%26aufirst%3DC.%26atitle%3DDelta9-tetrahydrocannabinol%2520inhibits%2520cell%2520cycle%2520progression%2520in%2520human%2520breast%2520cancer%2520cells%2520through%2520Cdc2%2520regulation%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D6615%26epage%3D6621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Ligresti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriello, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starowicz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matias, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pisanti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Petrocellis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laezza, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Portella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bifulco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Marzo, V.</span><span> </span><span class="NLM_article-title">Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">318</span><span class="NLM_x">, </span> <span class="NLM_fpage">1375</span><span class="NLM_x">–</span> <span class="NLM_lpage">1387</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1124%2Fjpet.106.105247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=16728591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BD28XovFygtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=2006&pages=1375-1387&author=A.+Ligrestiauthor=A.+S.+Morielloauthor=K.+Starowiczauthor=I.+Matiasauthor=S.+Pisantiauthor=L.+De+Petrocellisauthor=C.+Laezzaauthor=G.+Portellaauthor=M.+Bifulcoauthor=V.+Di+Marzo&title=Antitumor+activity+of+plant+cannabinoids+with+emphasis+on+the+effect+of+cannabidiol+on+human+breast+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma</span></div><div class="casAuthors">Ligresti, Alessia; Moriello, Aniello Schiano; Starowicz, Katarzyna; Matias, Isabel; Pisanti, Simona; De Petrocellis, Luciano; Laezza, Chiara; Portella, Giuseppe; Bifulco, Maurizio; Di Marzo, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">318</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1375-1387</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Δ9-Tetrahydrocannabinol (THC) exhibits antitumor effects on various cancer cell types, but its use in chemotherapy is limited by its psychotropic activity.  We investigated the antitumor activities of other plant cannabinoids, i.e., cannabidiol, cannabigerol, cannabichromene, cannabidiol acid and THC acid, and assessed whether there is any advantage in using Cannabis exts. (enriched in either cannabidiol or THC) over pure cannabinoids.  Results obtained in a panel of tumor cell lines clearly indicate that, of the five natural compds. tested, cannabidiol is the most potent inhibitor of cancer cell growth (IC50 between 6.0 and 10.6 μM), with significantly lower potency in noncancer cells.  The cannabidiol-rich ext. was equipotent to cannabidiol, whereas cannabigerol and cannabichromene followed in the rank of potency.  Both cannabidiol and the cannabidiol-rich ext. inhibited the growth of xenograft tumors obtained by s.c. injection into athymic mice of human MDA-MB-231 breast carcinoma or rat v-K-ras-transformed thyroid epithelial cells and reduced lung metastases deriving from intrapaw injection of MDA-MB-231 cells.  Judging from several expts. on its possible cellular and mol. mechanisms of action, we propose that cannabidiol lacks a unique mode of action in the cell lines investigated.  At least for MDA-MB-231 cells, however, our expts. indicate that cannabidiol effect is due to its capability of inducing apoptosis via: direct or indirect activation of cannabinoid CB2 and vanilloid transient receptor potential vanilloid type-1 receptors and cannabinoid/vanilloid receptor-independent elevation of intracellular Ca2+ and reactive oxygen species.  Our data support the further testing of cannabidiol and cannabidiol-rich exts. for the potential treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH79Q23ih9-LVg90H21EOLACvtfcHk0lgqGY9UbeaIIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XovFygtLY%253D&md5=55d944aa9d80801fea0e364b72ac6a0e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.105247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.105247%26sid%3Dliteratum%253Aachs%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DMoriello%26aufirst%3DA.%2BS.%26aulast%3DStarowicz%26aufirst%3DK.%26aulast%3DMatias%26aufirst%3DI.%26aulast%3DPisanti%26aufirst%3DS.%26aulast%3DDe%2BPetrocellis%26aufirst%3DL.%26aulast%3DLaezza%26aufirst%3DC.%26aulast%3DPortella%26aufirst%3DG.%26aulast%3DBifulco%26aufirst%3DM.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26atitle%3DAntitumor%2520activity%2520of%2520plant%2520cannabinoids%2520with%2520emphasis%2520on%2520the%2520effect%2520of%2520cannabidiol%2520on%2520human%2520breast%2520carcinoma%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D318%26spage%3D1375%26epage%3D1387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Shrivastava, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuzontkoski, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groopman, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prasad, A.</span><span> </span><span class="NLM_article-title">Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1161</span><span class="NLM_x">–</span> <span class="NLM_lpage">1172</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1158%2F1535-7163.MCT-10-1100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=21566064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1Sitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=1161-1172&author=A.+Shrivastavaauthor=P.+M.+Kuzontkoskiauthor=J.+E.+Groopmanauthor=A.+Prasad&title=Cannabidiol+induces+programmed+cell+death+in+breast+cancer+cells+by+coordinating+the+cross-talk+between+apoptosis+and+autophagy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabidiol Induces Programmed Cell Death in Breast Cancer Cells by Coordinating the Cross-talk between Apoptosis and Autophagy</span></div><div class="casAuthors">Shrivastava, Ashutosh; Kuzontkoski, Paula M.; Groopman, Jerome E.; Prasad, Anil</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1161-1172</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cannabidiol (CBD), a major nonpsychoactive constituent of cannabis, is considered an antineoplastic agent on the basis of its in vitro and in vivo activity against tumor cells.  However, the exact mol. mechanism through which CBD mediates this activity is yet to be elucidated.  Here, we have shown CBD-induced cell death of breast cancer cells, independent of cannabinoid and vallinoid receptor activation.  Electron microscopy revealed morphologies consistent with the coexistence of autophagy and apoptosis.  Western blot anal. confirmed these findings.  We showed that CBD induces endoplasmic reticulum stress and, subsequently, inhibits AKT and mTOR signaling as shown by decreased levels of phosphorylated mTOR and 4EBP1, and cyclin D1.  Analyzing further the cross-talk between the autophagic and apoptotic signaling pathways, we found that beclin1 plays a central role in the induction of CBD-mediated apoptosis in MDA-MB-231 breast cancer cells.  Although CBD enhances the interaction between beclin1 and Vps34, it inhibits the assocn. between beclin1 and Bcl-2.  In addn., we showed that CBD reduces mitochondrial membrane potential, triggers the translocation of BID to the mitochondria, the release of cytochrome c to the cytosol, and, ultimately, the activation of the intrinsic apoptotic pathway in breast cancer cells.  CBD increased the generation of reactive oxygen species (ROS), and ROS inhibition blocked the induction of apoptosis and autophagy.  Our study revealed an intricate interplay between apoptosis and autophagy in CBD-treated breast cancer cells and highlighted the value of continued investigation into the potential use of CBD as an antineoplastic agent.  Mol Cancer Ther; 10(7); 1161-72.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJEa2-oTrVOrVg90H21EOLACvtfcHk0lgqGY9UbeaIIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1Sitb4%253D&md5=f52599e25679acf7d378d2850d4eb25f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-1100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-1100%26sid%3Dliteratum%253Aachs%26aulast%3DShrivastava%26aufirst%3DA.%26aulast%3DKuzontkoski%26aufirst%3DP.%2BM.%26aulast%3DGroopman%26aufirst%3DJ.%2BE.%26aulast%3DPrasad%26aufirst%3DA.%26atitle%3DCannabidiol%2520induces%2520programmed%2520cell%2520death%2520in%2520breast%2520cancer%2520cells%2520by%2520coordinating%2520the%2520cross-talk%2520between%2520apoptosis%2520and%2520autophagy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D1161%26epage%3D1172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Caffarel, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno-Bueno, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerutti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palacios, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mechta-Grigoriou, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, C.</span><span> </span><span class="NLM_article-title">JunD is involved in the antiproliferative effect of Δ<sup>9</sup>-tetrahydrocannabinol on human breast cancer cells</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">5033</span><span class="NLM_x">–</span> <span class="NLM_lpage">5044</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=5033-5044&author=M.+M.+Caffarelauthor=G.+Moreno-Buenoauthor=C.+Ceruttiauthor=J.+Palaciosauthor=M.+Guzmanauthor=F.+Mechta-Grigoriouauthor=C.+Sanchez&title=JunD+is+involved+in+the+antiproliferative+effect+of+%CE%949-tetrahydrocannabinol+on+human+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCaffarel%26aufirst%3DM.%2BM.%26aulast%3DMoreno-Bueno%26aufirst%3DG.%26aulast%3DCerutti%26aufirst%3DC.%26aulast%3DPalacios%26aufirst%3DJ.%26aulast%3DGuzman%26aufirst%3DM.%26aulast%3DMechta-Grigoriou%26aufirst%3DF.%26aulast%3DSanchez%26aufirst%3DC.%26atitle%3DJunD%2520is%2520involved%2520in%2520the%2520antiproliferative%2520effect%2520of%2520%25CE%25949-tetrahydrocannabinol%2520on%2520human%2520breast%2520cancer%2520cells%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D5033%26epage%3D5044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Laezza, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pisanti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crescenzi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bifulco, M.</span><span> </span><span class="NLM_article-title">Anandamide inhibits Cdk2 and activates Chk1 leading to cell cycle arrest in human breast cancer cells</span> <span class="citation_source-journal">FEBS Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">580</span><span class="NLM_x">, </span> <span class="NLM_fpage">6076</span><span class="NLM_x">–</span> <span class="NLM_lpage">6082</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=580&publication_year=2006&pages=6076-6082&author=C.+Laezzaauthor=S.+Pisantiauthor=E.+Crescenziauthor=M.+Bifulco&title=Anandamide+inhibits+Cdk2+and+activates+Chk1+leading+to+cell+cycle+arrest+in+human+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLaezza%26aufirst%3DC.%26aulast%3DPisanti%26aufirst%3DS.%26aulast%3DCrescenzi%26aufirst%3DE.%26aulast%3DBifulco%26aufirst%3DM.%26atitle%3DAnandamide%2520inhibits%2520Cdk2%2520and%2520activates%2520Chk1%2520leading%2520to%2520cell%2520cycle%2520arrest%2520in%2520human%2520breast%2520cancer%2520cells%26jtitle%3DFEBS%2520Lett.%26date%3D2006%26volume%3D580%26spage%3D6076%26epage%3D6082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Qamri, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preet, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nasser, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bass, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leone, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barsky, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganju, R. K.</span><span> </span><span class="NLM_article-title">Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">3117</span><span class="NLM_x">–</span> <span class="NLM_lpage">3129</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1158%2F1535-7163.MCT-09-0448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=19887554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlyrt7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=3117-3129&author=Z.+Qamriauthor=A.+Preetauthor=M.+W.+Nasserauthor=C.+E.+Bassauthor=G.+Leoneauthor=S.+H.+Barskyauthor=R.+K.+Ganju&title=Synthetic+cannabinoid+receptor+agonists+inhibit+tumor+growth+and+metastasis+of+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer</span></div><div class="casAuthors">Qamri, Zahida; Preet, Anju; Nasser, Mohd W.; Bass, Caroline E.; Leone, Gustavo; Barsky, Sanford H.; Ganju, Ramesh K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3117-3129</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cannabinoids have been reported to possess antitumorogenic activity.  Not much is known, however, about the effects and mechanism of action of synthetic nonpsychotic cannabinoids on breast cancer growth and metastasis.  We have shown that the cannabinoid receptors CB1 and CB2 are overexpressed in primary human breast tumors compared with normal breast tissue.  We have also obsd. that the breast cancer cell lines MDA-MB231, MDA-MB231-luc, and MDA-MB468 express CB1 and CB2 receptors.  Furthermore, we have shown that the CB2 synthetic agonist JWH-133 and the CB1 and CB2 agonist WIN-55,212-2 inhibit cell proliferation and migration under in vitro conditions.  These results were confirmed in vivo in various mouse model systems.  Mice treated with JWH-133 or WIN-55,212-2 showed a 40% to 50% redn. in tumor growth and a 65% to 80% redn. in lung metastasis.  These effects were reversed by CB1 and CB2 antagonists AM 251 and SR144528, resp., suggesting involvement of CB1 and CB2 receptors.  In addn., the CB2 agonist JWH-133 was shown to delay and reduce mammary gland tumors in the polyoma middle T oncoprotein (PyMT) transgenic mouse model system.  Upon further elucidation, we obsd. that JWH-133 and WIN-55,212-2 mediate the breast tumor-suppressive effects via a coordinated regulation of cyclooxygenase-2/prostaglandin E2 signaling pathways and induction of apoptosis.  These results indicate that CB1 and CB2 receptors could be used to develop novel therapeutic strategies against breast cancer growth and metastasis. [Mol Cancer Ther 2009;8(11):3117-29].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBezp28v9cX7Vg90H21EOLACvtfcHk0liaqzIQ7tDX8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlyrt7%252FE&md5=d78894337a2b8ae32a9379df1abca9bd</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0448%26sid%3Dliteratum%253Aachs%26aulast%3DQamri%26aufirst%3DZ.%26aulast%3DPreet%26aufirst%3DA.%26aulast%3DNasser%26aufirst%3DM.%2BW.%26aulast%3DBass%26aufirst%3DC.%2BE.%26aulast%3DLeone%26aufirst%3DG.%26aulast%3DBarsky%26aufirst%3DS.%2BH.%26aulast%3DGanju%26aufirst%3DR.%2BK.%26atitle%3DSynthetic%2520cannabinoid%2520receptor%2520agonists%2520inhibit%2520tumor%2520growth%2520and%2520metastasis%2520of%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D3117%26epage%3D3129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Oesch, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wachtel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pretre, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salazar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzmán, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schäfer, B. W.</span><span> </span><span class="NLM_article-title">Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1838</span><span class="NLM_x">–</span> <span class="NLM_lpage">1845</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1158%2F1535-7163.MCT-08-1147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=19509271" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVymsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=1838-1845&author=S.+Oeschauthor=D.+Walterauthor=M.+Wachtelauthor=K.+Pretreauthor=M.+Salazarauthor=M.+Guzm%C3%A1nauthor=G.+Velascoauthor=B.+W.+Sch%C3%A4fer&title=Cannabinoid+receptor+1+is+a+potential+drug+target+for+treatment+of+translocation-positive+rhabdomyosarcoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma</span></div><div class="casAuthors">Oesch, Susanne; Walter, Dagmar; Wachtel, Marco; Pretre, Kathya; Salazar, Maria; Guzman, Manuel; Velasco, Guillermo; Schaefer, Beat W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1838-1845</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Gene expression profiling has revealed that the gene coding for cannabinoid receptor 1 (CB1) is highly up-regulated in rhabdomyosarcoma biopsies bearing the typical chromosomal translocations PAX3/FKHR or PAX7/FKHR.  Because cannabinoid receptor agonists are capable of reducing proliferation and inducing apoptosis in diverse cancer cells such as glioma, breast cancer, and melanoma, we evaluated whether CB1 is a potential drug target in rhabdomyosarcoma.  Our study shows that treatment with the cannabinoid receptor agonists HU210 and Δ9-tetrahydrocannabinol lowers the viability of translocation-pos. rhabdomyosarcoma cells through the induction of apoptosis.  This effect relies on inhibition of AKT signaling and induction of the stress-assocd. transcription factor p8 because small interfering RNA-mediated down-regulation of p8 rescued cell viability upon cannabinoid treatment.  Finally, treatment of xenografts with HU210 led to a significant suppression of tumor growth in vivo.  These results support the notion that cannabinoid receptor agonists could represent a novel targeted approach for treatment of translocation-pos. rhabdomyosarcoma. [Mol Cancer Ther 2009;8(7):1838-45].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMh5egpxSj8bVg90H21EOLACvtfcHk0liaqzIQ7tDX8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVymsrc%253D&md5=92ce70ba239e376a33044be2ab6a3938</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-1147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-1147%26sid%3Dliteratum%253Aachs%26aulast%3DOesch%26aufirst%3DS.%26aulast%3DWalter%26aufirst%3DD.%26aulast%3DWachtel%26aufirst%3DM.%26aulast%3DPretre%26aufirst%3DK.%26aulast%3DSalazar%26aufirst%3DM.%26aulast%3DGuzm%25C3%25A1n%26aufirst%3DM.%26aulast%3DVelasco%26aufirst%3DG.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DB.%2BW.%26atitle%3DCannabinoid%2520receptor%25201%2520is%2520a%2520potential%2520drug%2520target%2520for%2520treatment%2520of%2520translocation-positive%2520rhabdomyosarcoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D1838%26epage%3D1845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Olea-Herrero, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vara, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malagarie-Cazenave, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz-Laviada, I.</span><span> </span><span class="NLM_article-title">Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-methanandamide and JWH-015: involvement of CB2</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">940</span><span class="NLM_x">–</span> <span class="NLM_lpage">950</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1038%2Fsj.bjc.6605248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=19690545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtV2qsrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2009&pages=940-950&author=N.+Olea-Herreroauthor=D.+Varaauthor=S.+Malagarie-Cazenaveauthor=I.+Diaz-Laviada&title=Inhibition+of+human+tumour+prostate+PC-3+cell+growth+by+cannabinoids+R%28%2B%29-methanandamide+and+JWH-015%3A+involvement+of+CB2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of human tumor prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: Involvement of CB2</span></div><div class="casAuthors">Olea-Herrero, N.; Vara, D.; Malagarie-Cazenave, S.; Diaz-Laviada, I.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">940-950</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: We have previously shown that cannabinoids induce growth inhibition and apoptosis in prostate cancer PC-3 cells, which express high levels of cannabinoid receptor types 1 and 2 (CB1 and CB2).  In this study, we investigated the role of CB2 receptor in the anti-proliferative action of cannabinoids and the signal transduction triggered by receptor ligation.  Methods: The human prostate cancer cell lines, namely PC-3, DU-145 and LNCaP, were used for this study.  Cell proliferation was measured using MTT proliferation assay, [3H]-thymidine incorporation assay and cell-cycle study by flow cytometry.  Ceramide quantification was performed using the DAG kinase method.  The CB2 receptor was silenced with specific small interfering RNA, and was blocked pharmacol. with SR 144528.  In vivo studies were conducted by the induction of prostate xenograft tumors in nude mice.  Results: We found that the anandamide analog, R(+)-Methanandamide (MET), as well as JWH-015, a synthetic CB2 agonist, exerted anti-proliferative effects in PC-3 cells.  R(+)-Methanandamide- and JWH-015-induced cell death was rescued by treatment with the CB2 receptor antagonist, SR 144528.  Downregulation of CB2 expression reversed the effects of JWH-015, confirming the involvement of CB2 in the pro-apoptotic effect of cannabinoids.  Further analyzing the mechanism of JWH-015-induced cell growth inhibition, we found that JWH-015 triggered a de novo synthesis of ceramide, which was involved in cannabinoid-induced cell death, insofar as blocking ceramide synthesis with Fumonisin B1 reduced cell death.  Signalling pathways activated by JWH-015 included JNK (c-Jun N-terminal kinase) activation and Akt inhibition.  In vivo treatment with JWH-015 caused a significant redn. in tumor growth in mice.  Conclusions: This study defines the involvement of CB2-mediated signalling in the in vivo and in vitro growth inhibition of prostate cancer cells and suggests that CB2 agonists have potential therapeutic interest and deserve to be explored in the management of prostate cancer.  British Journal of Cancer (2009) 101, 940-950; doi:10.1038/sj.bjc.6605248 www.bjcancer.com Published online 18 August 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8n-thjFjaLLVg90H21EOLACvtfcHk0liVyBc6jWy2wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtV2qsrjO&md5=9bea0fa09288d7e3886584781f74b462</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6605248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6605248%26sid%3Dliteratum%253Aachs%26aulast%3DOlea-Herrero%26aufirst%3DN.%26aulast%3DVara%26aufirst%3DD.%26aulast%3DMalagarie-Cazenave%26aufirst%3DS.%26aulast%3DDiaz-Laviada%26aufirst%3DI.%26atitle%3DInhibition%2520of%2520human%2520tumour%2520prostate%2520PC-3%2520cell%2520growth%2520by%2520cannabinoids%2520R%2528%252B%2529-methanandamide%2520and%2520JWH-015%253A%2520involvement%2520of%2520CB2%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2009%26volume%3D101%26spage%3D940%26epage%3D950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatte, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buzard, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. M.</span><span> </span><span class="NLM_article-title">Therapeutic utility of cannabinoid receptor type 2 (CB2) selective agonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">8224</span><span class="NLM_x">–</span> <span class="NLM_lpage">8256</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm4005626" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFeru7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8224-8256&author=S.+Hanauthor=J.+Thatteauthor=D.+J.+Buzardauthor=R.+M.+Jones&title=Therapeutic+utility+of+cannabinoid+receptor+type+2+%28CB2%29+selective+agonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Utility of Cannabinoid Receptor Type 2 (CB2) Selective Agonists</span></div><div class="casAuthors">Han, Sangdon; Thatte, Jayant; Buzard, Daniel J.; Jones, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8224-8256</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The cannabinoid receptor type 2 (CB2) is a class A GPCR that was cloned in 1993 while looking for an alternative receptor that could explain the pharmacol. properties of Δ9-tetrahydrocannabinol.  CB2 was identified among cDNAs based on its similarity in amino acid sequence to the CB1 receptor and helped provide an explanation for the established effects of cannabinoids on the immune system.  In addn. to the immune system, CB2 has widespread tissue expression and has been found in brain, peripheral nervous system, and gastrointestinal tract.  Several "mixed" cannabinoid agonists are currently in clin. use primarily for controlling pain, and it is believed that selective CB2 agonism may afford a superior analgesic agent devoid of the centrally mediated CB1 effects.  Thus, selective CB2 receptor agonists represent high value putative therapeutics for treating pain and other disease states.  In this Perspective, we seek to provide a concise update of progress in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqncpGbOhjA5bVg90H21EOLACvtfcHk0liVyBc6jWy2wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFeru7bO&md5=bb532e5c81b475aa04a3311a017c82f1</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm4005626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4005626%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DS.%26aulast%3DThatte%26aufirst%3DJ.%26aulast%3DBuzard%26aufirst%3DD.%2BJ.%26aulast%3DJones%26aufirst%3DR.%2BM.%26atitle%3DTherapeutic%2520utility%2520of%2520cannabinoid%2520receptor%2520type%25202%2520%2528CB2%2529%2520selective%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8224%26epage%3D8256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Sánchez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Ceballos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gómez del Pulgar, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rueda, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbacho, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galve-Roperh, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huffman, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramón y Cajal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzmán, M.</span><span> </span><span class="NLM_article-title">Inhibition of glioma growth in vivo by selective activation of the CB 2 cannabinoid receptor inhibition of glioma growth in vivo by selective activation of the CB 2</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">5784</span><span class="NLM_x">–</span> <span class="NLM_lpage">5789</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=5784-5789&author=C.+S%C3%A1nchezauthor=M.+L.+de+Ceballosauthor=T.+G%C3%B3mez+del+Pulgarauthor=D.+Ruedaauthor=C.+Corbachoauthor=G.+Velascoauthor=I.+Galve-Roperhauthor=J.+W.+Huffmanauthor=S.+Ram%C3%B3n+y+Cajalauthor=M.+Guzm%C3%A1n&title=Inhibition+of+glioma+growth+in+vivo+by+selective+activation+of+the+CB+2+cannabinoid+receptor+inhibition+of+glioma+growth+in+vivo+by+selective+activation+of+the+CB+2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A1nchez%26aufirst%3DC.%26aulast%3Dde%2BCeballos%26aufirst%3DM.%2BL.%26aulast%3DG%25C3%25B3mez%2Bdel%2BPulgar%26aufirst%3DT.%26aulast%3DRueda%26aufirst%3DD.%26aulast%3DCorbacho%26aufirst%3DC.%26aulast%3DVelasco%26aufirst%3DG.%26aulast%3DGalve-Roperh%26aufirst%3DI.%26aulast%3DHuffman%26aufirst%3DJ.%2BW.%26aulast%3DRam%25C3%25B3n%2By%2BCajal%26aufirst%3DS.%26aulast%3DGuzm%25C3%25A1n%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520glioma%2520growth%2520in%2520vivo%2520by%2520selective%2520activation%2520of%2520the%2520CB%25202%2520cannabinoid%2520receptor%2520inhibition%2520of%2520glioma%2520growth%2520in%2520vivo%2520by%2520selective%2520activation%2520of%2520the%2520CB%25202%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D5784%26epage%3D5789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Duntsch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Divi, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnamurthy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehm, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sills, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, B. M.</span><span> </span><span class="NLM_article-title">Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma</span> <span class="citation_source-journal">J. Neurooncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">143</span><span class="NLM_x">–</span> <span class="NLM_lpage">152</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1007%2Fs11060-005-9031-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=16314952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A280%3ADC%252BD283mvFeitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2006&pages=143-152&author=C.+Duntschauthor=M.+K.+Diviauthor=T.+Jonesauthor=Q.+Zhouauthor=M.+Krishnamurthyauthor=P.+Boehmauthor=G.+Woodauthor=A.+Sillsauthor=B.+M.+Moore&title=Safety+and+efficacy+of+a+novel+cannabinoid+chemotherapeutic%2C+KM-233%2C+for+the+treatment+of+high-grade+glioma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma</span></div><div class="casAuthors">Duntsch Christopher; Divi Murali Krishna; Jones Terreia; Zhou Qihong; Krishnamurthy Mathangi; Boehm Peter; Wood George; Sills Allen; Moore Bob M 2nd</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuro-oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">143-52</span>
        ISSN:<span class="NLM_cas:issn">0167-594X</span>.
    </div><div class="casAbstract">OBJECTIVE:  To test in vitro and in vivo the safety and efficacy of a novel chemotherapeutic agent, KM-233, for the treatment of glioma.  METHODS:  In vitro cell cytotoxicity assays were used to measure and compare the cytotoxic effects of KM-233, Delta(8)-tetrahydrocannabinol (THC), and bis-chloroethyl-nitrosurea (BCNU) against human U87 glioma cells.  An organotypic brain slice culture model was used for safety and toxicity studies.  A human glioma-SCID mouse side-pocket tumor model was used to test in vivo the safety and efficacy of KM-233 with intratumoral and intra-peritoneal administration.  RESULTS:  KM-233 is a classical cannabinoid with good blood brain barrier penetration that possesses a selective affinity for the CB2 receptors relative to THC.  KM-233 was as efficacious in its cytotoxicity against human U87 glioma as Delta(8)-tetrahydrocannabinol, and superior to the commonly used anti-glioma chemotherapeutic agent, BCNU.  The cytotoxic effects of KM-233 against human glioma cells in vitro occur as early as two hours after administration, and dosing of KM-233 can be cycled without compromising cytotoxic efficacy and while improving safety.  Cyclical dosing of KM-233 to treat U87 glioma in a SCID mouse xenograft side pocket model was effective at reducing the tumor burden with both systemic and intratumoral administration.  CONCLUSION:  These studies provide both in vitro and in vivo evidence that KM-233 shows promising efficacy against human glioma cell lines in both in vitro and in vivo studies, minimal toxicity to healthy cultured brain tissue, and should be considered for definitive preclinical development in animal models of glioma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTy1HeLuTdN-tts4TFFB11gfW6udTcc2eYekQ2kjMnHfrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD283mvFeitg%253D%253D&md5=375cad819c61fdf2ec9a0593667922bd</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs11060-005-9031-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11060-005-9031-y%26sid%3Dliteratum%253Aachs%26aulast%3DDuntsch%26aufirst%3DC.%26aulast%3DDivi%26aufirst%3DM.%2BK.%26aulast%3DJones%26aufirst%3DT.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DKrishnamurthy%26aufirst%3DM.%26aulast%3DBoehm%26aufirst%3DP.%26aulast%3DWood%26aufirst%3DG.%26aulast%3DSills%26aufirst%3DA.%26aulast%3DMoore%26aufirst%3DB.%2BM.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520a%2520novel%2520cannabinoid%2520chemotherapeutic%252C%2520KM-233%252C%2520for%2520the%2520treatment%2520of%2520high-grade%2520glioma%26jtitle%3DJ.%2520Neurooncol.%26date%3D2006%26volume%3D77%26spage%3D143%26epage%3D152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Palazuelos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguado, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mechoulam, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzmán, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galve-Roperh, I.</span><span> </span><span class="NLM_article-title">Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2405</span><span class="NLM_x">–</span> <span class="NLM_lpage">2407</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=2405-2407&author=J.+Palazuelosauthor=T.+Aguadoauthor=A.+Egiaauthor=R.+Mechoulamauthor=M.+Guzm%C3%A1nauthor=I.+Galve-Roperh&title=Non-psychoactive+CB2+cannabinoid+agonists+stimulate+neural+progenitor+proliferation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPalazuelos%26aufirst%3DJ.%26aulast%3DAguado%26aufirst%3DT.%26aulast%3DEgia%26aufirst%3DA.%26aulast%3DMechoulam%26aufirst%3DR.%26aulast%3DGuzm%25C3%25A1n%26aufirst%3DM.%26aulast%3DGalve-Roperh%26aufirst%3DI.%26atitle%3DNon-psychoactive%2520CB2%2520cannabinoid%2520agonists%2520stimulate%2520neural%2520progenitor%2520proliferation%26jtitle%3DFASEB%2520J.%26date%3D2006%26volume%3D20%26spage%3D2405%26epage%3D2407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Pertwee, R. G.</span><span> </span><span class="NLM_article-title">Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities</span> <span class="citation_source-journal">Philos. Trans. R. Soc., B</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x">, </span> <span class="NLM_fpage">3353</span><span class="NLM_x">–</span> <span class="NLM_lpage">3363</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1098%2Frstb.2011.0381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=23108552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVKgtL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=3353-3363&author=R.+G.+Pertwee&title=Targeting+the+endocannabinoid+system+with+cannabinoid+receptor+agonists%3A+pharmacological+strategies+and+therapeutic+possibilities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities</span></div><div class="casAuthors">Pertwee, Roger G.</div><div class="citationInfo"><span class="NLM_cas:title">Philosophical Transactions of the Royal Society, B: Biological Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">1607</span>),
    <span class="NLM_cas:pages">3353-3363</span>CODEN:
                <span class="NLM_cas:coden">PTRBAE</span>;
        ISSN:<span class="NLM_cas:issn">0962-8436</span>.
    
            (<span class="NLM_cas:orgname">Royal Society</span>)
        </div><div class="casAbstract">A review.  Human tissues express cannabinoid CB1 and CB2 receptors that can be activated by endogenously released 'endocannabinoids' or exogenously administered compds. in a manner that reduces the symptoms or opposes the underlying causes of several disorders in need of effective therapy.  Three medicines that activate cannabinoid CB1/CB2 receptors are now in the clinic: Cesamet (nabilone), Marinol (dronabinol; Δ9-tetrahydrocannabinol (Δ9-THC)) and Sativex (Δ9-THC with cannabidiol).  These can be prescribed for the amelioration of chemotherapy-induced nausea and vomiting (Cesamet and Marinol), stimulation of appetite (Marinol) and symptomatic relief of cancer pain and/or management of neuropathic pain and spasticity in adults with multiple sclerosis (Sativex).  This review mentions several possible addnl. therapeutic targets for cannabinoid receptor agonists.  These include other kinds of pain, epilepsy, anxiety, depression, Parkinson's and Huntington's diseases, amyotrophic lateral sclerosis, stroke, cancer, drug dependence, glaucoma, autoimmune uveitis, osteoporosis, sepsis, and hepatic, renal, intestinal and cardiovascular disorders.  It also describes potential strategies for improving the efficacy and/or benefit-to-risk ratio of these agonists in the clinic.  These are strategies that involve (i) targeting cannabinoid receptors located outside the blood-brain barrier, (ii) targeting cannabinoid receptors expressed by a particular tissue, (iii) targeting upregulated cannabinoid receptors, (iv) selectively targeting cannabinoid CB2 receptors, and/or (v) adjunctive 'multi-targeting'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3Q3tFouTow7Vg90H21EOLACvtfcHk0lh-PySdT3Qxlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVKgtL3L&md5=520dda552cdeb306560444cf7c5932f6</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1098%2Frstb.2011.0381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frstb.2011.0381%26sid%3Dliteratum%253Aachs%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26atitle%3DTargeting%2520the%2520endocannabinoid%2520system%2520with%2520cannabinoid%2520receptor%2520agonists%253A%2520pharmacological%2520strategies%2520and%2520therapeutic%2520possibilities%26jtitle%3DPhilos.%2520Trans.%2520R.%2520Soc.%252C%2520B%26date%3D2012%26volume%3D367%26spage%3D3353%26epage%3D3363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Chiorean, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braicu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berindan-Neagoe, I.</span><span> </span><span class="NLM_article-title">Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth?</span> <span class="citation_source-journal">Breast</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1026</span><span class="NLM_x">–</span> <span class="NLM_lpage">1033</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2013&pages=1026-1033&author=R.+Chioreanauthor=C.+Braicuauthor=I.+Berindan-Neagoe&title=Another+review+on+triple+negative+breast+cancer.+Are+we+on+the+right+way+towards+the+exit+from+the+labyrinth%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChiorean%26aufirst%3DR.%26aulast%3DBraicu%26aufirst%3DC.%26aulast%3DBerindan-Neagoe%26aufirst%3DI.%26atitle%3DAnother%2520review%2520on%2520triple%2520negative%2520breast%2520cancer.%2520Are%2520we%2520on%2520the%2520right%2520way%2520towards%2520the%2520exit%2520from%2520the%2520labyrinth%253F%26jtitle%3DBreast%26date%3D2013%26volume%3D22%26spage%3D1026%26epage%3D1033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Abramson, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballinger, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietenpol, J. A.</span><span> </span><span class="NLM_article-title">Subtyping of triple-negative breast cancer: implications for therapy</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&pages=1-9&author=V.+G.+Abramsonauthor=B.+D.+Lehmannauthor=T.+J.+Ballingerauthor=J.+A.+Pietenpol&title=Subtyping+of+triple-negative+breast+cancer%3A+implications+for+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAbramson%26aufirst%3DV.%2BG.%26aulast%3DLehmann%26aufirst%3DB.%2BD.%26aulast%3DBallinger%26aufirst%3DT.%2BJ.%26aulast%3DPietenpol%26aufirst%3DJ.%2BA.%26atitle%3DSubtyping%2520of%2520triple-negative%2520breast%2520cancer%253A%2520implications%2520for%2520therapy%26jtitle%3DCancer%26date%3D2014%26spage%3D1%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Hoeferlin, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">E.Chalfant, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, M. A.</span><span> </span><span class="NLM_article-title">Challenges in the treatment of triple negative and HER2-overexpressing breast cancer</span> <span class="citation_source-journal">J. Surg. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">7</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=3-7&author=L.+A.+Hoeferlinauthor=C.+E.+E.Chalfantauthor=M.+A.+Park&title=Challenges+in+the+treatment+of+triple+negative+and+HER2-overexpressing+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHoeferlin%26aufirst%3DL.%2BA.%26aulast%3DE.Chalfant%26aufirst%3DC.%2BE.%26aulast%3DPark%26aufirst%3DM.%2BA.%26atitle%3DChallenges%2520in%2520the%2520treatment%2520of%2520triple%2520negative%2520and%2520HER2-overexpressing%2520breast%2520cancer%26jtitle%3DJ.%2520Surg.%2520Sci.%26date%3D2013%26volume%3D1%26spage%3D3%26epage%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Foulkes, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reis-Filho, J. S.</span><span> </span><span class="NLM_article-title">Triple-negative breast cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1938</span><span class="NLM_x">–</span> <span class="NLM_lpage">1948</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1056%2FNEJMra1001389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=21067385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVCltr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1938-1948&author=W.+D.+Foulkesauthor=I.+E.+Smithauthor=J.+S.+Reis-Filho&title=Triple-negative+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Triple-negative breast cancer</span></div><div class="casAuthors">Foulkes, William D.; Smith, Ian E.; Reis-Filho, Jorge S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1938-1948</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiN8P8IsovvLVg90H21EOLACvtfcHk0lh-PySdT3Qxlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVCltr7P&md5=641fe4726e6a7118208aa6b3502c9df6</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1001389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1001389%26sid%3Dliteratum%253Aachs%26aulast%3DFoulkes%26aufirst%3DW.%2BD.%26aulast%3DSmith%26aufirst%3DI.%2BE.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26atitle%3DTriple-negative%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1938%26epage%3D1948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Hudis, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gianni, L.</span><span> </span><span class="NLM_article-title">Triple-negative breast cancer: an unmet medical need</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">11</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=1-11&author=C.+A.+Hudisauthor=L.+Gianni&title=Triple-negative+breast+cancer%3A+an+unmet+medical+need"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHudis%26aufirst%3DC.%2BA.%26aulast%3DGianni%26aufirst%3DL.%26atitle%3DTriple-negative%2520breast%2520cancer%253A%2520an%2520unmet%2520medical%2520need%26jtitle%3DOncologist%26date%3D2011%26volume%3D16%26spage%3D1%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Engebraaten, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vollan, H. K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Børresen-Dale, A.-L.</span><span> </span><span class="NLM_article-title">Triple-negative breast cancer and the need for new therapeutic targets</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">183</span><span class="NLM_x">, </span> <span class="NLM_fpage">1064</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1016%2Fj.ajpath.2013.05.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=23920327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2ktrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2013&pages=1064-1074&author=O.+Engebraatenauthor=H.+K.+M.+Vollanauthor=A.-L.+B%C3%B8rresen-Dale&title=Triple-negative+breast+cancer+and+the+need+for+new+therapeutic+targets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Triple-Negative Breast Cancer and the Need for New Therapeutic Targets</span></div><div class="casAuthors">Engebraaten, Olav; Vollan, Hans Kristian Moen; Boerresen-Dale, Anne-Lise</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1064-1074</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Triple-neg. breast cancers (TNBCs) are a diverse and heterogeneous group of tumors that by definition lack estrogen and progesterone receptors and amplification of the HER2 gene.  The majority of the tumors classified as TNBCs are highly malignant, and only a subgroup responds to conventional chemotherapy with a favorable prognosis.  Results from decades of research have identified important mol. characteristics that can subdivide this group of breast cancers further.  High-throughput mol. analyses including sequencing, pathway analyses, and integrated analyses of alterations at the genomic and transcriptomic levels have improved our understanding of the mol. alterations involved in tumor development and progression.  How this knowledge should be used for rational selection of therapy is a challenging task and the subject of numerous ongoing research programs.  This review summarizes the current knowledge on the clin. characteristics and mol. alterations of TNBCs.  Currently used conventional therapeutic strategies and targeted therapy studies are discussed, with refs. to recently published results on the mol. characterization of TNBCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox7RPjyK4CDrVg90H21EOLACvtfcHk0liXo4N0t-ElgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2ktrjP&md5=d3b2dd27ab0981e380877cec7f28c453</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.ajpath.2013.05.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajpath.2013.05.033%26sid%3Dliteratum%253Aachs%26aulast%3DEngebraaten%26aufirst%3DO.%26aulast%3DVollan%26aufirst%3DH.%2BK.%2BM.%26aulast%3DB%25C3%25B8rresen-Dale%26aufirst%3DA.-L.%26atitle%3DTriple-negative%2520breast%2520cancer%2520and%2520the%2520need%2520for%2520new%2520therapeutic%2520targets%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2013%26volume%3D183%26spage%3D1064%26epage%3D1074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Caffarel, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andradas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pérez-Gómez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzmán, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sánchez, C.</span><span> </span><span class="NLM_article-title">Cannabinoids: a new hope for breast cancer therapy?</span> <span class="citation_source-journal">Cancer Treat. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">911</span><span class="NLM_x">–</span> <span class="NLM_lpage">918</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1016%2Fj.ctrv.2012.06.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=22776349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFGgs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2012&pages=911-918&author=M.+M.+Caffarelauthor=C.+Andradasauthor=E.+P%C3%A9rez-G%C3%B3mezauthor=M.+Guzm%C3%A1nauthor=C.+S%C3%A1nchez&title=Cannabinoids%3A+a+new+hope+for+breast+cancer+therapy%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoids: A new hope for breast cancer therapy?</span></div><div class="casAuthors">Caffarel, Maria M.; Andradas, Clara; Perez-Gomez, Eduardo; Guzman, Manuel; Sanchez, Cristina</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">911-918</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Breast cancer is a very common disease that affects approx. 1 in 10 women at some point in their lives.  Importantly, breast cancer cannot be considered a single disease as it is characterized by distinct pathol. and mol. subtypes that are treated with different therapies and have diverse clin. outcomes.  Although some highly successful treatments have been developed, certain breast tumors are resistant to conventional therapies and a considerable no. of them relapse.  Therefore, new strategies are urgently needed, and the challenge for the future will most likely be the development of individualized therapies that specifically target each patient's tumor.  Exptl. evidence accumulated during the last decade supports that cannabinoids, the active components of Cannabis sativa and their derivs., possess anticancer activity.  Thus, these compds. exert anti-proliferative, pro-apoptotic, anti-migratory and anti-invasive actions in a wide spectrum of cancer cells in culture.  Moreover, tumor growth, angiogenesis and metastasis are hampered by cannabinoids in xenograft-based and genetically-engineered mouse models of cancer.  This review summarizes our current knowledge on the anti-tumor potential of cannabinoids in breast cancer, which suggests that cannabinoid-based medicines may be useful for the treatment of most breast tumor subtypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBlC9cAlRexbVg90H21EOLACvtfcHk0liXo4N0t-ElgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFGgs78%253D&md5=1918aae12cfc16fb2045bdab2929fc9b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2012.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2012.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DCaffarel%26aufirst%3DM.%2BM.%26aulast%3DAndradas%26aufirst%3DC.%26aulast%3DP%25C3%25A9rez-G%25C3%25B3mez%26aufirst%3DE.%26aulast%3DGuzm%25C3%25A1n%26aufirst%3DM.%26aulast%3DS%25C3%25A1nchez%26aufirst%3DC.%26atitle%3DCannabinoids%253A%2520a%2520new%2520hope%2520for%2520breast%2520cancer%2520therapy%253F%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2012%26volume%3D38%26spage%3D911%26epage%3D918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Morales, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vara, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goméz-Cañas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zúñiga, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olea-Azar, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goya, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernández-Ruiz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Díaz-Laviada, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagerovic, N.</span><span> </span><span class="NLM_article-title">Synthetic cannabinoid quinones: preparation, in vitro antiproliferative effects and in vivo prostate antitumor activity</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">119</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1016%2Fj.ejmech.2013.09.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=24141201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOqu7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2013&pages=111-119&author=P.+Moralesauthor=D.+Varaauthor=M.+Gom%C3%A9z-Ca%C3%B1asauthor=M.+C.+Z%C3%BA%C3%B1igaauthor=C.+Olea-Azarauthor=P.+Goyaauthor=J.+Fern%C3%A1ndez-Ruizauthor=I.+D%C3%ADaz-Laviadaauthor=N.+Jagerovic&title=Synthetic+cannabinoid+quinones%3A+preparation%2C+in+vitro+antiproliferative+effects+and+in+vivo+prostate+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic cannabinoid quinones: Preparation, in vitro antiproliferative effects and in vivo prostate antitumor activity</span></div><div class="casAuthors">Morales, Paula; Vara, Diana; Gomez-Canas, Maria; Zuniga, Maria C.; Olea-Azar, Claudio; Goya, Pilar; Fernandez-Ruiz, Javier; Diaz-Laviada, Ines; Jagerovic, Nadine</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111-119</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Chromenopyrazolediones I (R = H, Me or Et) were designed and synthesized as anticancer agents using the multi-biol. target concept that involves quinone cytotoxicity and cannabinoid antitumor properties.  In cell cytotoxicity assays, these chromenopyrazolediones have antiproliferative activity against human prostate cancer and hepatocellular carcinoma.  The most potent, deriv. I (R = H) (PM49), inhibits prostate LNCaP cell viability (IC50 = 15 μM) through a mechanism involving oxidative stress, PPARγ receptor and partially CB1 receptor.  It acts on prostate cell growth by causing G0/G1 phase arrest and triggering apoptosis as assessed by flow cytometry measurements.  In the in vivo treatment, compd. 4 at 2 mg/kg, blocks the growth of LNCaP tumors and reduces the growth of PC-3 tumors generated in mice.  These studies suggest that 4 is a good potential anticancer agent against hormone-sensitive prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO5NQIw5F-dLVg90H21EOLACvtfcHk0liXo4N0t-ElgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOqu7zM&md5=bc7077307179432b6631f1cade5b9b37</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.09.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.09.043%26sid%3Dliteratum%253Aachs%26aulast%3DMorales%26aufirst%3DP.%26aulast%3DVara%26aufirst%3DD.%26aulast%3DGom%25C3%25A9z-Ca%25C3%25B1as%26aufirst%3DM.%26aulast%3DZ%25C3%25BA%25C3%25B1iga%26aufirst%3DM.%2BC.%26aulast%3DOlea-Azar%26aufirst%3DC.%26aulast%3DGoya%26aufirst%3DP.%26aulast%3DFern%25C3%25A1ndez-Ruiz%26aufirst%3DJ.%26aulast%3DD%25C3%25ADaz-Laviada%26aufirst%3DI.%26aulast%3DJagerovic%26aufirst%3DN.%26atitle%3DSynthetic%2520cannabinoid%2520quinones%253A%2520preparation%252C%2520in%2520vitro%2520antiproliferative%2520effects%2520and%2520in%2520vivo%2520prostate%2520antitumor%2520activity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D70%26spage%3D111%26epage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Cumella, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernández-Folgado, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girón, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sánchez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morales, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurst, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gómez-Cañas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gómez-Ruiz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinto, D. C. G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goya, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reggio, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernández-Ruiz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silva, A. M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagerovic, N.</span><span> </span><span class="NLM_article-title">Chromenopyrazoles: non-psychoactive and selective CB1 cannabinoid agonists with peripheral antinociceptive properties</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">452</span><span class="NLM_x">–</span> <span class="NLM_lpage">463</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=452-463&author=J.+Cumellaauthor=L.+Hern%C3%A1ndez-Folgadoauthor=R.+Gir%C3%B3nauthor=E.+S%C3%A1nchezauthor=P.+Moralesauthor=D.+P.+Hurstauthor=M.+G%C3%B3mez-Ca%C3%B1asauthor=M.+G%C3%B3mez-Ruizauthor=D.+C.+G.+A.+Pintoauthor=P.+Goyaauthor=P.+H.+Reggioauthor=M.+I.+Martinauthor=J.+Fern%C3%A1ndez-Ruizauthor=A.+M.+S.+Silvaauthor=N.+Jagerovic&title=Chromenopyrazoles%3A+non-psychoactive+and+selective+CB1+cannabinoid+agonists+with+peripheral+antinociceptive+properties"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCumella%26aufirst%3DJ.%26aulast%3DHern%25C3%25A1ndez-Folgado%26aufirst%3DL.%26aulast%3DGir%25C3%25B3n%26aufirst%3DR.%26aulast%3DS%25C3%25A1nchez%26aufirst%3DE.%26aulast%3DMorales%26aufirst%3DP.%26aulast%3DHurst%26aufirst%3DD.%2BP.%26aulast%3DG%25C3%25B3mez-Ca%25C3%25B1as%26aufirst%3DM.%26aulast%3DG%25C3%25B3mez-Ruiz%26aufirst%3DM.%26aulast%3DPinto%26aufirst%3DD.%2BC.%2BG.%2BA.%26aulast%3DGoya%26aufirst%3DP.%26aulast%3DReggio%26aufirst%3DP.%2BH.%26aulast%3DMartin%26aufirst%3DM.%2BI.%26aulast%3DFern%25C3%25A1ndez-Ruiz%26aufirst%3DJ.%26aulast%3DSilva%26aufirst%3DA.%2BM.%2BS.%26aulast%3DJagerovic%26aufirst%3DN.%26atitle%3DChromenopyrazoles%253A%2520non-psychoactive%2520and%2520selective%2520CB1%2520cannabinoid%2520agonists%2520with%2520peripheral%2520antinociceptive%2520properties%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D452%26epage%3D463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Wu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penning, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, R. G.</span><span> </span><span class="NLM_article-title">Regiospecific oxidation of polycyclic aromatic phenols to quinones by hypervalent iodine reagents</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">2111</span><span class="NLM_x">–</span> <span class="NLM_lpage">2118</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=2111-2118&author=A.+Wuauthor=Y.+Duanauthor=D.+Xuauthor=T.+M.+Penningauthor=R.+G.+Harvey&title=Regiospecific+oxidation+of+polycyclic+aromatic+phenols+to+quinones+by+hypervalent+iodine+reagents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DA.%26aulast%3DDuan%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DPenning%26aufirst%3DT.%2BM.%26aulast%3DHarvey%26aufirst%3DR.%2BG.%26atitle%3DRegiospecific%2520oxidation%2520of%2520polycyclic%2520aromatic%2520phenols%2520to%2520quinones%2520by%2520hypervalent%2520iodine%2520reagents%26jtitle%3DTetrahedron%26date%3D2010%26volume%3D66%26spage%3D2111%26epage%3D2118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Magdziak, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van De Water, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettus, T. R. R.</span><span> </span><span class="NLM_article-title">Regioselective oxidation of phenols to <i>o</i>-quinones with <i>o</i>-iodoxybenzoic acid (IBX)</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_fpage">285</span><span class="NLM_x">–</span> <span class="NLM_lpage">288</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&pages=285-288&author=D.+Magdziakauthor=A.+A.+Rodriguezauthor=R.+W.+Van+De+Waterauthor=T.+R.+R.+Pettus&title=Regioselective+oxidation+of+phenols+to+o-quinones+with+o-iodoxybenzoic+acid+%28IBX%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMagdziak%26aufirst%3DD.%26aulast%3DRodriguez%26aufirst%3DA.%2BA.%26aulast%3DVan%2BDe%2BWater%26aufirst%3DR.%2BW.%26aulast%3DPettus%26aufirst%3DT.%2BR.%2BR.%26atitle%3DRegioselective%2520oxidation%2520of%2520phenols%2520to%2520o-quinones%2520with%2520o-iodoxybenzoic%2520acid%2520%2528IBX%2529%26jtitle%3DOrg.%2520Lett.%26date%3D2002%26spage%3D285%26epage%3D288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Harvey, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ran, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penning, T. M.</span><span> </span><span class="NLM_article-title">Synthesis of the <i>o</i>-quinones and other oxidized metabolites of polycyclic aromatic hydrocarbons implicated in carcinogenesis</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">2024</span><span class="NLM_x">–</span> <span class="NLM_lpage">2032</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo030348n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2004&pages=2024-2032&author=R.+G.+Harveyauthor=Q.+Daiauthor=C.+Ranauthor=T.+M.+Penning&title=Synthesis+of+the+o-quinones+and+other+oxidized+metabolites+of+polycyclic+aromatic+hydrocarbons+implicated+in+carcinogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjo030348n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo030348n%26sid%3Dliteratum%253Aachs%26aulast%3DHarvey%26aufirst%3DR.%2BG.%26aulast%3DDai%26aufirst%3DQ.%26aulast%3DRan%26aufirst%3DC.%26aulast%3DPenning%26aufirst%3DT.%2BM.%26atitle%3DSynthesis%2520of%2520the%2520o-quinones%2520and%2520other%2520oxidized%2520metabolites%2520of%2520polycyclic%2520aromatic%2520hydrocarbons%2520implicated%2520in%2520carcinogenesis%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2004%26volume%3D69%26spage%3D2024%26epage%3D2032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Barontini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crisante, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabrizi, G.</span><span> </span><span class="NLM_article-title">Selective and efficient oxidative modifications of flavonoids with 2-iodoxybenzoic acid (IBX)</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">6047</span><span class="NLM_x">–</span> <span class="NLM_lpage">6053</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=6047-6053&author=M.+Barontiniauthor=R.+Berniniauthor=F.+Crisanteauthor=G.+Fabrizi&title=Selective+and+efficient+oxidative+modifications+of+flavonoids+with+2-iodoxybenzoic+acid+%28IBX%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBarontini%26aufirst%3DM.%26aulast%3DBernini%26aufirst%3DR.%26aulast%3DCrisante%26aufirst%3DF.%26aulast%3DFabrizi%26aufirst%3DG.%26atitle%3DSelective%2520and%2520efficient%2520oxidative%2520modifications%2520of%2520flavonoids%2520with%25202-iodoxybenzoic%2520acid%2520%2528IBX%2529%26jtitle%3DTetrahedron%26date%3D2010%26volume%3D66%26spage%3D6047%26epage%3D6053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Ekins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waller, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaan, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruciani, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrighton, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wikel, J. H.</span><span> </span><span class="NLM_article-title">Progress in predicting human ADME parameters in silico</span> <span class="citation_source-journal">J. Pharmacol. Toxicol. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1016%2FS1056-8719%2800%2900109-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=11274894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A280%3ADC%252BD3M7os1Ojtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2000&pages=251-272&author=S.+Ekinsauthor=C.+L.+Wallerauthor=P.+W.+Swaanauthor=G.+Crucianiauthor=S.+A.+Wrightonauthor=J.+H.+Wikel&title=Progress+in+predicting+human+ADME+parameters+in+silico"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in predicting human ADME parameters in silico</span></div><div class="casAuthors">Ekins S; Waller C L; Swaan P W; Cruciani G; Wrighton S A; Wikel J H</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmacological and toxicological methods</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">251-72</span>
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    </div><div class="casAbstract">Understanding the development of a scientific approach is a valuable exercise in gauging the potential directions the process could take in the future.  The relatively short history of applying computational methods to absorption, distribution, metabolism and excretion (ADME) can be split into defined periods.  The first began in the 1960s and continued through the 1970s with the work of Corwin Hansch et al.  Their models utilized small sets of in vivo ADME data.  The second era from the 1980s through 1990s witnessed the widespread incorporation of in vitro approaches as surrogates of in vivo ADME studies.  These approaches fostered the initiation and increase in interpretable computational ADME models available in the literature.  The third era is the present were there are many literature data sets derived from in vitro data for absorption, drug-drug interactions (DDI), drug transporters and efflux pumps [P-glycoprotein (P-gp), MRP], intrinsic clearance and brain penetration, which can theoretically be used to predict the situation in vivo in humans.  Combinatorial synthesis, high throughput screening and computational approaches have emerged as a result of continual pressure on pharmaceutical companies to accelerate drug discovery while decreasing drug development costs.  The goal has become to reduce the drop-out rate of drug candidates in the latter, most expensive stages of drug development.  This is accomplished by increasing the failure rate of candidate compounds in the preclinical stages and increasing the speed of nomination of likely clinical candidates.  The industry now understands the reasons for clinical failure other than efficacy are mainly related to pharmacokinetics and toxicity.  The late 1990s saw significant company investment in ADME and drug safety departments to assess properties such as metabolic stability, cytochrome P-450 inhibition, absorption and genotoxicity earlier in the drug discovery paradigm.  The next logical step in this process is the evaluation of higher throughput data to determine if computational (in silico) models can be constructed and validated from it.  Such models would allow an exponential increase in the number of compounds screened virtually for ADME parameters.  A number of researchers have started to utilize in silico, in vitro and in vivo approaches in parallel to address intestinal permeability and cytochrome P-450-mediated DDI.  This review will assess how computational approaches for ADME parameters have evolved and how they are likely to progress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmUcEou3dTay6Ufuk_1xoTfW6udTcc2eaUWrCY36-nbLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M7os1Ojtg%253D%253D&md5=d1ac16400ca299c81372e71b36517565</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2FS1056-8719%2800%2900109-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1056-8719%252800%252900109-X%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DWaller%26aufirst%3DC.%2BL.%26aulast%3DSwaan%26aufirst%3DP.%2BW.%26aulast%3DCruciani%26aufirst%3DG.%26aulast%3DWrighton%26aufirst%3DS.%2BA.%26aulast%3DWikel%26aufirst%3DJ.%2BH.%26atitle%3DProgress%2520in%2520predicting%2520human%2520ADME%2520parameters%2520in%2520silico%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2000%26volume%3D44%26spage%3D251%26epage%3D272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Van de Waterbeemd, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gifford, E.</span><span> </span><span class="NLM_article-title">ADMET in silico modelling: towards prediction paradise?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">192</span><span class="NLM_x">–</span> <span class="NLM_lpage">204</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=192-204&author=H.+Van+de+Waterbeemdauthor=E.+Gifford&title=ADMET+in+silico+modelling%3A+towards+prediction+paradise%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bde%2BWaterbeemd%26aufirst%3DH.%26aulast%3DGifford%26aufirst%3DE.%26atitle%3DADMET%2520in%2520silico%2520modelling%253A%2520towards%2520prediction%2520paradise%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26spage%3D192%26epage%3D204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Jorgensen, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffy, E. M.</span><span> </span><span class="NLM_article-title">Prediction of drug solubility from structure</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">366</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1016%2FS0169-409X%2802%2900008-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=11922952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BD38Xitlartbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2002&pages=355-366&author=W.+L.+Jorgensenauthor=E.+M.+Duffy&title=Prediction+of+drug+solubility+from+structure"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of drug solubility from structure</span></div><div class="casAuthors">Jorgensen, William L.; Duffy, Erin M.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">355-366</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with refs.  The aq. soly. of a drug is an important factor affecting its bioavailability.  Numerous computational methods have been developed for the prediction of aq. soly. from a compd.'s structure.  A review is provided of the methodol. and quality of results for the most useful procedures including the model implemented in the QikProp program.  Viable methods now exist for predictions with <1 log unit uncertainty, which is adequate for prescreening synthetic candidates or design of combinatorial libraries.  Further progress with predictive methods would require an exptl. database of highly accurate solubilities for a large, diverse collection of drug-like mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUQSdPbpSK_rVg90H21EOLACvtfcHk0liWMdzghwgWHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xitlartbc%253D&md5=bc749286d56bf55c26d25b70806217e1</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2802%2900008-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252802%252900008-X%26sid%3Dliteratum%253Aachs%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DDuffy%26aufirst%3DE.%2BM.%26atitle%3DPrediction%2520of%2520drug%2520solubility%2520from%2520structure%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2002%26volume%3D54%26spage%3D355%26epage%3D366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Lipinski, C. A.</span><span> </span><span class="NLM_article-title">Drug-like properties and the causes of poor solubility and poor permeability</span> <span class="citation_source-journal">J. Pharmacol. Toxicol. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">249</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1016%2FS1056-8719%2800%2900107-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitF2ksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=235-249&author=C.+A.+Lipinski&title=Drug-like+properties+and+the+causes+of+poor+solubility+and+poor+permeability"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-like properties and the causes of poor solubility and poor permeability</span></div><div class="casAuthors">Lipinski, C. A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">235-249</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with 18 refs.  There are currently about 10,000 drug-like compds.  These are sparsely, rather than uniformly, distributed through chem. space.  True diversity does not exist in exptl. combinatorial chem. screening libraries.  Absorption, distribution, metab., and excretion (ADME) and chem. reactivity-related toxicity is low, while biol. receptor activity is higher dimensional in chem. space, and this is partly explainable by evolutionary pressures on ADME to deal with endobiotics and exobiotics.  ADME is hard to predict for large data sets because current ADME exptl. screens are multi-mechanisms, and predictions get worse as more data accumulates.  Currently, screening for biol. receptor activity precedes or is concurrent with screening for properties related to "drugability.  " In the future, "drugability" screening may precede biol. receptor activity screening.  The level of permeability or soly. needed for oral absorption is related to potency.  The relative importance of poor soly. and poor permeability towards the problem of poor oral absorption depends on the research approach used for lead generation.  A "rational drug design" approach as exemplified by Merck advanced clin. candidates leads to time-dependent higher mol. wt., higher H-bonding properties, unchanged lipophilicity, and, hence, poorer permeability.  A high throughput screening (HTS)-based approach as exemplified by unpublished data on Pfizer (Groton, CT) early candidates leads to higher mol. wt., unchanged H-bonding properties, higher lipophilicity, and, hence, poorer aq. soly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorZQtrQpa9GLVg90H21EOLACvtfcHk0ljbNo8p8Eb25g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitF2ksrc%253D&md5=d93f92471ea034b286e3d3098e0a6d99</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2FS1056-8719%2800%2900107-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1056-8719%252800%252900107-6%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26atitle%3DDrug-like%2520properties%2520and%2520the%2520causes%2520of%2520poor%2520solubility%2520and%2520poor%2520permeability%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2001%26volume%3D44%26spage%3D235%26epage%3D249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Metzger-Filho, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Azambuja, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saini, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viale, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradbury, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bliss, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azim, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Leo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sotiriou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piccart-Gebhart, M.</span><span> </span><span class="NLM_article-title">Dissecting the heterogeneity of triple-negative breast cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1879</span><span class="NLM_x">–</span> <span class="NLM_lpage">1887</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1200%2FJCO.2011.38.2010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=22454417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVantr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=1879-1887&author=O.+Metzger-Filhoauthor=A.+Tuttauthor=E.+de+Azambujaauthor=K.+S.+Sainiauthor=G.+Vialeauthor=S.+Loiauthor=I.+Bradburyauthor=J.+M.+Blissauthor=H.+A.+Azimauthor=P.+Ellisauthor=A.+Di+Leoauthor=J.+Baselgaauthor=C.+Sotiriouauthor=M.+Piccart-Gebhart&title=Dissecting+the+heterogeneity+of+triple-negative+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting the heterogeneity of triple-negative breast cancer</span></div><div class="casAuthors">Metzger-Filho, Otto; Tutt, Andrew; de Azambuja, Evandro; Saini, Kamal S.; Viale, Giuseppe; Loi, Sherene; Bradbury, Ian; Bliss, Judith M.; Azim, Hatem A., Jr.; Ellis, Paul; Di Leo, Angelo; Baselga, Jose; Sotiriou, Christos; Piccart-Gebhart, Martine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1879-1887</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Triple-neg. breast cancer (TNBC) accounts for 15% to 20% of breast cancers.  It is a heterogeneous disease, not only on the mol. level, but also on the pathol. and clin. levels.  TNBC is assocd. with a significantly higher probability of relapse and poorer overall survival in the first few years after diagnosis when compared with other breast cancer subtypes.  This is obsd. despite its usual high sensitivity to chemotherapy.  In the advanced setting, responses obsd. with chemotherapy lack durability.  Early-stage clin. studies suggested impressive potential when a poly (ADP-ribose) polymerase (PARP) inhibitor is given for the treatment of advanced TNBC with BRCA gene dysfunction.  The mol. complexity of TNBC has led to proposed subclassifications, which will be of great value for the development of targeted therapies.  In this review, we discuss the biol. of TNBC at the pathol. and the mol. levels.  We also elaborate on the role of systemic therapies and the results of the first phase III clin. trial evaluating the addn. of iniparib, a novel investigational anticancer agent that does not possess characteristics typical of the PARP inhibitor class, in combination with chemotherapy in advanced TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfs4COhEhde7Vg90H21EOLACvtfcHk0ljbNo8p8Eb25g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVantr%252FP&md5=3b5c98bda8556e03ae999abe84d2e3e1</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.38.2010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.38.2010%26sid%3Dliteratum%253Aachs%26aulast%3DMetzger-Filho%26aufirst%3DO.%26aulast%3DTutt%26aufirst%3DA.%26aulast%3Dde%2BAzambuja%26aufirst%3DE.%26aulast%3DSaini%26aufirst%3DK.%2BS.%26aulast%3DViale%26aufirst%3DG.%26aulast%3DLoi%26aufirst%3DS.%26aulast%3DBradbury%26aufirst%3DI.%26aulast%3DBliss%26aufirst%3DJ.%2BM.%26aulast%3DAzim%26aufirst%3DH.%2BA.%26aulast%3DEllis%26aufirst%3DP.%26aulast%3DDi%2BLeo%26aufirst%3DA.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DSotiriou%26aufirst%3DC.%26aulast%3DPiccart-Gebhart%26aufirst%3DM.%26atitle%3DDissecting%2520the%2520heterogeneity%2520of%2520triple-negative%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D1879%26epage%3D1887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Criscitiello, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azim, H. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schouten, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linn, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sotiriou, C.</span><span> </span><span class="NLM_article-title">Understanding the biology of triple-negative breast cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 6</span><span class="NLM_x">) </span> <span class="NLM_fpage">vi13</span><span class="NLM_x">–</span> <span class="NLM_lpage">vi18</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1093%2Fannonc%2Fmds188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=23012296" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=vi13-vi18&issue=Suppl.+6&author=C.+Criscitielloauthor=H.+A.+Azimauthor=P.+C.+Schoutenauthor=S.+C.+Linnauthor=C.+Sotiriou&title=Understanding+the+biology+of+triple-negative+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmds188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmds188%26sid%3Dliteratum%253Aachs%26aulast%3DCriscitiello%26aufirst%3DC.%26aulast%3DAzim%26aufirst%3DH.%2BA.%26aulast%3DSchouten%26aufirst%3DP.%2BC.%26aulast%3DLinn%26aufirst%3DS.%2BC.%26aulast%3DSotiriou%26aufirst%3DC.%26atitle%3DUnderstanding%2520the%2520biology%2520of%2520triple-negative%2520breast%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2012%26volume%3D23%26issue%3DSuppl.%25206%26spage%3Dvi13%26epage%3Dvi18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Rocha, F. C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dos Santos Júnior, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefano, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">da Silveira, D. X.</span><span> </span><span class="NLM_article-title">Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas</span> <span class="citation_source-journal">J. Neurooncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">24</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1007%2Fs11060-013-1277-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=24142199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252FotlajtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2014&pages=11-24&author=F.+C.+M.+Rochaauthor=J.+G.+Dos+Santos+J%C3%BAniorauthor=S.+C.+Stefanoauthor=D.+X.+da+Silveira&title=Systematic+review+of+the+literature+on+clinical+and+experimental+trials+on+the+antitumor+effects+of+cannabinoids+in+gliomas"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas</span></div><div class="casAuthors">Rocha Francisco Carlos Machado; Dos Santos Junior Jair Guilherme; Stefano Sergio Carlos; da Silveira Dartiu Xavier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuro-oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-24</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">To evaluate, through a systematic review of the literature, the antitumoral effects of cannabinoids on gliomas.  Research included the following electronic databases: PUBMED, EMBASE, LILACS and The Cochrane Collaboration Controlled Trials Register.  All published studies involving the antitumoral effects (cellular and molecular mechanisms) of cannabinoids were considered for this review.  The bibliography search strategy included all publications of each of these databases until December 31, 2012.  From 2,260 initially identified articles, 35 fulfilled the inclusion criteria for this review.  All the studies included in this systematic review were experimental (in vivo and/or in vitro), except for one pilot clinical trial phase I/II involving humans.  In all experimental studies included, cannabinoids exerted antitumoral activity in vitro and/or antitumoral evidence in vivo in several models of tumor cells and tumors.  The antitumor activity included: antiproliferative effects (cell cycle arrest), decreased viability and cell death by toxicity, apoptosis, necrosis, autophagy, as well as antiangiogenic and antimigratory effects.  Antitumoral evidence included: reduction in tumor size, antiangiogenic, and antimetastatic effects.  Additionally, most of the studies described that the canabinnoids exercised selective antitumoral action in several distinct tumor models.  Thereby, normal cells used as controls were not affected.  The safety factor in the cannabinoids' administration has also been demonstrated in vivo.  The various cannabinoids tested in multiple tumor models showed antitumoral effects both in vitro and in vivo.  These findings indicate that cannabinoids are promising compounds for the treatment of gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ2cs4aVLDjK2hHGZei4OW9fW6udTcc2eZ9piS4lT1eNrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FotlajtA%253D%253D&md5=1c69b5d07ae0daa213f7196f108f770a</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1007%2Fs11060-013-1277-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11060-013-1277-1%26sid%3Dliteratum%253Aachs%26aulast%3DRocha%26aufirst%3DF.%2BC.%2BM.%26aulast%3DDos%2BSantos%2BJ%25C3%25BAnior%26aufirst%3DJ.%2BG.%26aulast%3DStefano%26aufirst%3DS.%2BC.%26aulast%3Dda%2BSilveira%26aufirst%3DD.%2BX.%26atitle%3DSystematic%2520review%2520of%2520the%2520literature%2520on%2520clinical%2520and%2520experimental%2520trials%2520on%2520the%2520antitumor%2520effects%2520of%2520cannabinoids%2520in%2520gliomas%26jtitle%3DJ.%2520Neurooncol.%26date%3D2014%26volume%3D116%26spage%3D11%26epage%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Guzmán, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duarte, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blázquez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravina, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosa, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galve-Roperh, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sánchez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">González-Feria, L.</span><span> </span><span class="NLM_article-title">A pilot clinical study of Δ<sup>9</sup>-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">203</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1038%2Fsj.bjc.6603236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=16804518" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFajsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2006&pages=197-203&author=M.+Guzm%C3%A1nauthor=M.+J.+Duarteauthor=C.+Bl%C3%A1zquezauthor=J.+Ravinaauthor=M.+C.+Rosaauthor=I.+Galve-Roperhauthor=C.+S%C3%A1nchezauthor=G.+Velascoauthor=L.+Gonz%C3%A1lez-Feria&title=A+pilot+clinical+study+of+%CE%949-tetrahydrocannabinol+in+patients+with+recurrent+glioblastoma+multiforme"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme</span></div><div class="casAuthors">Guzman, M.; Duarte, M. J.; Blazquez, C.; Ravina, J.; Rosa, M. C.; Galve-Roperh, I.; Sanchez, C.; Velasco, G.; Gonzalez-Feria, L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">197-203</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Δ9-Tetrahydrocannabinol (THC) and other cannabinoids inhibit tumor growth and angiogenesis in animal models, so their potential application as antitumoral drugs has been suggested.  However, the antitumoral effect of cannabinoids has never been tested in humans.  Here we report the first clin. study aimed at assessing cannabinoid antitumoral action, specifically a pilot phase I trial in which nine patients with recurrent glioblastoma multiforme were administered THC intratumoraly.  The patients had previously failed std. therapy (surgery and radiotherapy) and had clear evidence of tumor progression.  The primary end point of the study was to det. the safety of intracranial THC administration.  We also evaluated THC action on the length of survival and various tumor-cell parameters.  A dose escalation regimen for THC administration was assessed.  Cannabinoid delivery was safe and could be achieved without overt psychoactive effects.  Median survival of the cohort from the beginning of cannabinoid administration was 24 wk (95% confidence interval: 15-33). Δ9-Tetrahydrocannabinol inhibited tumor-cell proliferation in vitro and decreased tumor-cell Ki67 immunostaining when administered to two patients.  The fair safety profile of THC, together with its possible antiproliferative action on tumor cells reported here and in other studies, may set the basis for future trials aimed at evaluating the potential antitumoral activity of cannabinoids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokrBEQa1plhbVg90H21EOLACvtfcHk0lh3h5Jts8VKKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFajsLo%253D&md5=bd262bc9925ba29efb9c43615a5b98e6</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6603236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6603236%26sid%3Dliteratum%253Aachs%26aulast%3DGuzm%25C3%25A1n%26aufirst%3DM.%26aulast%3DDuarte%26aufirst%3DM.%2BJ.%26aulast%3DBl%25C3%25A1zquez%26aufirst%3DC.%26aulast%3DRavina%26aufirst%3DJ.%26aulast%3DRosa%26aufirst%3DM.%2BC.%26aulast%3DGalve-Roperh%26aufirst%3DI.%26aulast%3DS%25C3%25A1nchez%26aufirst%3DC.%26aulast%3DVelasco%26aufirst%3DG.%26aulast%3DGonz%25C3%25A1lez-Feria%26aufirst%3DL.%26atitle%3DA%2520pilot%2520clinical%2520study%2520of%2520%25CE%25949-tetrahydrocannabinol%2520in%2520patients%2520with%2520recurrent%2520glioblastoma%2520multiforme%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2006%26volume%3D95%26spage%3D197%26epage%3D203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Anighoro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rastelli, G.</span><span> </span><span class="NLM_article-title">Polypharmacology: challenges and opportunities in drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">7874</span><span class="NLM_x">–</span> <span class="NLM_lpage">7887</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+challenges+and+opportunities+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0lhBDE9TjZfOFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520challenges%2520and%2520opportunities%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7874%26epage%3D7887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Gediya, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Njar, V. C. O.</span><span> </span><span class="NLM_article-title">Promise and challenges in drug discovery and development of hybrid anticancer drugs</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1099</span><span class="NLM_x">–</span> <span class="NLM_lpage">1111</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=1099-1111&author=L.+K.+Gediyaauthor=V.+C.+O.+Njar&title=Promise+and+challenges+in+drug+discovery+and+development+of+hybrid+anticancer+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGediya%26aufirst%3DL.%2BK.%26aulast%3DNjar%26aufirst%3DV.%2BC.%2BO.%26atitle%3DPromise%2520and%2520challenges%2520in%2520drug%2520discovery%2520and%2520development%2520of%2520hybrid%2520anticancer%2520drugs%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2009%26volume%3D4%26spage%3D1099%26epage%3D1111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Kogan, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabinowitz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandor, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlesinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mechoulam, R.</span><span> </span><span class="NLM_article-title">Synthesis and antitumor activity of quinonoid derivatives of cannabinoids</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">3800</span><span class="NLM_x">–</span> <span class="NLM_lpage">3806</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm040042o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=3800-3806&author=N.+M.+Koganauthor=R.+Rabinowitzauthor=P.+Leviauthor=D.+Gibsonauthor=P.+Sandorauthor=M.+Schlesingerauthor=R.+Mechoulam&title=Synthesis+and+antitumor+activity+of+quinonoid+derivatives+of+cannabinoids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm040042o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040042o%26sid%3Dliteratum%253Aachs%26aulast%3DKogan%26aufirst%3DN.%2BM.%26aulast%3DRabinowitz%26aufirst%3DR.%26aulast%3DLevi%26aufirst%3DP.%26aulast%3DGibson%26aufirst%3DD.%26aulast%3DSandor%26aufirst%3DP.%26aulast%3DSchlesinger%26aufirst%3DM.%26aulast%3DMechoulam%26aufirst%3DR.%26atitle%3DSynthesis%2520and%2520antitumor%2520activity%2520of%2520quinonoid%2520derivatives%2520of%2520cannabinoids%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D3800%26epage%3D3806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Gorrini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, T. W.</span><span> </span><span class="NLM_article-title">Modulation of oxidative stress as an anticancer strategy</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">931</span><span class="NLM_x">–</span> <span class="NLM_lpage">947</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1038%2Fnrd4002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=24287781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVGqs7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=931-947&author=C.+Gorriniauthor=I.+S.+Harrisauthor=T.+W.+Mak&title=Modulation+of+oxidative+stress+as+an+anticancer+strategy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of oxidative stress as an anticancer strategy</span></div><div class="casAuthors">Gorrini, Chiara; Harris, Isaac S.; Mak, Tak W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">931-947</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The regulation of oxidative stress is an important factor in both tumor development and responses to anticancer therapies.  Many signalling pathways that are linked to tumorigenesis can also regulate the metab. of reactive oxygen species (ROS) through direct or indirect mechanisms.  High ROS levels are generally detrimental to cells, and the redox status of cancer cells usually differs from that of normal cells.  Because of metabolic and signalling aberrations, cancer cells exhibit elevated ROS levels.  The observation that this is balanced by an increased antioxidant capacity suggests that high ROS levels may constitute a barrier to tumorigenesis.  However, ROS can also promote tumor formation by inducing DNA mutations and pro-oncogenic signalling pathways.  These contradictory effects have important implications for potential anticancer strategies that aim to modulate levels of ROS.  In this Review, we address the controversial role of ROS in tumor development and in responses to anticancer therapies, and elaborate on the idea that targeting the antioxidant capacity of tumor cells can have a pos. therapeutic impact.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVKYMoILuOfbVg90H21EOLACvtfcHk0lhBDE9TjZfOFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVGqs7%252FI&md5=7f135a1b32b1134a88cfa28b35c53de7</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fnrd4002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4002%26sid%3Dliteratum%253Aachs%26aulast%3DGorrini%26aufirst%3DC.%26aulast%3DHarris%26aufirst%3DI.%2BS.%26aulast%3DMak%26aufirst%3DT.%2BW.%26atitle%3DModulation%2520of%2520oxidative%2520stress%2520as%2520an%2520anticancer%2520strategy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D931%26epage%3D947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Ross, R. A.</span><span> </span><span class="NLM_article-title">The enigmatic pharmacology of GPR55</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">156</span><span class="NLM_x">–</span> <span class="NLM_lpage">163</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=156-163&author=R.+A.+Ross&title=The+enigmatic+pharmacology+of+GPR55"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRoss%26aufirst%3DR.%2BA.%26atitle%3DThe%2520enigmatic%2520pharmacology%2520of%2520GPR55%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2009%26volume%3D30%26spage%3D156%26epage%3D163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Pertwee, R. G.</span><span> </span><span class="NLM_article-title">GPR55: a new member of the cannabinoid receptor clan?</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">152</span><span class="NLM_x">, </span> <span class="NLM_fpage">984</span><span class="NLM_x">–</span> <span class="NLM_lpage">986</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1038%2Fsj.bjp.0707464" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=17876300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlCrsbnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2007&pages=984-986&author=R.+G.+Pertwee&title=GPR55%3A+a+new+member+of+the+cannabinoid+receptor+clan%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">GPR55: a new member of the cannabinoid receptor clan?</span></div><div class="casAuthors">Pertwee, R. G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">984-986</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In this issue of the British Journal of Pharmacol., Ryberg et al. present convincing in vitro evidence that the orphan GPCR, GPR55, is a cannabinoid receptor.  GPR55 was activated by a range of plant, synthetic and endogenous cannabinoids and blocked by the non-psychoactive phytocannabinoid, cannabidiol.  Their expts. have revealed several differences between the pharmacol. of GPR55 and the established cannabinoid CB1 and CB2 receptors.  For example, the CB1 receptor antagonist, AM251, activated GPR55 and the main psychoactive constituent of cannabis, Δ9-tetrahydrocannabinol, displayed greater efficacy at GPR55 than at CB1 or CB2 receptors.  They also compared the distribution of GPR55 and CB1 mRNA in mouse and report that GPR55 couples to Gα13, that it is activated by virodhamine, palmitoylethanolamide and oleoylethanolamide, and that virodhamine displays relatively high efficacy as a GPR55 agonist.  Still to be identified are the main roles played by GPR55 in health and disease and any potential therapeutic benefits of activating or blocking this receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdAjaBubV8mbVg90H21EOLACvtfcHk0lhBDE9TjZfOFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlCrsbnJ&md5=98389e36d4406144b1c8c8d34bd39fb1</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0707464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0707464%26sid%3Dliteratum%253Aachs%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26atitle%3DGPR55%253A%2520a%2520new%2520member%2520of%2520the%2520cannabinoid%2520receptor%2520clan%253F%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2007%26volume%3D152%26spage%3D984%26epage%3D986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Ford, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roelofs, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anavi-Goffer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mowat, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpson, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irving, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajnicek, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, R. A.</span><span> </span><span class="NLM_article-title">A role for L-α-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">160</span><span class="NLM_x">, </span> <span class="NLM_fpage">762</span><span class="NLM_x">–</span> <span class="NLM_lpage">771</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1111%2Fj.1476-5381.2010.00743.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=20590578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpslyqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2010&pages=762-771&author=L.+A.+Fordauthor=A.+J.+Roelofsauthor=S.+Anavi-Gofferauthor=L.+Mowatauthor=D.+G.+Simpsonauthor=A.+J.+Irvingauthor=M.+J.+Rogersauthor=A.+M.+Rajnicekauthor=R.+A.+Ross&title=A+role+for+L-%CE%B1-lysophosphatidylinositol+and+GPR55+in+the+modulation+of+migration%2C+orientation+and+polarization+of+human+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">A role for L-α-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells</span></div><div class="casAuthors">Ford, Lesley A.; Roelofs, Anke J.; Anavi-Goffer, Sharon; Mowat, Luisa; Simpson, Daniel G.; Irving, Andrew J.; Rogers, Michael J.; Rajnicek, Ann M.; Ross, Ruth A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">762-771</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and purpose: Increased circulating levels of L-α-lysophosphatidylinositol (LPI) are assocd. with cancer and LPI is a potent, ligand for the G-protein-coupled receptor GPR55.  Here we have assessed the modulation of breast cancer cell migration, orientation and polarization by LPI and GPR55.  Exptl. approach: Quant. RT-PCR was used to measure GPR55 expression in breast cancer cell lines.  Cell migration and invasion were measured using a Boyden chamber chemotaxis assay and Cultrex invasion assay, resp.  Cell polarization and orientation in response to the microenvironment were measured using slides contg. nanometric grooves.  Key results: GPR55 expression was detected in the highly metastatic MDA-MB-231 breast cancer cell line.  In these cells, LPI stimulated binding of [35S]GTPγS to cell membranes (pEC50 6.47 ± 0.45) and significantly enhanced cell chemotaxis towards serum.  MCF-7 cells expressed low levels of GPR55 and did not migrate or invade towards serum factors.  When GPR55 was over-expressed in MCF-7 cells, serum induced a robust migratory and invasive response, which was further enhanced by LPI and prevented by siRNA to GPR55.  The phys. microenvironment has been identified as a key factor in detg. breast tumor cell metastatic fate.  LPI endowed MDA-MB-231 cells with the capacity to detect shallow (40 nm deep) grooved slides and induced marked cancer cell polarization on both flat and grooved surfaces.  Conclusions and implications: LPI and GPR55 play a role in the modulation of migration, orientation and polarization of breast cancer cells in response to the tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZSA67DIv_J7Vg90H21EOLACvtfcHk0lgebL2_7243AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpslyqsrY%253D&md5=8c3879c19844159c7a1e5fe9617e6b68</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00743.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00743.x%26sid%3Dliteratum%253Aachs%26aulast%3DFord%26aufirst%3DL.%2BA.%26aulast%3DRoelofs%26aufirst%3DA.%2BJ.%26aulast%3DAnavi-Goffer%26aufirst%3DS.%26aulast%3DMowat%26aufirst%3DL.%26aulast%3DSimpson%26aufirst%3DD.%2BG.%26aulast%3DIrving%26aufirst%3DA.%2BJ.%26aulast%3DRogers%26aufirst%3DM.%2BJ.%26aulast%3DRajnicek%26aufirst%3DA.%2BM.%26aulast%3DRoss%26aufirst%3DR.%2BA.%26atitle%3DA%2520role%2520for%2520L-%25CE%25B1-lysophosphatidylinositol%2520and%2520GPR55%2520in%2520the%2520modulation%2520of%2520migration%252C%2520orientation%2520and%2520polarization%2520of%2520human%2520breast%2520cancer%2520cells%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D160%26spage%3D762%26epage%3D771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Bylund, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toews, M.</span><span> </span><span class="NLM_article-title">Radioligand binding methods—practical guide and tips</span> <span class="citation_source-journal">Am. J. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">265</span><span class="NLM_x">, </span> <span class="NLM_fpage">L421</span><span class="NLM_x">–</span> <span class="NLM_lpage">L429</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=265&publication_year=1993&pages=L421-L429&author=D.+Bylundauthor=M.+Toews&title=Radioligand+binding+methods%E2%80%94practical+guide+and+tips"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBylund%26aufirst%3DD.%26aulast%3DToews%26aufirst%3DM.%26atitle%3DRadioligand%2520binding%2520methods%25E2%2580%2594practical%2520guide%2520and%2520tips%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1993%26volume%3D265%26spage%3DL421%26epage%3DL429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 25 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paula  Morales</span>, <span class="hlFld-ContribAuthor ">Lauren S.  Whyte</span>, <span class="hlFld-ContribAuthor ">Roberto  Chicharro</span>, <span class="hlFld-ContribAuthor ">María  Gómez-Cañas</span>, <span class="hlFld-ContribAuthor ">M. Ruth  Pazos</span>, <span class="hlFld-ContribAuthor ">Pilar  Goya</span>, <span class="hlFld-ContribAuthor ">Andrew J.  Irving</span>, <span class="hlFld-ContribAuthor ">Javier  Fernández-Ruiz</span>, <span class="hlFld-ContribAuthor ">Ruth A.  Ross</span>, and <span class="hlFld-ContribAuthor ">Nadine  Jagerovic</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification of Novel GPR55 Modulators Using Cell-Impedance-Based Label-Free Technology. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (5)
                                     , 1840-1853. <a href="https://doi.org/10.1021/acs.jmedchem.5b01331" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01331</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01331%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BNovel%252BGPR55%252BModulators%252BUsing%252BCell-Impedance-Based%252BLabel-Free%252BTechnology%26aulast%3DMorales%26aufirst%3DPaula%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D28082015%26date%3D05022016%26date%3D10032016%26date%3D20012016%26volume%3D59%26issue%3D5%26spage%3D1840%26epage%3D1853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Benjamin  Brennecke</span>, <span class="hlFld-ContribAuthor ">Thais  Gazzi</span>, <span class="hlFld-ContribAuthor ">Kenneth  Atz</span>, <span class="hlFld-ContribAuthor ">Jürgen  Fingerle</span>, <span class="hlFld-ContribAuthor ">Pascal  Kuner</span>, <span class="hlFld-ContribAuthor ">Torsten  Schindler</span>, <span class="hlFld-ContribAuthor ">Guy de  Weck</span>, <span class="hlFld-ContribAuthor ">Marc  Nazaré</span>, <span class="hlFld-ContribAuthor ">Uwe  Grether</span>. </span><span class="cited-content_cbyCitation_article-title">Cannabinoid receptor type 2 ligands: an analysis of granted patents since 2010. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutical Patent Analyst</span><span> <strong>2021,</strong> <em>10 </em>
                                    (3)
                                     , 111-163. <a href="https://doi.org/10.4155/ppa-2021-0002" title="DOI URL">https://doi.org/10.4155/ppa-2021-0002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/ppa-2021-0002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Fppa-2021-0002%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutical%2520Patent%2520Analyst%26atitle%3DCannabinoid%252Breceptor%252Btype%252B2%2525C2%2525A0ligands%25253A%252Ban%252Banalysis%252Bof%252Bgranted%252Bpatents%252Bsince%252B2010%26aulast%3DBrennecke%26aufirst%3DBenjamin%26date%3D2021%26volume%3D10%26issue%3D3%26spage%3D111%26epage%3D163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Battistina  Asproni</span>, <span class="hlFld-ContribAuthor ">Gabriele  Murineddu</span>, <span class="hlFld-ContribAuthor ">Paola  Corona</span>, <span class="hlFld-ContribAuthor ">Gérard A.  Pinna</span>. </span><span class="cited-content_cbyCitation_article-title">Tricyclic Pyrazole-Based Compounds as Useful Scaffolds for Cannabinoid CB1/CB2 Receptor Interaction. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (8)
                                     , 2126. <a href="https://doi.org/10.3390/molecules26082126" title="DOI URL">https://doi.org/10.3390/molecules26082126</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26082126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26082126%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DTricyclic%252BPyrazole-Based%252BCompounds%252Bas%252BUseful%252BScaffolds%252Bfor%252BCannabinoid%252BCB1%25252FCB2%252BReceptor%252BInteraction%26aulast%3DAsproni%26aufirst%3DBattistina%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D8%26spage%3D2126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Natalya M.  Kogan</span>, <span class="hlFld-ContribAuthor ">Maximilian  Peters</span>, <span class="hlFld-ContribAuthor ">Raphael  Mechoulam</span>. </span><span class="cited-content_cbyCitation_article-title">Cannabinoid Quinones—A Review and Novel Observations. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (6)
                                     , 1761. <a href="https://doi.org/10.3390/molecules26061761" title="DOI URL">https://doi.org/10.3390/molecules26061761</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26061761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26061761%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DCannabinoid%252BQuinones%2525E2%252580%252594A%252BReview%252Band%252BNovel%252BObservations%26aulast%3DKogan%26aufirst%3DNatalya%2BM.%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D6%26spage%3D1761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paula  Morales</span>, <span class="hlFld-ContribAuthor ">Patricia H.  Reggio</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging Roles of Cannabinoids and Synthetic Cannabinoids in Clinical Experimental Models. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 47-65. <a href="https://doi.org/10.1007/978-3-030-57369-0_4" title="DOI URL">https://doi.org/10.1007/978-3-030-57369-0_4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-57369-0_4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-57369-0_4%26sid%3Dliteratum%253Aachs%26atitle%3DEmerging%252BRoles%252Bof%252BCannabinoids%252Band%252BSynthetic%252BCannabinoids%252Bin%252BClinical%252BExperimental%252BModels%26aulast%3DMorales%26aufirst%3DPaula%26date%3D2021%26date%3D2020%26spage%3D47%26epage%3D65%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DCannabinoids%252Band%252BNeuropsychiatric%252BDisorders%26aulast%3DMurillo-Rodriguez%26aufirst%3DEric%26date%3D2021%26volume%3D1264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rajibul  Islam</span>, <span class="hlFld-ContribAuthor ">Kok Wai  Lam</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress in small molecule agents for the targeted therapy of triple-negative breast cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>207 </em>, 112812. <a href="https://doi.org/10.1016/j.ejmech.2020.112812" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112812</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112812%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bprogress%252Bin%252Bsmall%252Bmolecule%252Bagents%252Bfor%252Bthe%252Btargeted%252Btherapy%252Bof%252Btriple-negative%252Bbreast%252Bcancer%26aulast%3DIslam%26aufirst%3DRajibul%26date%3D2020%26volume%3D207%26spage%3D112812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paula  Morales</span>, <span class="hlFld-ContribAuthor ">Nadine  Jagerovic</span>. </span><span class="cited-content_cbyCitation_article-title">Novel approaches and current challenges with targeting the endocannabinoid system. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2020,</strong> <em>15 </em>
                                    (8)
                                     , 917-930. <a href="https://doi.org/10.1080/17460441.2020.1752178" title="DOI URL">https://doi.org/10.1080/17460441.2020.1752178</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2020.1752178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2020.1752178%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DNovel%252Bapproaches%252Band%252Bcurrent%252Bchallenges%252Bwith%252Btargeting%252Bthe%252Bendocannabinoid%252Bsystem%26aulast%3DMorales%26aufirst%3DPaula%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D8%26spage%3D917%26epage%3D930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rama Rao  Malla</span>, <span class="hlFld-ContribAuthor ">KGK  Deepak</span>, <span class="hlFld-ContribAuthor ">Neha  Merchant</span>, <span class="hlFld-ContribAuthor ">Venkata Ramesh  Dasari</span>. </span><span class="cited-content_cbyCitation_article-title">Breast Tumor Microenvironment: Emerging target of therapeutic phytochemicals. </span><span class="cited-content_cbyCitation_journal-name">Phytomedicine</span><span> <strong>2020,</strong> <em>70 </em>, 153227. <a href="https://doi.org/10.1016/j.phymed.2020.153227" title="DOI URL">https://doi.org/10.1016/j.phymed.2020.153227</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phymed.2020.153227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phymed.2020.153227%26sid%3Dliteratum%253Aachs%26jtitle%3DPhytomedicine%26atitle%3DBreast%252BTumor%252BMicroenvironment%25253A%252BEmerging%252Btarget%252Bof%252Btherapeutic%252Bphytochemicals%26aulast%3DMalla%26aufirst%3DRama%2BRao%26date%3D2020%26volume%3D70%26spage%3D153227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paula  Morales</span>, <span class="hlFld-ContribAuthor ">Nadine  Jagerovic</span>. </span><span class="cited-content_cbyCitation_article-title">Antitumor Cannabinoid Chemotypes: Structural Insights. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2019,</strong> <em>10 </em><a href="https://doi.org/10.3389/fphar.2019.00621" title="DOI URL">https://doi.org/10.3389/fphar.2019.00621</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2019.00621&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2019.00621%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DAntitumor%252BCannabinoid%252BChemotypes%25253A%252BStructural%252BInsights%26aulast%3DMorales%26aufirst%3DPaula%26date%3D2019%26date%3D2019%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thanh C.  Ho</span>, <span class="hlFld-ContribAuthor ">Marcus A.  Tius</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Classical/Nonclassical Hybrid Cannabinoids and Related Compounds. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 247-289. <a href="https://doi.org/10.1007/978-981-13-6244-6_11" title="DOI URL">https://doi.org/10.1007/978-981-13-6244-6_11</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-981-13-6244-6_11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-981-13-6244-6_11%26sid%3Dliteratum%253Aachs%26atitle%3DSynthesis%252Bof%252BClassical%25252FNonclassical%252BHybrid%252BCannabinoids%252Band%252BRelated%252BCompounds%26aulast%3DHo%26aufirst%3DThanh%2BC.%26date%3D2019%26date%3D2019%26spage%3D247%26epage%3D289%26pub%3DSpringer%2520Singapore%26atitle%3DCutting-Edge%252BOrganic%252BSynthesis%252Band%252BChemical%252BBiology%252Bof%252BBioactive%252BMolecules%26aulast%3DKobayashi%26aufirst%3DYuichi%26date%3D2019%26volume%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiliang  Zhang</span>, <span class="hlFld-ContribAuthor ">Shaojuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Yang  Liu</span>, <span class="hlFld-ContribAuthor ">Meng  Su</span>, <span class="hlFld-ContribAuthor ">Xiaoxi  Ling</span>, <span class="hlFld-ContribAuthor ">Funan  Liu</span>, <span class="hlFld-ContribAuthor ">Yinghui  Ge</span>, <span class="hlFld-ContribAuthor ">Mingfeng  Bai</span>. </span><span class="cited-content_cbyCitation_article-title">Combined CB2 receptor agonist and photodynamic therapy synergistically inhibit tumor growth in triple negative breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Photodiagnosis and Photodynamic Therapy</span><span> <strong>2018,</strong> <em>24 </em>, 185-191. <a href="https://doi.org/10.1016/j.pdpdt.2018.09.006" title="DOI URL">https://doi.org/10.1016/j.pdpdt.2018.09.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pdpdt.2018.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pdpdt.2018.09.006%26sid%3Dliteratum%253Aachs%26jtitle%3DPhotodiagnosis%2520and%2520Photodynamic%2520Therapy%26atitle%3DCombined%252BCB2%252Breceptor%252Bagonist%252Band%252Bphotodynamic%252Btherapy%252Bsynergistically%252Binhibit%252Btumor%252Bgrowth%252Bin%252Btriple%252Bnegative%252Bbreast%252Bcancer%26aulast%3DZhang%26aufirst%3DJiliang%26date%3D2018%26volume%3D24%26spage%3D185%26epage%3D191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoxia  Guo</span>, <span class="hlFld-ContribAuthor ">Xiaoxi  Ling</span>, <span class="hlFld-ContribAuthor ">Fang  Du</span>, <span class="hlFld-ContribAuthor ">Qingbing  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Huang</span>, <span class="hlFld-ContribAuthor ">Zhongmin  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaoyi  Ding</span>, <span class="hlFld-ContribAuthor ">Mingfeng  Bai</span>, <span class="hlFld-ContribAuthor ">Zhiyuan  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Imaging of Pancreatic Duct Adenocarcinoma Using a Type 2 Cannabinoid Receptor-Targeted Near-Infrared Fluorescent Probe. </span><span class="cited-content_cbyCitation_journal-name">Translational Oncology</span><span> <strong>2018,</strong> <em>11 </em>
                                    (5)
                                     , 1065-1073. <a href="https://doi.org/10.1016/j.tranon.2018.06.009" title="DOI URL">https://doi.org/10.1016/j.tranon.2018.06.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tranon.2018.06.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tranon.2018.06.009%26sid%3Dliteratum%253Aachs%26jtitle%3DTranslational%2520Oncology%26atitle%3DMolecular%252BImaging%252Bof%252BPancreatic%252BDuct%252BAdenocarcinoma%252BUsing%252Ba%252BType%252B2%252BCannabinoid%252BReceptor-Targeted%252BNear-Infrared%252BFluorescent%252BProbe%26aulast%3DGuo%26aufirst%3DXiaoxia%26date%3D2018%26volume%3D11%26issue%3D5%26spage%3D1065%26epage%3D1073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuneize  Slater</span>, <span class="hlFld-ContribAuthor ">Pradeep B.  Lasonkar</span>, <span class="hlFld-ContribAuthor ">Saqlain  Haider</span>, <span class="hlFld-ContribAuthor ">Moneerah J.  Alqahtani</span>, <span class="hlFld-ContribAuthor ">Amar G.  Chittiboyina</span>, <span class="hlFld-ContribAuthor ">Ikhlas A.  Khan</span>. </span><span class="cited-content_cbyCitation_article-title">One-step, stereoselective synthesis of octahydrochromanes via the Prins reaction and their cannabinoid activities. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2018,</strong> <em>59 </em>
                                    (9)
                                     , 807-810. <a href="https://doi.org/10.1016/j.tetlet.2018.01.040" title="DOI URL">https://doi.org/10.1016/j.tetlet.2018.01.040</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2018.01.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2018.01.040%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DOne-step%25252C%252Bstereoselective%252Bsynthesis%252Bof%252Boctahydrochromanes%252Bvia%252Bthe%252BPrins%252Breaction%252Band%252Btheir%252Bcannabinoid%252Bactivities%26aulast%3DSlater%26aufirst%3DShuneize%26date%3D2018%26volume%3D59%26issue%3D9%26spage%3D807%26epage%3D810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuqi  Lin</span>, <span class="hlFld-ContribAuthor ">Rong  Liu</span>, <span class="hlFld-ContribAuthor ">Ping  Zhao</span>, <span class="hlFld-ContribAuthor ">Jinxiang  Ye</span>, <span class="hlFld-ContribAuthor ">Zheng  Zheng</span>, <span class="hlFld-ContribAuthor ">Jingan  Huang</span>, <span class="hlFld-ContribAuthor ">Yingying  Zhang</span>, <span class="hlFld-ContribAuthor ">Yu  Gao</span>, <span class="hlFld-ContribAuthor ">Haiying  Chen</span>, <span class="hlFld-ContribAuthor ">Suling  Liu</span>, <span class="hlFld-ContribAuthor ">Jia  Zhou</span>, <span class="hlFld-ContribAuthor ">Ceshi  Chen</span>, <span class="hlFld-ContribAuthor ">Haijun  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel mifepristone derivatives via suppressing KLF5 expression for the treatment of triple-negative breast cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>146 </em>, 354-367. <a href="https://doi.org/10.1016/j.ejmech.2018.01.056" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.01.056</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.01.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.01.056%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bmifepristone%252Bderivatives%252Bvia%252Bsuppressing%252BKLF5%252Bexpression%252Bfor%252Bthe%252Btreatment%252Bof%252Btriple-negative%252Bbreast%252Bcancer%26aulast%3DLin%26aufirst%3DYuqi%26date%3D2018%26volume%3D146%26spage%3D354%26epage%3D367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ana  Lago-Fernandez</span>, <span class="hlFld-ContribAuthor ">Vanessa  Redondo</span>, <span class="hlFld-ContribAuthor ">Laura  Hernandez-Folgado</span>, <span class="hlFld-ContribAuthor ">Laura  Figuerola-Asencio</span>, <span class="hlFld-ContribAuthor ">Nadine  Jagerovic</span>. </span><span class="cited-content_cbyCitation_article-title">New Methods for the Synthesis of Cannabidiol Derivatives. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 237-257. <a href="https://doi.org/10.1016/bs.mie.2017.05.006" title="DOI URL">https://doi.org/10.1016/bs.mie.2017.05.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.mie.2017.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.mie.2017.05.006%26sid%3Dliteratum%253Aachs%26atitle%3DNew%252BMethods%252Bfor%252Bthe%252BSynthesis%252Bof%252BCannabidiol%252BDerivatives%26aulast%3DLago-Fernandez%26aufirst%3DAna%26date%3D2017%26spage%3D237%26epage%3D257%26pub%3DElsevier%26atitle%3DCannabinoids%252Band%252BTheir%252BReceptors%26date%3D2017%26volume%3D593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paula  Morales</span>, <span class="hlFld-ContribAuthor ">Laura  Moreno</span>, <span class="hlFld-ContribAuthor ">Javier  Fernández-Ruiz</span>, <span class="hlFld-ContribAuthor ">Nadine  Jagerovic</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of a novel CB2 cannabinoid-porphyrin conjugate based on an antitumor chromenopyrazoledione. </span><span class="cited-content_cbyCitation_journal-name">Journal of Porphyrins and Phthalocyanines</span><span> <strong>2017,</strong> <em>21 </em>
                                    (01)
                                     , 67-76. <a href="https://doi.org/10.1142/S1088424617500092" title="DOI URL">https://doi.org/10.1142/S1088424617500092</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1142/S1088424617500092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1142%2FS1088424617500092%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Porphyrins%2520and%2520Phthalocyanines%26atitle%3DSynthesis%252Bof%252Ba%252Bnovel%252BCB2%252Bcannabinoid-porphyrin%252Bconjugate%252Bbased%252Bon%252Ban%252Bantitumor%252Bchromenopyrazoledione%26aulast%3DMorales%26aufirst%3DPaula%26date%3D2017%26date%3D2017%26volume%3D21%26issue%3D01%26spage%3D67%26epage%3D76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guillermo  de Anda-Jáuregui</span>, <span class="hlFld-ContribAuthor ">Tadeo E.  Velázquez-Caldelas</span>, <span class="hlFld-ContribAuthor ">Jesús  Espinal-Enríquez</span>, <span class="hlFld-ContribAuthor ">Enrique  Hernández-Lemus</span>. </span><span class="cited-content_cbyCitation_article-title">Transcriptional Network Architecture of Breast Cancer Molecular Subtypes. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Physiology</span><span> <strong>2016,</strong> <em>7 </em><a href="https://doi.org/10.3389/fphys.2016.00568" title="DOI URL">https://doi.org/10.3389/fphys.2016.00568</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphys.2016.00568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphys.2016.00568%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Physiology%26atitle%3DTranscriptional%252BNetwork%252BArchitecture%252Bof%252BBreast%252BCancer%252BMolecular%252BSubtypes%26aulast%3Dde%2BAnda-J%25C3%25A1uregui%26aufirst%3DGuillermo%26date%3D2016%26date%3D2016%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A. I.  Fraguas-Sánchez</span>, <span class="hlFld-ContribAuthor ">A.  Fernández-Carballido</span>, <span class="hlFld-ContribAuthor ">A. I.  Torres-Suárez</span>. </span><span class="cited-content_cbyCitation_article-title">Phyto-, endo- and synthetic cannabinoids: promising chemotherapeutic agents in the treatment of breast and prostate carcinomas. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2016,</strong> <em>25 </em>
                                    (11)
                                     , 1311-1323. <a href="https://doi.org/10.1080/13543784.2016.1236913" title="DOI URL">https://doi.org/10.1080/13543784.2016.1236913</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543784.2016.1236913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543784.2016.1236913%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DPhyto-%25252C%252Bendo-%252Band%252Bsynthetic%252Bcannabinoids%25253A%252Bpromising%252Bchemotherapeutic%252Bagents%252Bin%252Bthe%252Btreatment%252Bof%252Bbreast%252Band%252Bprostate%252Bcarcinomas%26aulast%3DFraguas-S%25C3%25A1nchez%26aufirst%3DA.%2BI.%26date%3D2016%26date%3D2016%26volume%3D25%26issue%3D11%26spage%3D1311%26epage%3D1323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel A.  Ladin</span>, <span class="hlFld-ContribAuthor ">Eman  Soliman</span>, <span class="hlFld-ContribAuthor ">LaToya  Griffin</span>, <span class="hlFld-ContribAuthor ">Rukiyah  Van Dross</span>. </span><span class="cited-content_cbyCitation_article-title">Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2016,</strong> <em>7 </em><a href="https://doi.org/10.3389/fphar.2016.00361" title="DOI URL">https://doi.org/10.3389/fphar.2016.00361</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2016.00361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2016.00361%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DPreclinical%252Band%252BClinical%252BAssessment%252Bof%252BCannabinoids%252Bas%252BAnti-Cancer%252BAgents%26aulast%3DLadin%26aufirst%3DDaniel%2BA.%26date%3D2016%26date%3D2016%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangling  Ren</span>, <span class="hlFld-ContribAuthor ">Jiejie  Ge</span>, <span class="hlFld-ContribAuthor ">Xianwei  Meng</span>, <span class="hlFld-ContribAuthor ">Xiaozhong  Qiu</span>, <span class="hlFld-ContribAuthor ">Jun  Ren</span>, <span class="hlFld-ContribAuthor ">Fangqiong  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Sensitive detection of dopamine and quinone drugs based on the quenching of the fluorescence of carbon dots. </span><span class="cited-content_cbyCitation_journal-name">Science Bulletin</span><span> <strong>2016,</strong> <em>61 </em>
                                    (20)
                                     , 1615-1623. <a href="https://doi.org/10.1007/s11434-016-1172-1" title="DOI URL">https://doi.org/10.1007/s11434-016-1172-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11434-016-1172-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11434-016-1172-1%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%2520Bulletin%26atitle%3DSensitive%252Bdetection%252Bof%252Bdopamine%252Band%252Bquinone%252Bdrugs%252Bbased%252Bon%252Bthe%252Bquenching%252Bof%252Bthe%252Bfluorescence%252Bof%252Bcarbon%252Bdots%26aulast%3DRen%26aufirst%3DXiangling%26date%3D2016%26volume%3D61%26issue%3D20%26spage%3D1615%26epage%3D1623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">M.  Gómez-Cañas</span>, <span class="hlFld-ContribAuthor ">P.  Morales</span>, <span class="hlFld-ContribAuthor ">L.  García-Toscano</span>, <span class="hlFld-ContribAuthor ">C.  Navarrete</span>, <span class="hlFld-ContribAuthor ">E.  Muñoz</span>, <span class="hlFld-ContribAuthor ">N.  Jagerovic</span>, <span class="hlFld-ContribAuthor ">J.  Fernández-Ruiz</span>, <span class="hlFld-ContribAuthor ">M.  García-Arencibia</span>, <span class="hlFld-ContribAuthor ">M.R.  Pazos</span>. </span><span class="cited-content_cbyCitation_article-title">Biological characterization of PM226, a chromenoisoxazole, as a selective CB 2 receptor agonist with neuroprotective profile. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2016,</strong> <em>110 </em>, 205-215. <a href="https://doi.org/10.1016/j.phrs.2016.03.021" title="DOI URL">https://doi.org/10.1016/j.phrs.2016.03.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2016.03.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2016.03.021%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DBiological%252Bcharacterization%252Bof%252BPM226%25252C%252Ba%252Bchromenoisoxazole%25252C%252Bas%252Ba%252Bselective%252BCB%252B2%252Breceptor%252Bagonist%252Bwith%252Bneuroprotective%252Bprofile%26aulast%3DG%25C3%25B3mez-Ca%25C3%25B1as%26aufirst%3DM.%26date%3D2016%26volume%3D110%26spage%3D205%26epage%3D215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paula  Morales</span>, <span class="hlFld-ContribAuthor ">Laura  Hernandez-Folgado</span>, <span class="hlFld-ContribAuthor ">Pilar  Goya</span>, <span class="hlFld-ContribAuthor ">Nadine  Jagerovic</span>. </span><span class="cited-content_cbyCitation_article-title">Cannabinoid receptor 2 (CB
              2
              ) agonists and antagonists: a patent update. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2016,</strong> <em>26 </em>
                                    (7)
                                     , 843-856. <a href="https://doi.org/10.1080/13543776.2016.1193157" title="DOI URL">https://doi.org/10.1080/13543776.2016.1193157</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2016.1193157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2016.1193157%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DCannabinoid%252Breceptor%252B2%252B%252528CB%252B2%252B%252529%252Bagonists%252Band%252Bantagonists%25253A%252Ba%252Bpatent%252Bupdate%26aulast%3DMorales%26aufirst%3DPaula%26date%3D2016%26date%3D2016%26volume%3D26%26issue%3D7%26spage%3D843%26epage%3D856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Farideh A.  Javid</span>, <span class="hlFld-ContribAuthor ">Roger M.  Phillips</span>, <span class="hlFld-ContribAuthor ">S.  Afshinjavid</span>, <span class="hlFld-ContribAuthor ">Roberta  Verde</span>, <span class="hlFld-ContribAuthor ">Alessia  Ligresti</span>. </span><span class="cited-content_cbyCitation_article-title">Cannabinoid pharmacology in cancer research: A new hope for cancer patients?. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmacology</span><span> <strong>2016,</strong> <em>775 </em>, 1-14. <a href="https://doi.org/10.1016/j.ejphar.2016.02.010" title="DOI URL">https://doi.org/10.1016/j.ejphar.2016.02.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejphar.2016.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejphar.2016.02.010%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmacology%26atitle%3DCannabinoid%252Bpharmacology%252Bin%252Bcancer%252Bresearch%25253A%252BA%252Bnew%252Bhope%252Bfor%252Bcancer%252Bpatients%25253F%26aulast%3DJavid%26aufirst%3DFarideh%2BA.%26date%3D2016%26volume%3D775%26spage%3D1%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Irmgard  Tegeder</span>. </span><span class="cited-content_cbyCitation_article-title">Endocannabinoids as Guardians of Metastasis. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2016,</strong> <em>17 </em>
                                    (2)
                                     , 230. <a href="https://doi.org/10.3390/ijms17020230" title="DOI URL">https://doi.org/10.3390/ijms17020230</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms17020230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms17020230%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DEndocannabinoids%252Bas%252BGuardians%252Bof%252BMetastasis%26aulast%3DTegeder%26aufirst%3DIrmgard%26date%3D2016%26date%3D2016%26volume%3D17%26issue%3D2%26spage%3D230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Taotao  Ling</span>, <span class="hlFld-ContribAuthor ">My  Tran</span>, <span class="hlFld-ContribAuthor ">Miguel A.  González</span>, <span class="hlFld-ContribAuthor ">Lekh Nath  Gautam</span>, <span class="hlFld-ContribAuthor ">Michele  Connelly</span>, <span class="hlFld-ContribAuthor ">Rachael K.  Wood</span>, <span class="hlFld-ContribAuthor ">Iram  Fatima</span>, <span class="hlFld-ContribAuthor ">Gustavo  Miranda-Carboni</span>, <span class="hlFld-ContribAuthor ">Fatima  Rivas</span>. </span><span class="cited-content_cbyCitation_article-title">(+)-Dehydroabietylamine derivatives target triple-negative breast cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>102 </em>, 9-13. <a href="https://doi.org/10.1016/j.ejmech.2015.07.034" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.07.034</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.07.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.07.034%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D%252528%25252B%252529-Dehydroabietylamine%252Bderivatives%252Btarget%252Btriple-negative%252Bbreast%252Bcancer%26aulast%3DLing%26aufirst%3DTaotao%26date%3D2015%26volume%3D102%26spage%3D9%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/medium/jm-2015-00078c_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/large/jm-2015-00078c_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00078&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/medium/jm-2015-00078c_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/large/jm-2015-00078c_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Oxidation of Chromenopyrazoles to the Corresponding Quinone Derivatives <b>8</b>–<b>13</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/large/jm-2015-00078c_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00078&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reaction conditions: (i) 3,3-dimethylacrylic acid, CH<sub>3</sub>SO<sub>3</sub>H, P<sub>2</sub>O<sub>5</sub>, 70 °C, microwave (MW), 10 min; (ii) NaH, THF, MW, 46 °C, 20 min, then ethyl formate, THF, MW, 46 °C, 20 min; (iii) 2-iodoxybenzoic acid, DMF, 30 min, room temperature; (iv) [bis(trifluoroacetoxy)iodo]benzene, MeCN/H<sub>2</sub>O (6:1), 15 min, room temperature.</p></p></figure><figure data-id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/medium/jm-2015-00078c_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/large/jm-2015-00078c_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Dose–response curves of the antiproliferative effect of chromenopyrazolediones <b>8</b>–<b>13</b> against the human breast cancer cell line MDA-MB-231.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/large/jm-2015-00078c_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00078&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/medium/jm-2015-00078c_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/large/jm-2015-00078c_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Effect of compound <b>10</b> on the viability of normal HMECs. HMECs were treated with increasing concentrations of the drug. Cell viability was determined 48 h after treatment. Values are the mean ± SE of three independent experiments performed in duplicate. Data were assessed by one-way analysis of variance followed by the Student–Newman–Keuls test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/large/jm-2015-00078c_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00078&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/medium/jm-2015-00078c_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/large/jm-2015-00078c_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Expression of CB<sub>2</sub> in transformed and nontransformed breast cancer cell lines. CB<sub>2</sub> mRNA expression in the indicated cell lines, as determined by real-time quantitative PCR. Results are expressed as arbitrary units vs CB<sub>2</sub> mRNA expression in HMECs that has been set as 1 unit.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/large/jm-2015-00078c_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00078&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/medium/jm-2015-00078c_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/large/jm-2015-00078c_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Molecular mechanisms involved in the growth inhibitory activity of compound <b>10</b>. MDA-MB-231 cell viability was determined by the MTT test. The CB<sub>1</sub>-selective antagonist is SR141716 (SR1), the CB<sub>2</sub>-selective antagonist is SR144528 (SR2), the GPR55-selective antagonist is CID16020046 (CID), and the antioxidant is α-tocopherol (α-Toc). The results represent the mean ± SE of three different experiments performed in triplicate. Data were assessed by two-way analysis of variance followed by the Student–Newman–Keuls test (*, <i>p</i> < 0.05 vs vehicle-treated cells; **, <i>p</i> < 0.01 vs vehicle-treated cells; #, <i>p</i> < 0.05 versus the compound alone).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/large/jm-2015-00078c_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00078&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/medium/jm-2015-00078c_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/large/jm-2015-00078c_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Analysis of caspase-3 protein expression. Western blot analysis of caspase 3 after 48 h of exposure to compound <b>10</b> at IC<sub>50</sub> in MDA-MB-231 cells. The graph represents the densimetric analysis of protein levels. The optical density is relative to that of control cells set as 1. <i>n</i> = 3. Data were assessed by Student’s <i>t</i> test (*, <i>p</i> < 0.05 vs vehicle-treated cells).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/large/jm-2015-00078c_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00078&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/medium/jm-2015-00078c_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/large/jm-2015-00078c_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>10</b> reduces tumor growth in vivo. (A) Effect of intraperitoneal administration of <b>10</b> on the growth of tumor xenografts generated in nude mice by injection of MDA-MB-231 human breast adenocarcinoma cells (mean ± SEM). The images show representative vehicle- and compound <b>10</b>-treated tumors. (B) Effect of <b>10</b> administration on tumor weight. Data were assessed by two-way (with repeated measures) analysis of variance followed by the Student–Newman–Keuls test (*, <i>p</i> < 0.05 vs vehicle-treated tumors).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/acs.jmedchem.5b00078/20150306/images/large/jm-2015-00078c_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00078&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i38">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36118" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36118" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 50 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Tramèr, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQuay, H. J.</span><span> </span><span class="NLM_article-title">Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review</span> <span class="citation_source-journal">Br. Med. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">323</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1136%2Fbmj.323.7303.16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVSitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2001&pages=16-21&author=M.+R.+Tram%C3%A8rauthor=D.+Carrollauthor=F.+Campbellauthor=D.+J.+Reynoldsauthor=R.+Mooreauthor=H.+J.+McQuay&title=Cannabinoids+for+control+of+chemotherapy+induced+nausea+and+vomiting%3A+quantitative+systematic+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoids for control of chemotherapy induced nausea and vomiting: Quantitative systematic review</span></div><div class="casAuthors">Tramer, Martin R.; Carroll, Dawn; Campbell, Fiona A.; Reynolds, D. John M.; Moore, R. Andrew; McQuay, Henry J.</div><div class="citationInfo"><span class="NLM_cas:title">BMJ [British Medical Journal]</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">7303</span>),
    <span class="NLM_cas:pages">16-21</span>CODEN:
                <span class="NLM_cas:coden">BMJBFE</span>;
        ISSN:<span class="NLM_cas:issn">0959-8146</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Aim of this study was to quantify the antiemetic efficacy and adverse effects of cannabis used for sickness induced by chemotherapy.  Systematic review.  Systematic search (Medline, Embase, Cochrane library, bibliogs.), any language, to August 2000.  30 Randomized comparisons of cannabis with placebo or antiemetics from which dichotomous data on efficacy and harm were available (1366 patients).  Oral nabilone, oral dronabinol (tetrahydrocannabinol), and i.m. levonantradol were tested.  No cannabis was smoked.  Follow up lasted 24 h.  Cannabinoids were more effective antiemetics than prochlorperazine, metoclopramide, chlorpromazine, thiethylperazine, haloperidol, domperidone, or alizapride: relative risk 1.38 (95% confidence interval 1.18 to 1.62), no. needed to treat 6 for complete control of nausea; 1.28 (1.08 to 1.51), NNT 8 for complete control of vomiting.  Cannabinoids were not more effective in patients receiving very low or very high emetogenic chemotherapy.  In crossover trials, patients preferred cannabinoids for future chemotherapy cycles: 2.39 (2.05 to 2.78), NNT 3.  Some potentially beneficial side effects occurred more often with cannabinoids: "high" 10.6 (6.86 to 16.5), NNT 3; sedation or drowsiness 1.66 (1.46 to 1.89), NNT 5; euphoria 12.5 (3.00 to 52.1), NNT 7.  Harmful side effects also occurred more often with cannabinoids: dizziness 2.97 (2.31 to 3.83), NNT 3; dysphoria or depression 8.06 (3.38 to 19.2), NNT 8; hallucinations 6.10 (2.41 to 15.4), NNT 17; paranoia 8.58 (6.38 to 11.5), NNT 20; and arterial hypotension 2.23 (1.75 to 2.83), NNT 7.  Patients given cannabinoids were more likely to withdraw due to side effects 4.67 (3.07 to 7.09), NNT 11.  In selected patients, the cannabinoids tested in these trials may be useful as mood enhancing adjuvants for controlling chemotherapy related sickness.  Potentially serious adverse effects, even when taken short term orally or i.m., are likely to limit their widespread use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPdwo9eb8Co7Vg90H21EOLACvtfcHk0ljzrEEchuUZ9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVSitA%253D%253D&md5=fec3eef87a6007455f5ca07956c23c9a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1136%2Fbmj.323.7303.16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.323.7303.16%26sid%3Dliteratum%253Aachs%26aulast%3DTram%25C3%25A8r%26aufirst%3DM.%2BR.%26aulast%3DCarroll%26aufirst%3DD.%26aulast%3DCampbell%26aufirst%3DF.%26aulast%3DReynolds%26aufirst%3DD.%2BJ.%26aulast%3DMoore%26aufirst%3DR.%26aulast%3DMcQuay%26aufirst%3DH.%2BJ.%26atitle%3DCannabinoids%2520for%2520control%2520of%2520chemotherapy%2520induced%2520nausea%2520and%2520vomiting%253A%2520quantitative%2520systematic%2520review%26jtitle%3DBr.%2520Med.%2520J.%26date%3D2001%26volume%3D323%26spage%3D16%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Sharkey, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darmani, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, L. A.</span><span> </span><span class="NLM_article-title">Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">722</span><span class="NLM_x">, </span> <span class="NLM_fpage">134</span><span class="NLM_x">–</span> <span class="NLM_lpage">146</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1016%2Fj.ejphar.2013.09.068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=24184696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslyqtbnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=722&publication_year=2014&pages=134-146&author=K.+A.+Sharkeyauthor=N.+A.+Darmaniauthor=L.+A.+Parker&title=Regulation+of+nausea+and+vomiting+by+cannabinoids+and+the+endocannabinoid+system"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system</span></div><div class="casAuthors">Sharkey, Keith A.; Darmani, Nissar A.; Parker, Linda A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">722</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">134-146</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Nausea and vomiting (emesis) are important elements in defensive or protective responses that animals use to avoid ingestion or digestion of potentially harmful substances.  However, these neurally-mediated responses are at times manifested as symptoms of disease and they are frequently obsd. as side-effects of a variety of medications, notably those used to treat cancer.  Cannabis has long been known to limit or prevent nausea and vomiting from a variety of causes.  This has led to extensive investigations that have revealed an important role for cannabinoids and their receptors in the regulation of nausea and emesis.  With the discovery of the endocannabinoid system, novel ways to regulate both nausea and vomiting have been discovered that involve the prodn. of endogenous cannabinoids acting centrally.  Here we review recent progress in understanding the regulation of nausea and vomiting by cannabinoids and the endocannabinoid system, and we discuss the potential to utilize the endocannabinoid system in the treatment of these frequently debilitating conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdD3X4DMvEz7Vg90H21EOLACvtfcHk0ljzrEEchuUZ9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslyqtbnJ&md5=435db4360b96bc8c63f7ccb2e94ab9ad</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2013.09.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2013.09.068%26sid%3Dliteratum%253Aachs%26aulast%3DSharkey%26aufirst%3DK.%2BA.%26aulast%3DDarmani%26aufirst%3DN.%2BA.%26aulast%3DParker%26aufirst%3DL.%2BA.%26atitle%3DRegulation%2520of%2520nausea%2520and%2520vomiting%2520by%2520cannabinoids%2520and%2520the%2520endocannabinoid%2520system%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D722%26spage%3D134%26epage%3D146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Cridge, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosengren, R. J.</span><span> </span><span class="NLM_article-title">Critical appraisal of the potential use of cannabinoids in cancer management</span> <span class="citation_source-journal">Cancer Manage. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">301</span><span class="NLM_x">–</span> <span class="NLM_lpage">313</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=24039449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFKmt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=301-313&author=B.+J.+Cridgeauthor=R.+J.+Rosengren&title=Critical+appraisal+of+the+potential+use+of+cannabinoids+in+cancer+management"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Critical appraisal of the potential use of cannabinoids in cancer management</span></div><div class="casAuthors">Cridge, Belinda J.; Rosengren, Rhonda J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Management and Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">301-313, pp.</span>CODEN:
                <span class="NLM_cas:coden">CMRACP</span>;
        ISSN:<span class="NLM_cas:issn">1179-1322</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Cannabinoids have been attracting a great deal of interest as potential anticancer agents.  Originally derived from the plant Cannabis sativa, there are now a no. of endo-, phyto- and synthetic cannabinoids available.  This review summarizes the key literature to date around the actions, antitumor activity, and mechanisms of action for this broad range of compds.  Cannabinoids are largely defined by an ability to activate the cannabinoid receptors - CB1 or CB2.  The action of the cannabinoids is very dependent on the exact ligand tested, the dose, and the duration of exposure.  Some cannabinoids, synthetic or plant-derived, show potential as therapeutic agents, and evidence across a range of cancers and evidence in vitro and in vivo is starting to be accumulated.  Studies have now been conducted in a wide range of cell lines, including glioma, breast, prostate, endothelial, liver, and lung.  This work is complemented by an increasing body of evidence from in vivo models.  However, many of these results remain contradictory, an issue that is not currently able to be resolved through current knowledge of mechanisms of action.  While there is a developing understanding of potential mechanisms of action, with the extracellular signal-regulated kinase pathway emerging as a crit. signaling juncture in combination with an important role for ceramide and lipid signaling, the relative importance of each pathway is yet to be detd.  The interplay between the intracellular pathways of autophagy vs. apoptosis is a recent development that is discussed.  Overall, there is still a great deal of conflicting evidence around the future utility of the cannabinoids, natural or synthetic, as therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrse4lnbMcrzrVg90H21EOLACvtfcHk0ljzrEEchuUZ9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFKmt7o%253D&md5=ff3c01baec1b9250c675cb13525b3cea</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCridge%26aufirst%3DB.%2BJ.%26aulast%3DRosengren%26aufirst%3DR.%2BJ.%26atitle%3DCritical%2520appraisal%2520of%2520the%2520potential%2520use%2520of%2520cannabinoids%2520in%2520cancer%2520management%26jtitle%3DCancer%2520Manage.%2520Res.%26date%3D2013%26volume%3D5%26spage%3D301%26epage%3D313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Velasco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sánchez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzmán, M.</span><span> </span><span class="NLM_article-title">Towards the use of cannabinoids as antitumour agents</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">436</span><span class="NLM_x">–</span> <span class="NLM_lpage">444</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1038%2Fnrc3247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=22555283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsFCgs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=436-444&author=G.+Velascoauthor=C.+S%C3%A1nchezauthor=M.+Guzm%C3%A1n&title=Towards+the+use+of+cannabinoids+as+antitumour+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Towards the use of cannabinoids as antitumour agents</span></div><div class="casAuthors">Velasco, Guillermo; Sanchez, Cristina; Guzman, Manuel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">436-444</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Various reports have shown that cannabinoids (the active components of marijuana and their derivs.) can reduce tumor growth and progression in animal models of cancer, in addn. to their well-known palliative effects on some cancer-assocd. symptoms.  This Opinion article discusses our current understanding of cannabinoids as antitumor agents, focusing on recent insights into the mol. mechanisms of action, including emerging resistance mechanisms and opportunities for combination therapy approaches.  Such knowledge is required for the optimization of preclin. cannabinoid-based therapies and for the preliminary clin. testing that is currently underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIsOuHpKgJRLVg90H21EOLACvtfcHk0lgx6XMFlo93kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsFCgs70%253D&md5=4ec6d1bee283a5145c5c83f4c3eb5cfb</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrc3247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3247%26sid%3Dliteratum%253Aachs%26aulast%3DVelasco%26aufirst%3DG.%26aulast%3DS%25C3%25A1nchez%26aufirst%3DC.%26aulast%3DGuzm%25C3%25A1n%26aufirst%3DM.%26atitle%3DTowards%2520the%2520use%2520of%2520cannabinoids%2520as%2520antitumour%2520agents%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D436%26epage%3D444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Guzmán, M.</span><span> </span><span class="NLM_article-title">Cannabinoids: potential anticancer agents</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">745</span><span class="NLM_x">–</span> <span class="NLM_lpage">755</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1038%2Fnrc1188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=14570037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotFCiu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=745-755&author=M.+Guzm%C3%A1n&title=Cannabinoids%3A+potential+anticancer+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoids: Potential anticancer agents</span></div><div class="casAuthors">Guzman, Manuel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">745-755</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cannabinoids, the active components of Cannabis sativa and their derivs., exert palliative effects in cancer patients by preventing nausea, vomiting and pain and by stimulating appetite.  In addn., these compds. have been show to inhibit the growth of tumor cells in culture and animal models by modulating key cell-signaling pathways.  Cannabinoids are usually well tolerated, and do not produce the generalized toxic effects of conventional chemotherapies.  So, could cannabinoids be used to develop new anticancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRgBVHSjJfJrVg90H21EOLACvtfcHk0lgx6XMFlo93kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotFCiu7c%253D&md5=22894eccf99e509e3948c6c2a5dcd513</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrc1188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1188%26sid%3Dliteratum%253Aachs%26aulast%3DGuzm%25C3%25A1n%26aufirst%3DM.%26atitle%3DCannabinoids%253A%2520potential%2520anticancer%2520agents%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26spage%3D745%26epage%3D755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Chakravarti, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganju, R. K.</span><span> </span><span class="NLM_article-title">Cannabinoids as therapeutic agents in cancer: current status and future implications</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">5852</span><span class="NLM_x">–</span> <span class="NLM_lpage">5872</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=5852-5872&author=B.+Chakravartiauthor=J.+Raviauthor=R.+K.+Ganju&title=Cannabinoids+as+therapeutic+agents+in+cancer%3A+current+status+and+future+implications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChakravarti%26aufirst%3DB.%26aulast%3DRavi%26aufirst%3DJ.%26aulast%3DGanju%26aufirst%3DR.%2BK.%26atitle%3DCannabinoids%2520as%2520therapeutic%2520agents%2520in%2520cancer%253A%2520current%2520status%2520and%2520future%2520implications%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D5852%26epage%3D5872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Guindon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohmann, A. G.</span><span> </span><span class="NLM_article-title">The endocannabinoid system and cancer: therapeutic implication</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">1447</span><span class="NLM_x">–</span> <span class="NLM_lpage">1463</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1111%2Fj.1476-5381.2011.01327.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=21410463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BC3MXps1Sju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2011&pages=1447-1463&author=J.+Guindonauthor=A.+G.+Hohmann&title=The+endocannabinoid+system+and+cancer%3A+therapeutic+implication"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The endocannabinoid system and cancer: therapeutic implication</span></div><div class="casAuthors">Guindon, Josee; Hohmann, Andrea G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1447-1463</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The endocannabinoid system is implicated in a variety of physiol. and pathol. conditions (inflammation, immunomodulation, analgesia, cancer and others).  The main active ingredient of cannabis, Δ9-tetrahydrocannabinol (Δ9-THC), produces its effects through activation of CB1 and CB2 receptors.  CB1 receptors are expressed at high levels in the central nervous system (CNS), whereas CB2 receptors are concd. predominantly, although not exclusively, in cells of the immune system.  Endocannabinoids are endogenous lipid-signaling mols. that are generated in the cell membrane from phospholipid precursors.  The 2 best characterized endocannabinoids identified to date are anandamide (AEA) and 2-arachidonoylglycerol (2-AG).  Here we review the relationship between the endocannabinoid system and anti-tumor actions (inhibition of cell proliferation and migration, induction of apoptosis, redn. of tumor growth) of the cannabinoids in different types of cancer.  This review will focus on examg. how activation of the endocannabinoid system impacts breast, prostate and bone cancers in both in vitro and in vivo systems.  The therapeutic potential of cannabinoids for cancer, as identified in clin. trials, is also discussed.  Identification of safe and effective treatments to manage and improve cancer therapy is crit. to improve quality of life and reduce unnecessary suffering in cancer patients.  In this regard, cannabis-like compds. offer therapeutic potential for the treatment of breast, prostate and bone cancer in patients.  Further basic research on anti-cancer properties of cannabinoids as well as clin. trials of cannabinoid therapeutic efficacy in breast, prostate and bone cancer is therefore warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_omB4D6NVN7Vg90H21EOLACvtfcHk0lgx6XMFlo93kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXps1Sju7g%253D&md5=fb5ec332b401d12e51c229d291c1909d</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01327.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01327.x%26sid%3Dliteratum%253Aachs%26aulast%3DGuindon%26aufirst%3DJ.%26aulast%3DHohmann%26aufirst%3DA.%2BG.%26atitle%3DThe%2520endocannabinoid%2520system%2520and%2520cancer%253A%2520therapeutic%2520implication%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D163%26spage%3D1447%26epage%3D1463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Van Dross, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soliman, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jha, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukhopadhyay, S.</span><span> </span><span class="NLM_article-title">Receptor-dependent and receptor-independent endocannabinoid signaling: a therapeutic target for regulation of cancer growth</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">466</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2013&pages=463-466&author=R.+Van+Drossauthor=E.+Solimanauthor=S.+Jhaauthor=T.+Johnsonauthor=S.+Mukhopadhyay&title=Receptor-dependent+and+receptor-independent+endocannabinoid+signaling%3A+a+therapeutic+target+for+regulation+of+cancer+growth"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BDross%26aufirst%3DR.%26aulast%3DSoliman%26aufirst%3DE.%26aulast%3DJha%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DMukhopadhyay%26aufirst%3DS.%26atitle%3DReceptor-dependent%2520and%2520receptor-independent%2520endocannabinoid%2520signaling%253A%2520a%2520therapeutic%2520target%2520for%2520regulation%2520of%2520cancer%2520growth%26jtitle%3DLife%2520Sci.%26date%3D2013%26volume%3D92%26spage%3D463%26epage%3D466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Caffarel, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarrió, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palacios, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzmán, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sánchez, C.</span><span> </span><span class="NLM_article-title">Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">6615</span><span class="NLM_x">–</span> <span class="NLM_lpage">6621</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=6615-6621&author=M.+M.+Caffarelauthor=D.+Sarri%C3%B3author=J.+Palaciosauthor=M.+Guzm%C3%A1nauthor=C.+S%C3%A1nchez&title=Delta9-tetrahydrocannabinol+inhibits+cell+cycle+progression+in+human+breast+cancer+cells+through+Cdc2+regulation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCaffarel%26aufirst%3DM.%2BM.%26aulast%3DSarri%25C3%25B3%26aufirst%3DD.%26aulast%3DPalacios%26aufirst%3DJ.%26aulast%3DGuzm%25C3%25A1n%26aufirst%3DM.%26aulast%3DS%25C3%25A1nchez%26aufirst%3DC.%26atitle%3DDelta9-tetrahydrocannabinol%2520inhibits%2520cell%2520cycle%2520progression%2520in%2520human%2520breast%2520cancer%2520cells%2520through%2520Cdc2%2520regulation%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D6615%26epage%3D6621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Ligresti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriello, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starowicz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matias, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pisanti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Petrocellis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laezza, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Portella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bifulco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Marzo, V.</span><span> </span><span class="NLM_article-title">Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">318</span><span class="NLM_x">, </span> <span class="NLM_fpage">1375</span><span class="NLM_x">–</span> <span class="NLM_lpage">1387</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1124%2Fjpet.106.105247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=16728591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BD28XovFygtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=2006&pages=1375-1387&author=A.+Ligrestiauthor=A.+S.+Morielloauthor=K.+Starowiczauthor=I.+Matiasauthor=S.+Pisantiauthor=L.+De+Petrocellisauthor=C.+Laezzaauthor=G.+Portellaauthor=M.+Bifulcoauthor=V.+Di+Marzo&title=Antitumor+activity+of+plant+cannabinoids+with+emphasis+on+the+effect+of+cannabidiol+on+human+breast+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma</span></div><div class="casAuthors">Ligresti, Alessia; Moriello, Aniello Schiano; Starowicz, Katarzyna; Matias, Isabel; Pisanti, Simona; De Petrocellis, Luciano; Laezza, Chiara; Portella, Giuseppe; Bifulco, Maurizio; Di Marzo, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">318</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1375-1387</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Δ9-Tetrahydrocannabinol (THC) exhibits antitumor effects on various cancer cell types, but its use in chemotherapy is limited by its psychotropic activity.  We investigated the antitumor activities of other plant cannabinoids, i.e., cannabidiol, cannabigerol, cannabichromene, cannabidiol acid and THC acid, and assessed whether there is any advantage in using Cannabis exts. (enriched in either cannabidiol or THC) over pure cannabinoids.  Results obtained in a panel of tumor cell lines clearly indicate that, of the five natural compds. tested, cannabidiol is the most potent inhibitor of cancer cell growth (IC50 between 6.0 and 10.6 μM), with significantly lower potency in noncancer cells.  The cannabidiol-rich ext. was equipotent to cannabidiol, whereas cannabigerol and cannabichromene followed in the rank of potency.  Both cannabidiol and the cannabidiol-rich ext. inhibited the growth of xenograft tumors obtained by s.c. injection into athymic mice of human MDA-MB-231 breast carcinoma or rat v-K-ras-transformed thyroid epithelial cells and reduced lung metastases deriving from intrapaw injection of MDA-MB-231 cells.  Judging from several expts. on its possible cellular and mol. mechanisms of action, we propose that cannabidiol lacks a unique mode of action in the cell lines investigated.  At least for MDA-MB-231 cells, however, our expts. indicate that cannabidiol effect is due to its capability of inducing apoptosis via: direct or indirect activation of cannabinoid CB2 and vanilloid transient receptor potential vanilloid type-1 receptors and cannabinoid/vanilloid receptor-independent elevation of intracellular Ca2+ and reactive oxygen species.  Our data support the further testing of cannabidiol and cannabidiol-rich exts. for the potential treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH79Q23ih9-LVg90H21EOLACvtfcHk0lj2UnxKCwxwVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XovFygtLY%253D&md5=55d944aa9d80801fea0e364b72ac6a0e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.105247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.105247%26sid%3Dliteratum%253Aachs%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DMoriello%26aufirst%3DA.%2BS.%26aulast%3DStarowicz%26aufirst%3DK.%26aulast%3DMatias%26aufirst%3DI.%26aulast%3DPisanti%26aufirst%3DS.%26aulast%3DDe%2BPetrocellis%26aufirst%3DL.%26aulast%3DLaezza%26aufirst%3DC.%26aulast%3DPortella%26aufirst%3DG.%26aulast%3DBifulco%26aufirst%3DM.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26atitle%3DAntitumor%2520activity%2520of%2520plant%2520cannabinoids%2520with%2520emphasis%2520on%2520the%2520effect%2520of%2520cannabidiol%2520on%2520human%2520breast%2520carcinoma%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D318%26spage%3D1375%26epage%3D1387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Shrivastava, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuzontkoski, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groopman, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prasad, A.</span><span> </span><span class="NLM_article-title">Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1161</span><span class="NLM_x">–</span> <span class="NLM_lpage">1172</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1158%2F1535-7163.MCT-10-1100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=21566064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1Sitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=1161-1172&author=A.+Shrivastavaauthor=P.+M.+Kuzontkoskiauthor=J.+E.+Groopmanauthor=A.+Prasad&title=Cannabidiol+induces+programmed+cell+death+in+breast+cancer+cells+by+coordinating+the+cross-talk+between+apoptosis+and+autophagy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabidiol Induces Programmed Cell Death in Breast Cancer Cells by Coordinating the Cross-talk between Apoptosis and Autophagy</span></div><div class="casAuthors">Shrivastava, Ashutosh; Kuzontkoski, Paula M.; Groopman, Jerome E.; Prasad, Anil</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1161-1172</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cannabidiol (CBD), a major nonpsychoactive constituent of cannabis, is considered an antineoplastic agent on the basis of its in vitro and in vivo activity against tumor cells.  However, the exact mol. mechanism through which CBD mediates this activity is yet to be elucidated.  Here, we have shown CBD-induced cell death of breast cancer cells, independent of cannabinoid and vallinoid receptor activation.  Electron microscopy revealed morphologies consistent with the coexistence of autophagy and apoptosis.  Western blot anal. confirmed these findings.  We showed that CBD induces endoplasmic reticulum stress and, subsequently, inhibits AKT and mTOR signaling as shown by decreased levels of phosphorylated mTOR and 4EBP1, and cyclin D1.  Analyzing further the cross-talk between the autophagic and apoptotic signaling pathways, we found that beclin1 plays a central role in the induction of CBD-mediated apoptosis in MDA-MB-231 breast cancer cells.  Although CBD enhances the interaction between beclin1 and Vps34, it inhibits the assocn. between beclin1 and Bcl-2.  In addn., we showed that CBD reduces mitochondrial membrane potential, triggers the translocation of BID to the mitochondria, the release of cytochrome c to the cytosol, and, ultimately, the activation of the intrinsic apoptotic pathway in breast cancer cells.  CBD increased the generation of reactive oxygen species (ROS), and ROS inhibition blocked the induction of apoptosis and autophagy.  Our study revealed an intricate interplay between apoptosis and autophagy in CBD-treated breast cancer cells and highlighted the value of continued investigation into the potential use of CBD as an antineoplastic agent.  Mol Cancer Ther; 10(7); 1161-72.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJEa2-oTrVOrVg90H21EOLACvtfcHk0lj2UnxKCwxwVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1Sitb4%253D&md5=f52599e25679acf7d378d2850d4eb25f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-1100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-1100%26sid%3Dliteratum%253Aachs%26aulast%3DShrivastava%26aufirst%3DA.%26aulast%3DKuzontkoski%26aufirst%3DP.%2BM.%26aulast%3DGroopman%26aufirst%3DJ.%2BE.%26aulast%3DPrasad%26aufirst%3DA.%26atitle%3DCannabidiol%2520induces%2520programmed%2520cell%2520death%2520in%2520breast%2520cancer%2520cells%2520by%2520coordinating%2520the%2520cross-talk%2520between%2520apoptosis%2520and%2520autophagy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D1161%26epage%3D1172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Caffarel, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno-Bueno, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerutti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palacios, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mechta-Grigoriou, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, C.</span><span> </span><span class="NLM_article-title">JunD is involved in the antiproliferative effect of Δ<sup>9</sup>-tetrahydrocannabinol on human breast cancer cells</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">5033</span><span class="NLM_x">–</span> <span class="NLM_lpage">5044</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=5033-5044&author=M.+M.+Caffarelauthor=G.+Moreno-Buenoauthor=C.+Ceruttiauthor=J.+Palaciosauthor=M.+Guzmanauthor=F.+Mechta-Grigoriouauthor=C.+Sanchez&title=JunD+is+involved+in+the+antiproliferative+effect+of+%CE%949-tetrahydrocannabinol+on+human+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCaffarel%26aufirst%3DM.%2BM.%26aulast%3DMoreno-Bueno%26aufirst%3DG.%26aulast%3DCerutti%26aufirst%3DC.%26aulast%3DPalacios%26aufirst%3DJ.%26aulast%3DGuzman%26aufirst%3DM.%26aulast%3DMechta-Grigoriou%26aufirst%3DF.%26aulast%3DSanchez%26aufirst%3DC.%26atitle%3DJunD%2520is%2520involved%2520in%2520the%2520antiproliferative%2520effect%2520of%2520%25CE%25949-tetrahydrocannabinol%2520on%2520human%2520breast%2520cancer%2520cells%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D5033%26epage%3D5044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Laezza, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pisanti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crescenzi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bifulco, M.</span><span> </span><span class="NLM_article-title">Anandamide inhibits Cdk2 and activates Chk1 leading to cell cycle arrest in human breast cancer cells</span> <span class="citation_source-journal">FEBS Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">580</span><span class="NLM_x">, </span> <span class="NLM_fpage">6076</span><span class="NLM_x">–</span> <span class="NLM_lpage">6082</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=580&publication_year=2006&pages=6076-6082&author=C.+Laezzaauthor=S.+Pisantiauthor=E.+Crescenziauthor=M.+Bifulco&title=Anandamide+inhibits+Cdk2+and+activates+Chk1+leading+to+cell+cycle+arrest+in+human+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLaezza%26aufirst%3DC.%26aulast%3DPisanti%26aufirst%3DS.%26aulast%3DCrescenzi%26aufirst%3DE.%26aulast%3DBifulco%26aufirst%3DM.%26atitle%3DAnandamide%2520inhibits%2520Cdk2%2520and%2520activates%2520Chk1%2520leading%2520to%2520cell%2520cycle%2520arrest%2520in%2520human%2520breast%2520cancer%2520cells%26jtitle%3DFEBS%2520Lett.%26date%3D2006%26volume%3D580%26spage%3D6076%26epage%3D6082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Qamri, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preet, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nasser, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bass, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leone, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barsky, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganju, R. K.</span><span> </span><span class="NLM_article-title">Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">3117</span><span class="NLM_x">–</span> <span class="NLM_lpage">3129</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1158%2F1535-7163.MCT-09-0448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=19887554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlyrt7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=3117-3129&author=Z.+Qamriauthor=A.+Preetauthor=M.+W.+Nasserauthor=C.+E.+Bassauthor=G.+Leoneauthor=S.+H.+Barskyauthor=R.+K.+Ganju&title=Synthetic+cannabinoid+receptor+agonists+inhibit+tumor+growth+and+metastasis+of+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer</span></div><div class="casAuthors">Qamri, Zahida; Preet, Anju; Nasser, Mohd W.; Bass, Caroline E.; Leone, Gustavo; Barsky, Sanford H.; Ganju, Ramesh K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3117-3129</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cannabinoids have been reported to possess antitumorogenic activity.  Not much is known, however, about the effects and mechanism of action of synthetic nonpsychotic cannabinoids on breast cancer growth and metastasis.  We have shown that the cannabinoid receptors CB1 and CB2 are overexpressed in primary human breast tumors compared with normal breast tissue.  We have also obsd. that the breast cancer cell lines MDA-MB231, MDA-MB231-luc, and MDA-MB468 express CB1 and CB2 receptors.  Furthermore, we have shown that the CB2 synthetic agonist JWH-133 and the CB1 and CB2 agonist WIN-55,212-2 inhibit cell proliferation and migration under in vitro conditions.  These results were confirmed in vivo in various mouse model systems.  Mice treated with JWH-133 or WIN-55,212-2 showed a 40% to 50% redn. in tumor growth and a 65% to 80% redn. in lung metastasis.  These effects were reversed by CB1 and CB2 antagonists AM 251 and SR144528, resp., suggesting involvement of CB1 and CB2 receptors.  In addn., the CB2 agonist JWH-133 was shown to delay and reduce mammary gland tumors in the polyoma middle T oncoprotein (PyMT) transgenic mouse model system.  Upon further elucidation, we obsd. that JWH-133 and WIN-55,212-2 mediate the breast tumor-suppressive effects via a coordinated regulation of cyclooxygenase-2/prostaglandin E2 signaling pathways and induction of apoptosis.  These results indicate that CB1 and CB2 receptors could be used to develop novel therapeutic strategies against breast cancer growth and metastasis. [Mol Cancer Ther 2009;8(11):3117-29].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBezp28v9cX7Vg90H21EOLACvtfcHk0lhqtoQXBanS_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlyrt7%252FE&md5=d78894337a2b8ae32a9379df1abca9bd</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0448%26sid%3Dliteratum%253Aachs%26aulast%3DQamri%26aufirst%3DZ.%26aulast%3DPreet%26aufirst%3DA.%26aulast%3DNasser%26aufirst%3DM.%2BW.%26aulast%3DBass%26aufirst%3DC.%2BE.%26aulast%3DLeone%26aufirst%3DG.%26aulast%3DBarsky%26aufirst%3DS.%2BH.%26aulast%3DGanju%26aufirst%3DR.%2BK.%26atitle%3DSynthetic%2520cannabinoid%2520receptor%2520agonists%2520inhibit%2520tumor%2520growth%2520and%2520metastasis%2520of%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D3117%26epage%3D3129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Oesch, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wachtel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pretre, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salazar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzmán, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schäfer, B. W.</span><span> </span><span class="NLM_article-title">Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1838</span><span class="NLM_x">–</span> <span class="NLM_lpage">1845</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1158%2F1535-7163.MCT-08-1147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=19509271" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVymsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=1838-1845&author=S.+Oeschauthor=D.+Walterauthor=M.+Wachtelauthor=K.+Pretreauthor=M.+Salazarauthor=M.+Guzm%C3%A1nauthor=G.+Velascoauthor=B.+W.+Sch%C3%A4fer&title=Cannabinoid+receptor+1+is+a+potential+drug+target+for+treatment+of+translocation-positive+rhabdomyosarcoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma</span></div><div class="casAuthors">Oesch, Susanne; Walter, Dagmar; Wachtel, Marco; Pretre, Kathya; Salazar, Maria; Guzman, Manuel; Velasco, Guillermo; Schaefer, Beat W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1838-1845</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Gene expression profiling has revealed that the gene coding for cannabinoid receptor 1 (CB1) is highly up-regulated in rhabdomyosarcoma biopsies bearing the typical chromosomal translocations PAX3/FKHR or PAX7/FKHR.  Because cannabinoid receptor agonists are capable of reducing proliferation and inducing apoptosis in diverse cancer cells such as glioma, breast cancer, and melanoma, we evaluated whether CB1 is a potential drug target in rhabdomyosarcoma.  Our study shows that treatment with the cannabinoid receptor agonists HU210 and Δ9-tetrahydrocannabinol lowers the viability of translocation-pos. rhabdomyosarcoma cells through the induction of apoptosis.  This effect relies on inhibition of AKT signaling and induction of the stress-assocd. transcription factor p8 because small interfering RNA-mediated down-regulation of p8 rescued cell viability upon cannabinoid treatment.  Finally, treatment of xenografts with HU210 led to a significant suppression of tumor growth in vivo.  These results support the notion that cannabinoid receptor agonists could represent a novel targeted approach for treatment of translocation-pos. rhabdomyosarcoma. [Mol Cancer Ther 2009;8(7):1838-45].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMh5egpxSj8bVg90H21EOLACvtfcHk0lhqtoQXBanS_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVymsrc%253D&md5=92ce70ba239e376a33044be2ab6a3938</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-1147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-1147%26sid%3Dliteratum%253Aachs%26aulast%3DOesch%26aufirst%3DS.%26aulast%3DWalter%26aufirst%3DD.%26aulast%3DWachtel%26aufirst%3DM.%26aulast%3DPretre%26aufirst%3DK.%26aulast%3DSalazar%26aufirst%3DM.%26aulast%3DGuzm%25C3%25A1n%26aufirst%3DM.%26aulast%3DVelasco%26aufirst%3DG.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DB.%2BW.%26atitle%3DCannabinoid%2520receptor%25201%2520is%2520a%2520potential%2520drug%2520target%2520for%2520treatment%2520of%2520translocation-positive%2520rhabdomyosarcoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D1838%26epage%3D1845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Olea-Herrero, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vara, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malagarie-Cazenave, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz-Laviada, I.</span><span> </span><span class="NLM_article-title">Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-methanandamide and JWH-015: involvement of CB2</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">940</span><span class="NLM_x">–</span> <span class="NLM_lpage">950</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1038%2Fsj.bjc.6605248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=19690545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtV2qsrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2009&pages=940-950&author=N.+Olea-Herreroauthor=D.+Varaauthor=S.+Malagarie-Cazenaveauthor=I.+Diaz-Laviada&title=Inhibition+of+human+tumour+prostate+PC-3+cell+growth+by+cannabinoids+R%28%2B%29-methanandamide+and+JWH-015%3A+involvement+of+CB2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of human tumor prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: Involvement of CB2</span></div><div class="casAuthors">Olea-Herrero, N.; Vara, D.; Malagarie-Cazenave, S.; Diaz-Laviada, I.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">940-950</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: We have previously shown that cannabinoids induce growth inhibition and apoptosis in prostate cancer PC-3 cells, which express high levels of cannabinoid receptor types 1 and 2 (CB1 and CB2).  In this study, we investigated the role of CB2 receptor in the anti-proliferative action of cannabinoids and the signal transduction triggered by receptor ligation.  Methods: The human prostate cancer cell lines, namely PC-3, DU-145 and LNCaP, were used for this study.  Cell proliferation was measured using MTT proliferation assay, [3H]-thymidine incorporation assay and cell-cycle study by flow cytometry.  Ceramide quantification was performed using the DAG kinase method.  The CB2 receptor was silenced with specific small interfering RNA, and was blocked pharmacol. with SR 144528.  In vivo studies were conducted by the induction of prostate xenograft tumors in nude mice.  Results: We found that the anandamide analog, R(+)-Methanandamide (MET), as well as JWH-015, a synthetic CB2 agonist, exerted anti-proliferative effects in PC-3 cells.  R(+)-Methanandamide- and JWH-015-induced cell death was rescued by treatment with the CB2 receptor antagonist, SR 144528.  Downregulation of CB2 expression reversed the effects of JWH-015, confirming the involvement of CB2 in the pro-apoptotic effect of cannabinoids.  Further analyzing the mechanism of JWH-015-induced cell growth inhibition, we found that JWH-015 triggered a de novo synthesis of ceramide, which was involved in cannabinoid-induced cell death, insofar as blocking ceramide synthesis with Fumonisin B1 reduced cell death.  Signalling pathways activated by JWH-015 included JNK (c-Jun N-terminal kinase) activation and Akt inhibition.  In vivo treatment with JWH-015 caused a significant redn. in tumor growth in mice.  Conclusions: This study defines the involvement of CB2-mediated signalling in the in vivo and in vitro growth inhibition of prostate cancer cells and suggests that CB2 agonists have potential therapeutic interest and deserve to be explored in the management of prostate cancer.  British Journal of Cancer (2009) 101, 940-950; doi:10.1038/sj.bjc.6605248 www.bjcancer.com Published online 18 August 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8n-thjFjaLLVg90H21EOLACvtfcHk0li5KNFqmJh6Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtV2qsrjO&md5=9bea0fa09288d7e3886584781f74b462</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6605248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6605248%26sid%3Dliteratum%253Aachs%26aulast%3DOlea-Herrero%26aufirst%3DN.%26aulast%3DVara%26aufirst%3DD.%26aulast%3DMalagarie-Cazenave%26aufirst%3DS.%26aulast%3DDiaz-Laviada%26aufirst%3DI.%26atitle%3DInhibition%2520of%2520human%2520tumour%2520prostate%2520PC-3%2520cell%2520growth%2520by%2520cannabinoids%2520R%2528%252B%2529-methanandamide%2520and%2520JWH-015%253A%2520involvement%2520of%2520CB2%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2009%26volume%3D101%26spage%3D940%26epage%3D950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatte, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buzard, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. M.</span><span> </span><span class="NLM_article-title">Therapeutic utility of cannabinoid receptor type 2 (CB2) selective agonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">8224</span><span class="NLM_x">–</span> <span class="NLM_lpage">8256</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm4005626" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFeru7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8224-8256&author=S.+Hanauthor=J.+Thatteauthor=D.+J.+Buzardauthor=R.+M.+Jones&title=Therapeutic+utility+of+cannabinoid+receptor+type+2+%28CB2%29+selective+agonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Utility of Cannabinoid Receptor Type 2 (CB2) Selective Agonists</span></div><div class="casAuthors">Han, Sangdon; Thatte, Jayant; Buzard, Daniel J.; Jones, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8224-8256</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The cannabinoid receptor type 2 (CB2) is a class A GPCR that was cloned in 1993 while looking for an alternative receptor that could explain the pharmacol. properties of Δ9-tetrahydrocannabinol.  CB2 was identified among cDNAs based on its similarity in amino acid sequence to the CB1 receptor and helped provide an explanation for the established effects of cannabinoids on the immune system.  In addn. to the immune system, CB2 has widespread tissue expression and has been found in brain, peripheral nervous system, and gastrointestinal tract.  Several "mixed" cannabinoid agonists are currently in clin. use primarily for controlling pain, and it is believed that selective CB2 agonism may afford a superior analgesic agent devoid of the centrally mediated CB1 effects.  Thus, selective CB2 receptor agonists represent high value putative therapeutics for treating pain and other disease states.  In this Perspective, we seek to provide a concise update of progress in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqncpGbOhjA5bVg90H21EOLACvtfcHk0li5KNFqmJh6Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFeru7bO&md5=bb532e5c81b475aa04a3311a017c82f1</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm4005626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4005626%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DS.%26aulast%3DThatte%26aufirst%3DJ.%26aulast%3DBuzard%26aufirst%3DD.%2BJ.%26aulast%3DJones%26aufirst%3DR.%2BM.%26atitle%3DTherapeutic%2520utility%2520of%2520cannabinoid%2520receptor%2520type%25202%2520%2528CB2%2529%2520selective%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8224%26epage%3D8256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Sánchez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Ceballos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gómez del Pulgar, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rueda, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbacho, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galve-Roperh, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huffman, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramón y Cajal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzmán, M.</span><span> </span><span class="NLM_article-title">Inhibition of glioma growth in vivo by selective activation of the CB 2 cannabinoid receptor inhibition of glioma growth in vivo by selective activation of the CB 2</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">5784</span><span class="NLM_x">–</span> <span class="NLM_lpage">5789</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=5784-5789&author=C.+S%C3%A1nchezauthor=M.+L.+de+Ceballosauthor=T.+G%C3%B3mez+del+Pulgarauthor=D.+Ruedaauthor=C.+Corbachoauthor=G.+Velascoauthor=I.+Galve-Roperhauthor=J.+W.+Huffmanauthor=S.+Ram%C3%B3n+y+Cajalauthor=M.+Guzm%C3%A1n&title=Inhibition+of+glioma+growth+in+vivo+by+selective+activation+of+the+CB+2+cannabinoid+receptor+inhibition+of+glioma+growth+in+vivo+by+selective+activation+of+the+CB+2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A1nchez%26aufirst%3DC.%26aulast%3Dde%2BCeballos%26aufirst%3DM.%2BL.%26aulast%3DG%25C3%25B3mez%2Bdel%2BPulgar%26aufirst%3DT.%26aulast%3DRueda%26aufirst%3DD.%26aulast%3DCorbacho%26aufirst%3DC.%26aulast%3DVelasco%26aufirst%3DG.%26aulast%3DGalve-Roperh%26aufirst%3DI.%26aulast%3DHuffman%26aufirst%3DJ.%2BW.%26aulast%3DRam%25C3%25B3n%2By%2BCajal%26aufirst%3DS.%26aulast%3DGuzm%25C3%25A1n%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520glioma%2520growth%2520in%2520vivo%2520by%2520selective%2520activation%2520of%2520the%2520CB%25202%2520cannabinoid%2520receptor%2520inhibition%2520of%2520glioma%2520growth%2520in%2520vivo%2520by%2520selective%2520activation%2520of%2520the%2520CB%25202%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D5784%26epage%3D5789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Duntsch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Divi, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnamurthy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehm, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sills, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, B. M.</span><span> </span><span class="NLM_article-title">Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma</span> <span class="citation_source-journal">J. Neurooncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">143</span><span class="NLM_x">–</span> <span class="NLM_lpage">152</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1007%2Fs11060-005-9031-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=16314952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A280%3ADC%252BD283mvFeitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2006&pages=143-152&author=C.+Duntschauthor=M.+K.+Diviauthor=T.+Jonesauthor=Q.+Zhouauthor=M.+Krishnamurthyauthor=P.+Boehmauthor=G.+Woodauthor=A.+Sillsauthor=B.+M.+Moore&title=Safety+and+efficacy+of+a+novel+cannabinoid+chemotherapeutic%2C+KM-233%2C+for+the+treatment+of+high-grade+glioma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma</span></div><div class="casAuthors">Duntsch Christopher; Divi Murali Krishna; Jones Terreia; Zhou Qihong; Krishnamurthy Mathangi; Boehm Peter; Wood George; Sills Allen; Moore Bob M 2nd</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuro-oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">143-52</span>
        ISSN:<span class="NLM_cas:issn">0167-594X</span>.
    </div><div class="casAbstract">OBJECTIVE:  To test in vitro and in vivo the safety and efficacy of a novel chemotherapeutic agent, KM-233, for the treatment of glioma.  METHODS:  In vitro cell cytotoxicity assays were used to measure and compare the cytotoxic effects of KM-233, Delta(8)-tetrahydrocannabinol (THC), and bis-chloroethyl-nitrosurea (BCNU) against human U87 glioma cells.  An organotypic brain slice culture model was used for safety and toxicity studies.  A human glioma-SCID mouse side-pocket tumor model was used to test in vivo the safety and efficacy of KM-233 with intratumoral and intra-peritoneal administration.  RESULTS:  KM-233 is a classical cannabinoid with good blood brain barrier penetration that possesses a selective affinity for the CB2 receptors relative to THC.  KM-233 was as efficacious in its cytotoxicity against human U87 glioma as Delta(8)-tetrahydrocannabinol, and superior to the commonly used anti-glioma chemotherapeutic agent, BCNU.  The cytotoxic effects of KM-233 against human glioma cells in vitro occur as early as two hours after administration, and dosing of KM-233 can be cycled without compromising cytotoxic efficacy and while improving safety.  Cyclical dosing of KM-233 to treat U87 glioma in a SCID mouse xenograft side pocket model was effective at reducing the tumor burden with both systemic and intratumoral administration.  CONCLUSION:  These studies provide both in vitro and in vivo evidence that KM-233 shows promising efficacy against human glioma cell lines in both in vitro and in vivo studies, minimal toxicity to healthy cultured brain tissue, and should be considered for definitive preclinical development in animal models of glioma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTy1HeLuTdN-tts4TFFB11gfW6udTcc2ebPMtvnF0UURrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD283mvFeitg%253D%253D&md5=375cad819c61fdf2ec9a0593667922bd</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs11060-005-9031-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11060-005-9031-y%26sid%3Dliteratum%253Aachs%26aulast%3DDuntsch%26aufirst%3DC.%26aulast%3DDivi%26aufirst%3DM.%2BK.%26aulast%3DJones%26aufirst%3DT.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DKrishnamurthy%26aufirst%3DM.%26aulast%3DBoehm%26aufirst%3DP.%26aulast%3DWood%26aufirst%3DG.%26aulast%3DSills%26aufirst%3DA.%26aulast%3DMoore%26aufirst%3DB.%2BM.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520a%2520novel%2520cannabinoid%2520chemotherapeutic%252C%2520KM-233%252C%2520for%2520the%2520treatment%2520of%2520high-grade%2520glioma%26jtitle%3DJ.%2520Neurooncol.%26date%3D2006%26volume%3D77%26spage%3D143%26epage%3D152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Palazuelos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguado, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mechoulam, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzmán, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galve-Roperh, I.</span><span> </span><span class="NLM_article-title">Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2405</span><span class="NLM_x">–</span> <span class="NLM_lpage">2407</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=2405-2407&author=J.+Palazuelosauthor=T.+Aguadoauthor=A.+Egiaauthor=R.+Mechoulamauthor=M.+Guzm%C3%A1nauthor=I.+Galve-Roperh&title=Non-psychoactive+CB2+cannabinoid+agonists+stimulate+neural+progenitor+proliferation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPalazuelos%26aufirst%3DJ.%26aulast%3DAguado%26aufirst%3DT.%26aulast%3DEgia%26aufirst%3DA.%26aulast%3DMechoulam%26aufirst%3DR.%26aulast%3DGuzm%25C3%25A1n%26aufirst%3DM.%26aulast%3DGalve-Roperh%26aufirst%3DI.%26atitle%3DNon-psychoactive%2520CB2%2520cannabinoid%2520agonists%2520stimulate%2520neural%2520progenitor%2520proliferation%26jtitle%3DFASEB%2520J.%26date%3D2006%26volume%3D20%26spage%3D2405%26epage%3D2407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Pertwee, R. G.</span><span> </span><span class="NLM_article-title">Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities</span> <span class="citation_source-journal">Philos. Trans. R. Soc., B</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x">, </span> <span class="NLM_fpage">3353</span><span class="NLM_x">–</span> <span class="NLM_lpage">3363</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1098%2Frstb.2011.0381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=23108552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVKgtL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=3353-3363&author=R.+G.+Pertwee&title=Targeting+the+endocannabinoid+system+with+cannabinoid+receptor+agonists%3A+pharmacological+strategies+and+therapeutic+possibilities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities</span></div><div class="casAuthors">Pertwee, Roger G.</div><div class="citationInfo"><span class="NLM_cas:title">Philosophical Transactions of the Royal Society, B: Biological Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">1607</span>),
    <span class="NLM_cas:pages">3353-3363</span>CODEN:
                <span class="NLM_cas:coden">PTRBAE</span>;
        ISSN:<span class="NLM_cas:issn">0962-8436</span>.
    
            (<span class="NLM_cas:orgname">Royal Society</span>)
        </div><div class="casAbstract">A review.  Human tissues express cannabinoid CB1 and CB2 receptors that can be activated by endogenously released 'endocannabinoids' or exogenously administered compds. in a manner that reduces the symptoms or opposes the underlying causes of several disorders in need of effective therapy.  Three medicines that activate cannabinoid CB1/CB2 receptors are now in the clinic: Cesamet (nabilone), Marinol (dronabinol; Δ9-tetrahydrocannabinol (Δ9-THC)) and Sativex (Δ9-THC with cannabidiol).  These can be prescribed for the amelioration of chemotherapy-induced nausea and vomiting (Cesamet and Marinol), stimulation of appetite (Marinol) and symptomatic relief of cancer pain and/or management of neuropathic pain and spasticity in adults with multiple sclerosis (Sativex).  This review mentions several possible addnl. therapeutic targets for cannabinoid receptor agonists.  These include other kinds of pain, epilepsy, anxiety, depression, Parkinson's and Huntington's diseases, amyotrophic lateral sclerosis, stroke, cancer, drug dependence, glaucoma, autoimmune uveitis, osteoporosis, sepsis, and hepatic, renal, intestinal and cardiovascular disorders.  It also describes potential strategies for improving the efficacy and/or benefit-to-risk ratio of these agonists in the clinic.  These are strategies that involve (i) targeting cannabinoid receptors located outside the blood-brain barrier, (ii) targeting cannabinoid receptors expressed by a particular tissue, (iii) targeting upregulated cannabinoid receptors, (iv) selectively targeting cannabinoid CB2 receptors, and/or (v) adjunctive 'multi-targeting'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3Q3tFouTow7Vg90H21EOLACvtfcHk0lgrcWNPNJBUEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVKgtL3L&md5=520dda552cdeb306560444cf7c5932f6</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1098%2Frstb.2011.0381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frstb.2011.0381%26sid%3Dliteratum%253Aachs%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26atitle%3DTargeting%2520the%2520endocannabinoid%2520system%2520with%2520cannabinoid%2520receptor%2520agonists%253A%2520pharmacological%2520strategies%2520and%2520therapeutic%2520possibilities%26jtitle%3DPhilos.%2520Trans.%2520R.%2520Soc.%252C%2520B%26date%3D2012%26volume%3D367%26spage%3D3353%26epage%3D3363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Chiorean, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braicu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berindan-Neagoe, I.</span><span> </span><span class="NLM_article-title">Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth?</span> <span class="citation_source-journal">Breast</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1026</span><span class="NLM_x">–</span> <span class="NLM_lpage">1033</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2013&pages=1026-1033&author=R.+Chioreanauthor=C.+Braicuauthor=I.+Berindan-Neagoe&title=Another+review+on+triple+negative+breast+cancer.+Are+we+on+the+right+way+towards+the+exit+from+the+labyrinth%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChiorean%26aufirst%3DR.%26aulast%3DBraicu%26aufirst%3DC.%26aulast%3DBerindan-Neagoe%26aufirst%3DI.%26atitle%3DAnother%2520review%2520on%2520triple%2520negative%2520breast%2520cancer.%2520Are%2520we%2520on%2520the%2520right%2520way%2520towards%2520the%2520exit%2520from%2520the%2520labyrinth%253F%26jtitle%3DBreast%26date%3D2013%26volume%3D22%26spage%3D1026%26epage%3D1033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Abramson, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballinger, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietenpol, J. A.</span><span> </span><span class="NLM_article-title">Subtyping of triple-negative breast cancer: implications for therapy</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&pages=1-9&author=V.+G.+Abramsonauthor=B.+D.+Lehmannauthor=T.+J.+Ballingerauthor=J.+A.+Pietenpol&title=Subtyping+of+triple-negative+breast+cancer%3A+implications+for+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAbramson%26aufirst%3DV.%2BG.%26aulast%3DLehmann%26aufirst%3DB.%2BD.%26aulast%3DBallinger%26aufirst%3DT.%2BJ.%26aulast%3DPietenpol%26aufirst%3DJ.%2BA.%26atitle%3DSubtyping%2520of%2520triple-negative%2520breast%2520cancer%253A%2520implications%2520for%2520therapy%26jtitle%3DCancer%26date%3D2014%26spage%3D1%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Hoeferlin, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">E.Chalfant, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, M. A.</span><span> </span><span class="NLM_article-title">Challenges in the treatment of triple negative and HER2-overexpressing breast cancer</span> <span class="citation_source-journal">J. Surg. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">7</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=3-7&author=L.+A.+Hoeferlinauthor=C.+E.+E.Chalfantauthor=M.+A.+Park&title=Challenges+in+the+treatment+of+triple+negative+and+HER2-overexpressing+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHoeferlin%26aufirst%3DL.%2BA.%26aulast%3DE.Chalfant%26aufirst%3DC.%2BE.%26aulast%3DPark%26aufirst%3DM.%2BA.%26atitle%3DChallenges%2520in%2520the%2520treatment%2520of%2520triple%2520negative%2520and%2520HER2-overexpressing%2520breast%2520cancer%26jtitle%3DJ.%2520Surg.%2520Sci.%26date%3D2013%26volume%3D1%26spage%3D3%26epage%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Foulkes, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reis-Filho, J. S.</span><span> </span><span class="NLM_article-title">Triple-negative breast cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1938</span><span class="NLM_x">–</span> <span class="NLM_lpage">1948</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1056%2FNEJMra1001389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=21067385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVCltr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1938-1948&author=W.+D.+Foulkesauthor=I.+E.+Smithauthor=J.+S.+Reis-Filho&title=Triple-negative+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Triple-negative breast cancer</span></div><div class="casAuthors">Foulkes, William D.; Smith, Ian E.; Reis-Filho, Jorge S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1938-1948</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiN8P8IsovvLVg90H21EOLACvtfcHk0litZipaDfV_gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVCltr7P&md5=641fe4726e6a7118208aa6b3502c9df6</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1001389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1001389%26sid%3Dliteratum%253Aachs%26aulast%3DFoulkes%26aufirst%3DW.%2BD.%26aulast%3DSmith%26aufirst%3DI.%2BE.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26atitle%3DTriple-negative%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1938%26epage%3D1948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Hudis, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gianni, L.</span><span> </span><span class="NLM_article-title">Triple-negative breast cancer: an unmet medical need</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">11</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=1-11&author=C.+A.+Hudisauthor=L.+Gianni&title=Triple-negative+breast+cancer%3A+an+unmet+medical+need"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHudis%26aufirst%3DC.%2BA.%26aulast%3DGianni%26aufirst%3DL.%26atitle%3DTriple-negative%2520breast%2520cancer%253A%2520an%2520unmet%2520medical%2520need%26jtitle%3DOncologist%26date%3D2011%26volume%3D16%26spage%3D1%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Engebraaten, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vollan, H. K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Børresen-Dale, A.-L.</span><span> </span><span class="NLM_article-title">Triple-negative breast cancer and the need for new therapeutic targets</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">183</span><span class="NLM_x">, </span> <span class="NLM_fpage">1064</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1016%2Fj.ajpath.2013.05.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=23920327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2ktrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2013&pages=1064-1074&author=O.+Engebraatenauthor=H.+K.+M.+Vollanauthor=A.-L.+B%C3%B8rresen-Dale&title=Triple-negative+breast+cancer+and+the+need+for+new+therapeutic+targets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Triple-Negative Breast Cancer and the Need for New Therapeutic Targets</span></div><div class="casAuthors">Engebraaten, Olav; Vollan, Hans Kristian Moen; Boerresen-Dale, Anne-Lise</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1064-1074</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Triple-neg. breast cancers (TNBCs) are a diverse and heterogeneous group of tumors that by definition lack estrogen and progesterone receptors and amplification of the HER2 gene.  The majority of the tumors classified as TNBCs are highly malignant, and only a subgroup responds to conventional chemotherapy with a favorable prognosis.  Results from decades of research have identified important mol. characteristics that can subdivide this group of breast cancers further.  High-throughput mol. analyses including sequencing, pathway analyses, and integrated analyses of alterations at the genomic and transcriptomic levels have improved our understanding of the mol. alterations involved in tumor development and progression.  How this knowledge should be used for rational selection of therapy is a challenging task and the subject of numerous ongoing research programs.  This review summarizes the current knowledge on the clin. characteristics and mol. alterations of TNBCs.  Currently used conventional therapeutic strategies and targeted therapy studies are discussed, with refs. to recently published results on the mol. characterization of TNBCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox7RPjyK4CDrVg90H21EOLACvtfcHk0liukzcfh335HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2ktrjP&md5=d3b2dd27ab0981e380877cec7f28c453</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.ajpath.2013.05.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajpath.2013.05.033%26sid%3Dliteratum%253Aachs%26aulast%3DEngebraaten%26aufirst%3DO.%26aulast%3DVollan%26aufirst%3DH.%2BK.%2BM.%26aulast%3DB%25C3%25B8rresen-Dale%26aufirst%3DA.-L.%26atitle%3DTriple-negative%2520breast%2520cancer%2520and%2520the%2520need%2520for%2520new%2520therapeutic%2520targets%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2013%26volume%3D183%26spage%3D1064%26epage%3D1074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Caffarel, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andradas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pérez-Gómez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzmán, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sánchez, C.</span><span> </span><span class="NLM_article-title">Cannabinoids: a new hope for breast cancer therapy?</span> <span class="citation_source-journal">Cancer Treat. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">911</span><span class="NLM_x">–</span> <span class="NLM_lpage">918</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1016%2Fj.ctrv.2012.06.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=22776349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFGgs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2012&pages=911-918&author=M.+M.+Caffarelauthor=C.+Andradasauthor=E.+P%C3%A9rez-G%C3%B3mezauthor=M.+Guzm%C3%A1nauthor=C.+S%C3%A1nchez&title=Cannabinoids%3A+a+new+hope+for+breast+cancer+therapy%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoids: A new hope for breast cancer therapy?</span></div><div class="casAuthors">Caffarel, Maria M.; Andradas, Clara; Perez-Gomez, Eduardo; Guzman, Manuel; Sanchez, Cristina</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">911-918</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Breast cancer is a very common disease that affects approx. 1 in 10 women at some point in their lives.  Importantly, breast cancer cannot be considered a single disease as it is characterized by distinct pathol. and mol. subtypes that are treated with different therapies and have diverse clin. outcomes.  Although some highly successful treatments have been developed, certain breast tumors are resistant to conventional therapies and a considerable no. of them relapse.  Therefore, new strategies are urgently needed, and the challenge for the future will most likely be the development of individualized therapies that specifically target each patient's tumor.  Exptl. evidence accumulated during the last decade supports that cannabinoids, the active components of Cannabis sativa and their derivs., possess anticancer activity.  Thus, these compds. exert anti-proliferative, pro-apoptotic, anti-migratory and anti-invasive actions in a wide spectrum of cancer cells in culture.  Moreover, tumor growth, angiogenesis and metastasis are hampered by cannabinoids in xenograft-based and genetically-engineered mouse models of cancer.  This review summarizes our current knowledge on the anti-tumor potential of cannabinoids in breast cancer, which suggests that cannabinoid-based medicines may be useful for the treatment of most breast tumor subtypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBlC9cAlRexbVg90H21EOLACvtfcHk0liukzcfh335HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFGgs78%253D&md5=1918aae12cfc16fb2045bdab2929fc9b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2012.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2012.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DCaffarel%26aufirst%3DM.%2BM.%26aulast%3DAndradas%26aufirst%3DC.%26aulast%3DP%25C3%25A9rez-G%25C3%25B3mez%26aufirst%3DE.%26aulast%3DGuzm%25C3%25A1n%26aufirst%3DM.%26aulast%3DS%25C3%25A1nchez%26aufirst%3DC.%26atitle%3DCannabinoids%253A%2520a%2520new%2520hope%2520for%2520breast%2520cancer%2520therapy%253F%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2012%26volume%3D38%26spage%3D911%26epage%3D918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Morales, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vara, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goméz-Cañas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zúñiga, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olea-Azar, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goya, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernández-Ruiz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Díaz-Laviada, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagerovic, N.</span><span> </span><span class="NLM_article-title">Synthetic cannabinoid quinones: preparation, in vitro antiproliferative effects and in vivo prostate antitumor activity</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">119</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1016%2Fj.ejmech.2013.09.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=24141201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOqu7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2013&pages=111-119&author=P.+Moralesauthor=D.+Varaauthor=M.+Gom%C3%A9z-Ca%C3%B1asauthor=M.+C.+Z%C3%BA%C3%B1igaauthor=C.+Olea-Azarauthor=P.+Goyaauthor=J.+Fern%C3%A1ndez-Ruizauthor=I.+D%C3%ADaz-Laviadaauthor=N.+Jagerovic&title=Synthetic+cannabinoid+quinones%3A+preparation%2C+in+vitro+antiproliferative+effects+and+in+vivo+prostate+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic cannabinoid quinones: Preparation, in vitro antiproliferative effects and in vivo prostate antitumor activity</span></div><div class="casAuthors">Morales, Paula; Vara, Diana; Gomez-Canas, Maria; Zuniga, Maria C.; Olea-Azar, Claudio; Goya, Pilar; Fernandez-Ruiz, Javier; Diaz-Laviada, Ines; Jagerovic, Nadine</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111-119</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Chromenopyrazolediones I (R = H, Me or Et) were designed and synthesized as anticancer agents using the multi-biol. target concept that involves quinone cytotoxicity and cannabinoid antitumor properties.  In cell cytotoxicity assays, these chromenopyrazolediones have antiproliferative activity against human prostate cancer and hepatocellular carcinoma.  The most potent, deriv. I (R = H) (PM49), inhibits prostate LNCaP cell viability (IC50 = 15 μM) through a mechanism involving oxidative stress, PPARγ receptor and partially CB1 receptor.  It acts on prostate cell growth by causing G0/G1 phase arrest and triggering apoptosis as assessed by flow cytometry measurements.  In the in vivo treatment, compd. 4 at 2 mg/kg, blocks the growth of LNCaP tumors and reduces the growth of PC-3 tumors generated in mice.  These studies suggest that 4 is a good potential anticancer agent against hormone-sensitive prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO5NQIw5F-dLVg90H21EOLACvtfcHk0liukzcfh335HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOqu7zM&md5=bc7077307179432b6631f1cade5b9b37</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.09.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.09.043%26sid%3Dliteratum%253Aachs%26aulast%3DMorales%26aufirst%3DP.%26aulast%3DVara%26aufirst%3DD.%26aulast%3DGom%25C3%25A9z-Ca%25C3%25B1as%26aufirst%3DM.%26aulast%3DZ%25C3%25BA%25C3%25B1iga%26aufirst%3DM.%2BC.%26aulast%3DOlea-Azar%26aufirst%3DC.%26aulast%3DGoya%26aufirst%3DP.%26aulast%3DFern%25C3%25A1ndez-Ruiz%26aufirst%3DJ.%26aulast%3DD%25C3%25ADaz-Laviada%26aufirst%3DI.%26aulast%3DJagerovic%26aufirst%3DN.%26atitle%3DSynthetic%2520cannabinoid%2520quinones%253A%2520preparation%252C%2520in%2520vitro%2520antiproliferative%2520effects%2520and%2520in%2520vivo%2520prostate%2520antitumor%2520activity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D70%26spage%3D111%26epage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Cumella, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernández-Folgado, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girón, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sánchez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morales, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurst, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gómez-Cañas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gómez-Ruiz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinto, D. C. G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goya, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reggio, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernández-Ruiz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silva, A. M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagerovic, N.</span><span> </span><span class="NLM_article-title">Chromenopyrazoles: non-psychoactive and selective CB1 cannabinoid agonists with peripheral antinociceptive properties</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">452</span><span class="NLM_x">–</span> <span class="NLM_lpage">463</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=452-463&author=J.+Cumellaauthor=L.+Hern%C3%A1ndez-Folgadoauthor=R.+Gir%C3%B3nauthor=E.+S%C3%A1nchezauthor=P.+Moralesauthor=D.+P.+Hurstauthor=M.+G%C3%B3mez-Ca%C3%B1asauthor=M.+G%C3%B3mez-Ruizauthor=D.+C.+G.+A.+Pintoauthor=P.+Goyaauthor=P.+H.+Reggioauthor=M.+I.+Martinauthor=J.+Fern%C3%A1ndez-Ruizauthor=A.+M.+S.+Silvaauthor=N.+Jagerovic&title=Chromenopyrazoles%3A+non-psychoactive+and+selective+CB1+cannabinoid+agonists+with+peripheral+antinociceptive+properties"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCumella%26aufirst%3DJ.%26aulast%3DHern%25C3%25A1ndez-Folgado%26aufirst%3DL.%26aulast%3DGir%25C3%25B3n%26aufirst%3DR.%26aulast%3DS%25C3%25A1nchez%26aufirst%3DE.%26aulast%3DMorales%26aufirst%3DP.%26aulast%3DHurst%26aufirst%3DD.%2BP.%26aulast%3DG%25C3%25B3mez-Ca%25C3%25B1as%26aufirst%3DM.%26aulast%3DG%25C3%25B3mez-Ruiz%26aufirst%3DM.%26aulast%3DPinto%26aufirst%3DD.%2BC.%2BG.%2BA.%26aulast%3DGoya%26aufirst%3DP.%26aulast%3DReggio%26aufirst%3DP.%2BH.%26aulast%3DMartin%26aufirst%3DM.%2BI.%26aulast%3DFern%25C3%25A1ndez-Ruiz%26aufirst%3DJ.%26aulast%3DSilva%26aufirst%3DA.%2BM.%2BS.%26aulast%3DJagerovic%26aufirst%3DN.%26atitle%3DChromenopyrazoles%253A%2520non-psychoactive%2520and%2520selective%2520CB1%2520cannabinoid%2520agonists%2520with%2520peripheral%2520antinociceptive%2520properties%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D452%26epage%3D463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Wu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penning, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, R. G.</span><span> </span><span class="NLM_article-title">Regiospecific oxidation of polycyclic aromatic phenols to quinones by hypervalent iodine reagents</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">2111</span><span class="NLM_x">–</span> <span class="NLM_lpage">2118</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=2111-2118&author=A.+Wuauthor=Y.+Duanauthor=D.+Xuauthor=T.+M.+Penningauthor=R.+G.+Harvey&title=Regiospecific+oxidation+of+polycyclic+aromatic+phenols+to+quinones+by+hypervalent+iodine+reagents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DA.%26aulast%3DDuan%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DPenning%26aufirst%3DT.%2BM.%26aulast%3DHarvey%26aufirst%3DR.%2BG.%26atitle%3DRegiospecific%2520oxidation%2520of%2520polycyclic%2520aromatic%2520phenols%2520to%2520quinones%2520by%2520hypervalent%2520iodine%2520reagents%26jtitle%3DTetrahedron%26date%3D2010%26volume%3D66%26spage%3D2111%26epage%3D2118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Magdziak, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van De Water, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettus, T. R. R.</span><span> </span><span class="NLM_article-title">Regioselective oxidation of phenols to <i>o</i>-quinones with <i>o</i>-iodoxybenzoic acid (IBX)</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_fpage">285</span><span class="NLM_x">–</span> <span class="NLM_lpage">288</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&pages=285-288&author=D.+Magdziakauthor=A.+A.+Rodriguezauthor=R.+W.+Van+De+Waterauthor=T.+R.+R.+Pettus&title=Regioselective+oxidation+of+phenols+to+o-quinones+with+o-iodoxybenzoic+acid+%28IBX%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMagdziak%26aufirst%3DD.%26aulast%3DRodriguez%26aufirst%3DA.%2BA.%26aulast%3DVan%2BDe%2BWater%26aufirst%3DR.%2BW.%26aulast%3DPettus%26aufirst%3DT.%2BR.%2BR.%26atitle%3DRegioselective%2520oxidation%2520of%2520phenols%2520to%2520o-quinones%2520with%2520o-iodoxybenzoic%2520acid%2520%2528IBX%2529%26jtitle%3DOrg.%2520Lett.%26date%3D2002%26spage%3D285%26epage%3D288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Harvey, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ran, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penning, T. M.</span><span> </span><span class="NLM_article-title">Synthesis of the <i>o</i>-quinones and other oxidized metabolites of polycyclic aromatic hydrocarbons implicated in carcinogenesis</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">2024</span><span class="NLM_x">–</span> <span class="NLM_lpage">2032</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo030348n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2004&pages=2024-2032&author=R.+G.+Harveyauthor=Q.+Daiauthor=C.+Ranauthor=T.+M.+Penning&title=Synthesis+of+the+o-quinones+and+other+oxidized+metabolites+of+polycyclic+aromatic+hydrocarbons+implicated+in+carcinogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjo030348n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo030348n%26sid%3Dliteratum%253Aachs%26aulast%3DHarvey%26aufirst%3DR.%2BG.%26aulast%3DDai%26aufirst%3DQ.%26aulast%3DRan%26aufirst%3DC.%26aulast%3DPenning%26aufirst%3DT.%2BM.%26atitle%3DSynthesis%2520of%2520the%2520o-quinones%2520and%2520other%2520oxidized%2520metabolites%2520of%2520polycyclic%2520aromatic%2520hydrocarbons%2520implicated%2520in%2520carcinogenesis%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2004%26volume%3D69%26spage%3D2024%26epage%3D2032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Barontini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crisante, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabrizi, G.</span><span> </span><span class="NLM_article-title">Selective and efficient oxidative modifications of flavonoids with 2-iodoxybenzoic acid (IBX)</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">6047</span><span class="NLM_x">–</span> <span class="NLM_lpage">6053</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=6047-6053&author=M.+Barontiniauthor=R.+Berniniauthor=F.+Crisanteauthor=G.+Fabrizi&title=Selective+and+efficient+oxidative+modifications+of+flavonoids+with+2-iodoxybenzoic+acid+%28IBX%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBarontini%26aufirst%3DM.%26aulast%3DBernini%26aufirst%3DR.%26aulast%3DCrisante%26aufirst%3DF.%26aulast%3DFabrizi%26aufirst%3DG.%26atitle%3DSelective%2520and%2520efficient%2520oxidative%2520modifications%2520of%2520flavonoids%2520with%25202-iodoxybenzoic%2520acid%2520%2528IBX%2529%26jtitle%3DTetrahedron%26date%3D2010%26volume%3D66%26spage%3D6047%26epage%3D6053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Ekins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waller, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaan, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruciani, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrighton, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wikel, J. H.</span><span> </span><span class="NLM_article-title">Progress in predicting human ADME parameters in silico</span> <span class="citation_source-journal">J. Pharmacol. Toxicol. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1016%2FS1056-8719%2800%2900109-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=11274894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A280%3ADC%252BD3M7os1Ojtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2000&pages=251-272&author=S.+Ekinsauthor=C.+L.+Wallerauthor=P.+W.+Swaanauthor=G.+Crucianiauthor=S.+A.+Wrightonauthor=J.+H.+Wikel&title=Progress+in+predicting+human+ADME+parameters+in+silico"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in predicting human ADME parameters in silico</span></div><div class="casAuthors">Ekins S; Waller C L; Swaan P W; Cruciani G; Wrighton S A; Wikel J H</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmacological and toxicological methods</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">251-72</span>
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    </div><div class="casAbstract">Understanding the development of a scientific approach is a valuable exercise in gauging the potential directions the process could take in the future.  The relatively short history of applying computational methods to absorption, distribution, metabolism and excretion (ADME) can be split into defined periods.  The first began in the 1960s and continued through the 1970s with the work of Corwin Hansch et al.  Their models utilized small sets of in vivo ADME data.  The second era from the 1980s through 1990s witnessed the widespread incorporation of in vitro approaches as surrogates of in vivo ADME studies.  These approaches fostered the initiation and increase in interpretable computational ADME models available in the literature.  The third era is the present were there are many literature data sets derived from in vitro data for absorption, drug-drug interactions (DDI), drug transporters and efflux pumps [P-glycoprotein (P-gp), MRP], intrinsic clearance and brain penetration, which can theoretically be used to predict the situation in vivo in humans.  Combinatorial synthesis, high throughput screening and computational approaches have emerged as a result of continual pressure on pharmaceutical companies to accelerate drug discovery while decreasing drug development costs.  The goal has become to reduce the drop-out rate of drug candidates in the latter, most expensive stages of drug development.  This is accomplished by increasing the failure rate of candidate compounds in the preclinical stages and increasing the speed of nomination of likely clinical candidates.  The industry now understands the reasons for clinical failure other than efficacy are mainly related to pharmacokinetics and toxicity.  The late 1990s saw significant company investment in ADME and drug safety departments to assess properties such as metabolic stability, cytochrome P-450 inhibition, absorption and genotoxicity earlier in the drug discovery paradigm.  The next logical step in this process is the evaluation of higher throughput data to determine if computational (in silico) models can be constructed and validated from it.  Such models would allow an exponential increase in the number of compounds screened virtually for ADME parameters.  A number of researchers have started to utilize in silico, in vitro and in vivo approaches in parallel to address intestinal permeability and cytochrome P-450-mediated DDI.  This review will assess how computational approaches for ADME parameters have evolved and how they are likely to progress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmUcEou3dTay6Ufuk_1xoTfW6udTcc2eZ9OH5ly9I1H7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M7os1Ojtg%253D%253D&md5=d1ac16400ca299c81372e71b36517565</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2FS1056-8719%2800%2900109-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1056-8719%252800%252900109-X%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DWaller%26aufirst%3DC.%2BL.%26aulast%3DSwaan%26aufirst%3DP.%2BW.%26aulast%3DCruciani%26aufirst%3DG.%26aulast%3DWrighton%26aufirst%3DS.%2BA.%26aulast%3DWikel%26aufirst%3DJ.%2BH.%26atitle%3DProgress%2520in%2520predicting%2520human%2520ADME%2520parameters%2520in%2520silico%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2000%26volume%3D44%26spage%3D251%26epage%3D272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Van de Waterbeemd, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gifford, E.</span><span> </span><span class="NLM_article-title">ADMET in silico modelling: towards prediction paradise?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">192</span><span class="NLM_x">–</span> <span class="NLM_lpage">204</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=192-204&author=H.+Van+de+Waterbeemdauthor=E.+Gifford&title=ADMET+in+silico+modelling%3A+towards+prediction+paradise%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bde%2BWaterbeemd%26aufirst%3DH.%26aulast%3DGifford%26aufirst%3DE.%26atitle%3DADMET%2520in%2520silico%2520modelling%253A%2520towards%2520prediction%2520paradise%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26spage%3D192%26epage%3D204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Jorgensen, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffy, E. M.</span><span> </span><span class="NLM_article-title">Prediction of drug solubility from structure</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">366</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1016%2FS0169-409X%2802%2900008-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=11922952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BD38Xitlartbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2002&pages=355-366&author=W.+L.+Jorgensenauthor=E.+M.+Duffy&title=Prediction+of+drug+solubility+from+structure"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of drug solubility from structure</span></div><div class="casAuthors">Jorgensen, William L.; Duffy, Erin M.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">355-366</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with refs.  The aq. soly. of a drug is an important factor affecting its bioavailability.  Numerous computational methods have been developed for the prediction of aq. soly. from a compd.'s structure.  A review is provided of the methodol. and quality of results for the most useful procedures including the model implemented in the QikProp program.  Viable methods now exist for predictions with <1 log unit uncertainty, which is adequate for prescreening synthetic candidates or design of combinatorial libraries.  Further progress with predictive methods would require an exptl. database of highly accurate solubilities for a large, diverse collection of drug-like mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUQSdPbpSK_rVg90H21EOLACvtfcHk0lidntb_kpFFHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xitlartbc%253D&md5=bc749286d56bf55c26d25b70806217e1</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2802%2900008-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252802%252900008-X%26sid%3Dliteratum%253Aachs%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DDuffy%26aufirst%3DE.%2BM.%26atitle%3DPrediction%2520of%2520drug%2520solubility%2520from%2520structure%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2002%26volume%3D54%26spage%3D355%26epage%3D366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Lipinski, C. A.</span><span> </span><span class="NLM_article-title">Drug-like properties and the causes of poor solubility and poor permeability</span> <span class="citation_source-journal">J. Pharmacol. Toxicol. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">249</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1016%2FS1056-8719%2800%2900107-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitF2ksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=235-249&author=C.+A.+Lipinski&title=Drug-like+properties+and+the+causes+of+poor+solubility+and+poor+permeability"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-like properties and the causes of poor solubility and poor permeability</span></div><div class="casAuthors">Lipinski, C. A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">235-249</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with 18 refs.  There are currently about 10,000 drug-like compds.  These are sparsely, rather than uniformly, distributed through chem. space.  True diversity does not exist in exptl. combinatorial chem. screening libraries.  Absorption, distribution, metab., and excretion (ADME) and chem. reactivity-related toxicity is low, while biol. receptor activity is higher dimensional in chem. space, and this is partly explainable by evolutionary pressures on ADME to deal with endobiotics and exobiotics.  ADME is hard to predict for large data sets because current ADME exptl. screens are multi-mechanisms, and predictions get worse as more data accumulates.  Currently, screening for biol. receptor activity precedes or is concurrent with screening for properties related to "drugability.  " In the future, "drugability" screening may precede biol. receptor activity screening.  The level of permeability or soly. needed for oral absorption is related to potency.  The relative importance of poor soly. and poor permeability towards the problem of poor oral absorption depends on the research approach used for lead generation.  A "rational drug design" approach as exemplified by Merck advanced clin. candidates leads to time-dependent higher mol. wt., higher H-bonding properties, unchanged lipophilicity, and, hence, poorer permeability.  A high throughput screening (HTS)-based approach as exemplified by unpublished data on Pfizer (Groton, CT) early candidates leads to higher mol. wt., unchanged H-bonding properties, higher lipophilicity, and, hence, poorer aq. soly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorZQtrQpa9GLVg90H21EOLACvtfcHk0lidntb_kpFFHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitF2ksrc%253D&md5=d93f92471ea034b286e3d3098e0a6d99</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2FS1056-8719%2800%2900107-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1056-8719%252800%252900107-6%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26atitle%3DDrug-like%2520properties%2520and%2520the%2520causes%2520of%2520poor%2520solubility%2520and%2520poor%2520permeability%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2001%26volume%3D44%26spage%3D235%26epage%3D249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Metzger-Filho, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Azambuja, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saini, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viale, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradbury, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bliss, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azim, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Leo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sotiriou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piccart-Gebhart, M.</span><span> </span><span class="NLM_article-title">Dissecting the heterogeneity of triple-negative breast cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1879</span><span class="NLM_x">–</span> <span class="NLM_lpage">1887</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1200%2FJCO.2011.38.2010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=22454417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVantr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=1879-1887&author=O.+Metzger-Filhoauthor=A.+Tuttauthor=E.+de+Azambujaauthor=K.+S.+Sainiauthor=G.+Vialeauthor=S.+Loiauthor=I.+Bradburyauthor=J.+M.+Blissauthor=H.+A.+Azimauthor=P.+Ellisauthor=A.+Di+Leoauthor=J.+Baselgaauthor=C.+Sotiriouauthor=M.+Piccart-Gebhart&title=Dissecting+the+heterogeneity+of+triple-negative+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting the heterogeneity of triple-negative breast cancer</span></div><div class="casAuthors">Metzger-Filho, Otto; Tutt, Andrew; de Azambuja, Evandro; Saini, Kamal S.; Viale, Giuseppe; Loi, Sherene; Bradbury, Ian; Bliss, Judith M.; Azim, Hatem A., Jr.; Ellis, Paul; Di Leo, Angelo; Baselga, Jose; Sotiriou, Christos; Piccart-Gebhart, Martine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1879-1887</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Triple-neg. breast cancer (TNBC) accounts for 15% to 20% of breast cancers.  It is a heterogeneous disease, not only on the mol. level, but also on the pathol. and clin. levels.  TNBC is assocd. with a significantly higher probability of relapse and poorer overall survival in the first few years after diagnosis when compared with other breast cancer subtypes.  This is obsd. despite its usual high sensitivity to chemotherapy.  In the advanced setting, responses obsd. with chemotherapy lack durability.  Early-stage clin. studies suggested impressive potential when a poly (ADP-ribose) polymerase (PARP) inhibitor is given for the treatment of advanced TNBC with BRCA gene dysfunction.  The mol. complexity of TNBC has led to proposed subclassifications, which will be of great value for the development of targeted therapies.  In this review, we discuss the biol. of TNBC at the pathol. and the mol. levels.  We also elaborate on the role of systemic therapies and the results of the first phase III clin. trial evaluating the addn. of iniparib, a novel investigational anticancer agent that does not possess characteristics typical of the PARP inhibitor class, in combination with chemotherapy in advanced TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfs4COhEhde7Vg90H21EOLACvtfcHk0ljW88_5vJGCtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVantr%252FP&md5=3b5c98bda8556e03ae999abe84d2e3e1</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.38.2010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.38.2010%26sid%3Dliteratum%253Aachs%26aulast%3DMetzger-Filho%26aufirst%3DO.%26aulast%3DTutt%26aufirst%3DA.%26aulast%3Dde%2BAzambuja%26aufirst%3DE.%26aulast%3DSaini%26aufirst%3DK.%2BS.%26aulast%3DViale%26aufirst%3DG.%26aulast%3DLoi%26aufirst%3DS.%26aulast%3DBradbury%26aufirst%3DI.%26aulast%3DBliss%26aufirst%3DJ.%2BM.%26aulast%3DAzim%26aufirst%3DH.%2BA.%26aulast%3DEllis%26aufirst%3DP.%26aulast%3DDi%2BLeo%26aufirst%3DA.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DSotiriou%26aufirst%3DC.%26aulast%3DPiccart-Gebhart%26aufirst%3DM.%26atitle%3DDissecting%2520the%2520heterogeneity%2520of%2520triple-negative%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D1879%26epage%3D1887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Criscitiello, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azim, H. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schouten, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linn, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sotiriou, C.</span><span> </span><span class="NLM_article-title">Understanding the biology of triple-negative breast cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 6</span><span class="NLM_x">) </span> <span class="NLM_fpage">vi13</span><span class="NLM_x">–</span> <span class="NLM_lpage">vi18</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1093%2Fannonc%2Fmds188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=23012296" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=vi13-vi18&issue=Suppl.+6&author=C.+Criscitielloauthor=H.+A.+Azimauthor=P.+C.+Schoutenauthor=S.+C.+Linnauthor=C.+Sotiriou&title=Understanding+the+biology+of+triple-negative+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmds188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmds188%26sid%3Dliteratum%253Aachs%26aulast%3DCriscitiello%26aufirst%3DC.%26aulast%3DAzim%26aufirst%3DH.%2BA.%26aulast%3DSchouten%26aufirst%3DP.%2BC.%26aulast%3DLinn%26aufirst%3DS.%2BC.%26aulast%3DSotiriou%26aufirst%3DC.%26atitle%3DUnderstanding%2520the%2520biology%2520of%2520triple-negative%2520breast%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2012%26volume%3D23%26issue%3DSuppl.%25206%26spage%3Dvi13%26epage%3Dvi18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Rocha, F. C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dos Santos Júnior, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefano, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">da Silveira, D. X.</span><span> </span><span class="NLM_article-title">Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas</span> <span class="citation_source-journal">J. Neurooncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">24</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1007%2Fs11060-013-1277-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=24142199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252FotlajtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2014&pages=11-24&author=F.+C.+M.+Rochaauthor=J.+G.+Dos+Santos+J%C3%BAniorauthor=S.+C.+Stefanoauthor=D.+X.+da+Silveira&title=Systematic+review+of+the+literature+on+clinical+and+experimental+trials+on+the+antitumor+effects+of+cannabinoids+in+gliomas"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas</span></div><div class="casAuthors">Rocha Francisco Carlos Machado; Dos Santos Junior Jair Guilherme; Stefano Sergio Carlos; da Silveira Dartiu Xavier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuro-oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-24</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">To evaluate, through a systematic review of the literature, the antitumoral effects of cannabinoids on gliomas.  Research included the following electronic databases: PUBMED, EMBASE, LILACS and The Cochrane Collaboration Controlled Trials Register.  All published studies involving the antitumoral effects (cellular and molecular mechanisms) of cannabinoids were considered for this review.  The bibliography search strategy included all publications of each of these databases until December 31, 2012.  From 2,260 initially identified articles, 35 fulfilled the inclusion criteria for this review.  All the studies included in this systematic review were experimental (in vivo and/or in vitro), except for one pilot clinical trial phase I/II involving humans.  In all experimental studies included, cannabinoids exerted antitumoral activity in vitro and/or antitumoral evidence in vivo in several models of tumor cells and tumors.  The antitumor activity included: antiproliferative effects (cell cycle arrest), decreased viability and cell death by toxicity, apoptosis, necrosis, autophagy, as well as antiangiogenic and antimigratory effects.  Antitumoral evidence included: reduction in tumor size, antiangiogenic, and antimetastatic effects.  Additionally, most of the studies described that the canabinnoids exercised selective antitumoral action in several distinct tumor models.  Thereby, normal cells used as controls were not affected.  The safety factor in the cannabinoids' administration has also been demonstrated in vivo.  The various cannabinoids tested in multiple tumor models showed antitumoral effects both in vitro and in vivo.  These findings indicate that cannabinoids are promising compounds for the treatment of gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ2cs4aVLDjK2hHGZei4OW9fW6udTcc2eY3IxT_eGPbUbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FotlajtA%253D%253D&md5=1c69b5d07ae0daa213f7196f108f770a</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1007%2Fs11060-013-1277-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11060-013-1277-1%26sid%3Dliteratum%253Aachs%26aulast%3DRocha%26aufirst%3DF.%2BC.%2BM.%26aulast%3DDos%2BSantos%2BJ%25C3%25BAnior%26aufirst%3DJ.%2BG.%26aulast%3DStefano%26aufirst%3DS.%2BC.%26aulast%3Dda%2BSilveira%26aufirst%3DD.%2BX.%26atitle%3DSystematic%2520review%2520of%2520the%2520literature%2520on%2520clinical%2520and%2520experimental%2520trials%2520on%2520the%2520antitumor%2520effects%2520of%2520cannabinoids%2520in%2520gliomas%26jtitle%3DJ.%2520Neurooncol.%26date%3D2014%26volume%3D116%26spage%3D11%26epage%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Guzmán, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duarte, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blázquez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravina, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosa, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galve-Roperh, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sánchez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">González-Feria, L.</span><span> </span><span class="NLM_article-title">A pilot clinical study of Δ<sup>9</sup>-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">203</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1038%2Fsj.bjc.6603236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=16804518" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFajsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2006&pages=197-203&author=M.+Guzm%C3%A1nauthor=M.+J.+Duarteauthor=C.+Bl%C3%A1zquezauthor=J.+Ravinaauthor=M.+C.+Rosaauthor=I.+Galve-Roperhauthor=C.+S%C3%A1nchezauthor=G.+Velascoauthor=L.+Gonz%C3%A1lez-Feria&title=A+pilot+clinical+study+of+%CE%949-tetrahydrocannabinol+in+patients+with+recurrent+glioblastoma+multiforme"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme</span></div><div class="casAuthors">Guzman, M.; Duarte, M. J.; Blazquez, C.; Ravina, J.; Rosa, M. C.; Galve-Roperh, I.; Sanchez, C.; Velasco, G.; Gonzalez-Feria, L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">197-203</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Δ9-Tetrahydrocannabinol (THC) and other cannabinoids inhibit tumor growth and angiogenesis in animal models, so their potential application as antitumoral drugs has been suggested.  However, the antitumoral effect of cannabinoids has never been tested in humans.  Here we report the first clin. study aimed at assessing cannabinoid antitumoral action, specifically a pilot phase I trial in which nine patients with recurrent glioblastoma multiforme were administered THC intratumoraly.  The patients had previously failed std. therapy (surgery and radiotherapy) and had clear evidence of tumor progression.  The primary end point of the study was to det. the safety of intracranial THC administration.  We also evaluated THC action on the length of survival and various tumor-cell parameters.  A dose escalation regimen for THC administration was assessed.  Cannabinoid delivery was safe and could be achieved without overt psychoactive effects.  Median survival of the cohort from the beginning of cannabinoid administration was 24 wk (95% confidence interval: 15-33). Δ9-Tetrahydrocannabinol inhibited tumor-cell proliferation in vitro and decreased tumor-cell Ki67 immunostaining when administered to two patients.  The fair safety profile of THC, together with its possible antiproliferative action on tumor cells reported here and in other studies, may set the basis for future trials aimed at evaluating the potential antitumoral activity of cannabinoids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokrBEQa1plhbVg90H21EOLACvtfcHk0lhctjZl-NaTfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFajsLo%253D&md5=bd262bc9925ba29efb9c43615a5b98e6</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6603236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6603236%26sid%3Dliteratum%253Aachs%26aulast%3DGuzm%25C3%25A1n%26aufirst%3DM.%26aulast%3DDuarte%26aufirst%3DM.%2BJ.%26aulast%3DBl%25C3%25A1zquez%26aufirst%3DC.%26aulast%3DRavina%26aufirst%3DJ.%26aulast%3DRosa%26aufirst%3DM.%2BC.%26aulast%3DGalve-Roperh%26aufirst%3DI.%26aulast%3DS%25C3%25A1nchez%26aufirst%3DC.%26aulast%3DVelasco%26aufirst%3DG.%26aulast%3DGonz%25C3%25A1lez-Feria%26aufirst%3DL.%26atitle%3DA%2520pilot%2520clinical%2520study%2520of%2520%25CE%25949-tetrahydrocannabinol%2520in%2520patients%2520with%2520recurrent%2520glioblastoma%2520multiforme%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2006%26volume%3D95%26spage%3D197%26epage%3D203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Anighoro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rastelli, G.</span><span> </span><span class="NLM_article-title">Polypharmacology: challenges and opportunities in drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">7874</span><span class="NLM_x">–</span> <span class="NLM_lpage">7887</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+challenges+and+opportunities+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0lhctjZl-NaTfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520challenges%2520and%2520opportunities%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7874%26epage%3D7887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Gediya, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Njar, V. C. O.</span><span> </span><span class="NLM_article-title">Promise and challenges in drug discovery and development of hybrid anticancer drugs</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1099</span><span class="NLM_x">–</span> <span class="NLM_lpage">1111</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=1099-1111&author=L.+K.+Gediyaauthor=V.+C.+O.+Njar&title=Promise+and+challenges+in+drug+discovery+and+development+of+hybrid+anticancer+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGediya%26aufirst%3DL.%2BK.%26aulast%3DNjar%26aufirst%3DV.%2BC.%2BO.%26atitle%3DPromise%2520and%2520challenges%2520in%2520drug%2520discovery%2520and%2520development%2520of%2520hybrid%2520anticancer%2520drugs%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2009%26volume%3D4%26spage%3D1099%26epage%3D1111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Kogan, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabinowitz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandor, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlesinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mechoulam, R.</span><span> </span><span class="NLM_article-title">Synthesis and antitumor activity of quinonoid derivatives of cannabinoids</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">3800</span><span class="NLM_x">–</span> <span class="NLM_lpage">3806</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm040042o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=3800-3806&author=N.+M.+Koganauthor=R.+Rabinowitzauthor=P.+Leviauthor=D.+Gibsonauthor=P.+Sandorauthor=M.+Schlesingerauthor=R.+Mechoulam&title=Synthesis+and+antitumor+activity+of+quinonoid+derivatives+of+cannabinoids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm040042o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040042o%26sid%3Dliteratum%253Aachs%26aulast%3DKogan%26aufirst%3DN.%2BM.%26aulast%3DRabinowitz%26aufirst%3DR.%26aulast%3DLevi%26aufirst%3DP.%26aulast%3DGibson%26aufirst%3DD.%26aulast%3DSandor%26aufirst%3DP.%26aulast%3DSchlesinger%26aufirst%3DM.%26aulast%3DMechoulam%26aufirst%3DR.%26atitle%3DSynthesis%2520and%2520antitumor%2520activity%2520of%2520quinonoid%2520derivatives%2520of%2520cannabinoids%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D3800%26epage%3D3806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Gorrini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, T. W.</span><span> </span><span class="NLM_article-title">Modulation of oxidative stress as an anticancer strategy</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">931</span><span class="NLM_x">–</span> <span class="NLM_lpage">947</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1038%2Fnrd4002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=24287781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVGqs7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=931-947&author=C.+Gorriniauthor=I.+S.+Harrisauthor=T.+W.+Mak&title=Modulation+of+oxidative+stress+as+an+anticancer+strategy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of oxidative stress as an anticancer strategy</span></div><div class="casAuthors">Gorrini, Chiara; Harris, Isaac S.; Mak, Tak W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">931-947</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The regulation of oxidative stress is an important factor in both tumor development and responses to anticancer therapies.  Many signalling pathways that are linked to tumorigenesis can also regulate the metab. of reactive oxygen species (ROS) through direct or indirect mechanisms.  High ROS levels are generally detrimental to cells, and the redox status of cancer cells usually differs from that of normal cells.  Because of metabolic and signalling aberrations, cancer cells exhibit elevated ROS levels.  The observation that this is balanced by an increased antioxidant capacity suggests that high ROS levels may constitute a barrier to tumorigenesis.  However, ROS can also promote tumor formation by inducing DNA mutations and pro-oncogenic signalling pathways.  These contradictory effects have important implications for potential anticancer strategies that aim to modulate levels of ROS.  In this Review, we address the controversial role of ROS in tumor development and in responses to anticancer therapies, and elaborate on the idea that targeting the antioxidant capacity of tumor cells can have a pos. therapeutic impact.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVKYMoILuOfbVg90H21EOLACvtfcHk0ljte88hJdb3Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVGqs7%252FI&md5=7f135a1b32b1134a88cfa28b35c53de7</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fnrd4002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4002%26sid%3Dliteratum%253Aachs%26aulast%3DGorrini%26aufirst%3DC.%26aulast%3DHarris%26aufirst%3DI.%2BS.%26aulast%3DMak%26aufirst%3DT.%2BW.%26atitle%3DModulation%2520of%2520oxidative%2520stress%2520as%2520an%2520anticancer%2520strategy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D931%26epage%3D947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Ross, R. A.</span><span> </span><span class="NLM_article-title">The enigmatic pharmacology of GPR55</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">156</span><span class="NLM_x">–</span> <span class="NLM_lpage">163</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=156-163&author=R.+A.+Ross&title=The+enigmatic+pharmacology+of+GPR55"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRoss%26aufirst%3DR.%2BA.%26atitle%3DThe%2520enigmatic%2520pharmacology%2520of%2520GPR55%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2009%26volume%3D30%26spage%3D156%26epage%3D163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Pertwee, R. G.</span><span> </span><span class="NLM_article-title">GPR55: a new member of the cannabinoid receptor clan?</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">152</span><span class="NLM_x">, </span> <span class="NLM_fpage">984</span><span class="NLM_x">–</span> <span class="NLM_lpage">986</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1038%2Fsj.bjp.0707464" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=17876300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlCrsbnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2007&pages=984-986&author=R.+G.+Pertwee&title=GPR55%3A+a+new+member+of+the+cannabinoid+receptor+clan%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">GPR55: a new member of the cannabinoid receptor clan?</span></div><div class="casAuthors">Pertwee, R. G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">984-986</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In this issue of the British Journal of Pharmacol., Ryberg et al. present convincing in vitro evidence that the orphan GPCR, GPR55, is a cannabinoid receptor.  GPR55 was activated by a range of plant, synthetic and endogenous cannabinoids and blocked by the non-psychoactive phytocannabinoid, cannabidiol.  Their expts. have revealed several differences between the pharmacol. of GPR55 and the established cannabinoid CB1 and CB2 receptors.  For example, the CB1 receptor antagonist, AM251, activated GPR55 and the main psychoactive constituent of cannabis, Δ9-tetrahydrocannabinol, displayed greater efficacy at GPR55 than at CB1 or CB2 receptors.  They also compared the distribution of GPR55 and CB1 mRNA in mouse and report that GPR55 couples to Gα13, that it is activated by virodhamine, palmitoylethanolamide and oleoylethanolamide, and that virodhamine displays relatively high efficacy as a GPR55 agonist.  Still to be identified are the main roles played by GPR55 in health and disease and any potential therapeutic benefits of activating or blocking this receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdAjaBubV8mbVg90H21EOLACvtfcHk0ljte88hJdb3Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlCrsbnJ&md5=98389e36d4406144b1c8c8d34bd39fb1</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0707464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0707464%26sid%3Dliteratum%253Aachs%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26atitle%3DGPR55%253A%2520a%2520new%2520member%2520of%2520the%2520cannabinoid%2520receptor%2520clan%253F%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2007%26volume%3D152%26spage%3D984%26epage%3D986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Ford, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roelofs, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anavi-Goffer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mowat, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpson, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irving, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajnicek, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, R. A.</span><span> </span><span class="NLM_article-title">A role for L-α-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">160</span><span class="NLM_x">, </span> <span class="NLM_fpage">762</span><span class="NLM_x">–</span> <span class="NLM_lpage">771</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=10.1111%2Fj.1476-5381.2010.00743.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=20590578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpslyqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2010&pages=762-771&author=L.+A.+Fordauthor=A.+J.+Roelofsauthor=S.+Anavi-Gofferauthor=L.+Mowatauthor=D.+G.+Simpsonauthor=A.+J.+Irvingauthor=M.+J.+Rogersauthor=A.+M.+Rajnicekauthor=R.+A.+Ross&title=A+role+for+L-%CE%B1-lysophosphatidylinositol+and+GPR55+in+the+modulation+of+migration%2C+orientation+and+polarization+of+human+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">A role for L-α-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells</span></div><div class="casAuthors">Ford, Lesley A.; Roelofs, Anke J.; Anavi-Goffer, Sharon; Mowat, Luisa; Simpson, Daniel G.; Irving, Andrew J.; Rogers, Michael J.; Rajnicek, Ann M.; Ross, Ruth A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">762-771</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and purpose: Increased circulating levels of L-α-lysophosphatidylinositol (LPI) are assocd. with cancer and LPI is a potent, ligand for the G-protein-coupled receptor GPR55.  Here we have assessed the modulation of breast cancer cell migration, orientation and polarization by LPI and GPR55.  Exptl. approach: Quant. RT-PCR was used to measure GPR55 expression in breast cancer cell lines.  Cell migration and invasion were measured using a Boyden chamber chemotaxis assay and Cultrex invasion assay, resp.  Cell polarization and orientation in response to the microenvironment were measured using slides contg. nanometric grooves.  Key results: GPR55 expression was detected in the highly metastatic MDA-MB-231 breast cancer cell line.  In these cells, LPI stimulated binding of [35S]GTPγS to cell membranes (pEC50 6.47 ± 0.45) and significantly enhanced cell chemotaxis towards serum.  MCF-7 cells expressed low levels of GPR55 and did not migrate or invade towards serum factors.  When GPR55 was over-expressed in MCF-7 cells, serum induced a robust migratory and invasive response, which was further enhanced by LPI and prevented by siRNA to GPR55.  The phys. microenvironment has been identified as a key factor in detg. breast tumor cell metastatic fate.  LPI endowed MDA-MB-231 cells with the capacity to detect shallow (40 nm deep) grooved slides and induced marked cancer cell polarization on both flat and grooved surfaces.  Conclusions and implications: LPI and GPR55 play a role in the modulation of migration, orientation and polarization of breast cancer cells in response to the tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZSA67DIv_J7Vg90H21EOLACvtfcHk0liLEwFDcGG6hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpslyqsrY%253D&md5=8c3879c19844159c7a1e5fe9617e6b68</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00743.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00743.x%26sid%3Dliteratum%253Aachs%26aulast%3DFord%26aufirst%3DL.%2BA.%26aulast%3DRoelofs%26aufirst%3DA.%2BJ.%26aulast%3DAnavi-Goffer%26aufirst%3DS.%26aulast%3DMowat%26aufirst%3DL.%26aulast%3DSimpson%26aufirst%3DD.%2BG.%26aulast%3DIrving%26aufirst%3DA.%2BJ.%26aulast%3DRogers%26aufirst%3DM.%2BJ.%26aulast%3DRajnicek%26aufirst%3DA.%2BM.%26aulast%3DRoss%26aufirst%3DR.%2BA.%26atitle%3DA%2520role%2520for%2520L-%25CE%25B1-lysophosphatidylinositol%2520and%2520GPR55%2520in%2520the%2520modulation%2520of%2520migration%252C%2520orientation%2520and%2520polarization%2520of%2520human%2520breast%2520cancer%2520cells%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D160%26spage%3D762%26epage%3D771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Bylund, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toews, M.</span><span> </span><span class="NLM_article-title">Radioligand binding methods—practical guide and tips</span> <span class="citation_source-journal">Am. J. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">265</span><span class="NLM_x">, </span> <span class="NLM_fpage">L421</span><span class="NLM_x">–</span> <span class="NLM_lpage">L429</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=265&publication_year=1993&pages=L421-L429&author=D.+Bylundauthor=M.+Toews&title=Radioligand+binding+methods%E2%80%94practical+guide+and+tips"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBylund%26aufirst%3DD.%26aulast%3DToews%26aufirst%3DM.%26atitle%3DRadioligand%2520binding%2520methods%25E2%2580%2594practical%2520guide%2520and%2520tips%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1993%26volume%3D265%26spage%3DL421%26epage%3DL429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i34"><a href="/doi/suppl/10.1021/acs.jmedchem.5b00078">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_26874"></div></div></div></div></div><hr /></hr><p class="last">Viability assays of compound <b>10</b> in different TNBC cell lines (SUM149, SUM159, MDA-MB-231, and MDA-MB-468). Molecular formula strings are saved in .csv format. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00078/suppl_file/jm5b00078_si_001.pdf">jm5b00078_si_001.pdf (43.57 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00078/suppl_file/jm5b00078_si_002.csv">jm5b00078_si_002.csv (0.37 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b00078&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b00078%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2015.58.issue-5%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b00078" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799527a59cd3c88","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
